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ABSTRACT 
An analgesic effect is one of the reported results of Low Intensity Laser Therapy 
(LILT). Even though this therapy has been extensively used to treat 
musculoskeletal injury, pain and inflammation, there is still a lack of research 
concerning the ideal parameters and mechanism of action of LILT on painful 
Temporomandibular Disorders (TMD). This thesis sets out to compare clinical 
responses to the 820 nm Gallium Aluminium. Arsenide (GaAlAs) laser at two 
energy levels and placebo laser in TMD Pain patients. Additionally, in vitro 
studies were conducted to explore the effect of 820 nM radiation on 
Prostaglandin E2 (PGE2) production by myoblast cultures undergoing stretching 
and stimulation by Interleukin I alpha (IL-1). 
A double-blind clinical trial was conducted on 30 female TMD pain patients. The 
patients were randomly allocated into three groups based on LILT regimes 
namely 820 nm GaAlAs at energy density of 21 and 107 J/cml and placebo laser. 
Each patient had three LILT treatments in a week. The pressure pain threshold 
(PPT) of trigger points in masticatory muscles, unassisted maximum mouth 
opening without pain (MOSP) and symptom severity index (SSI) were recorded as 
baseline data and monitored after every treatment. jaw kinesiology and 
electromyography (EMG) were also recorded as baseline and final results. The 
analysis of covariance and the further analysis showed that the higher energy 
density laser group had significant increases in PPT and EMG amplitude 
recorded from voluntary clenching (cEMG) compared with the placebo group at P 
values 0.0001 and 0.022 respectively. A significantly greater number of patients 
recovered from myofascial. pain and TMJ arthralgia as assessed clinically in the 
higher energy group compared with the placebo (P value = 0.012 and 0.001 
respectively). There was no statistically significant difference of parameters of 
assessment among the groups at aP value 0.05. At a period of 
2 to 4 weeks 
review after LILT, there was an average 52% reduction of pain as assessed 
by SSI 
pain questionnaire. 
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The control in vitro studies on the influence of LELT on PGE2 production were 
conducted on differentiated C202 skeletal muscle cells stimulated by 
mechanical stretching and IL-I supplement. The two models of PGE2 
stimulation showed significantly higher amounts of PGE2 production compared 
with the no intervention group. The results from the model using mechanical 
stretching to stimulate PGE2 synthesis showed no inhibitory effect from 820 nm 
GaAlAs laser at least in the energy densities used in this study which were 0.6 
J/CM2 and 3.1 J/cmI. In the other experiment, IL-1 supplement was used to 
stimulate PGE2 which was observed to occur in the sham laser and lower energy 
laser at 4 J/CM2 groups. However, the higher energy laser group at 19 J/cm' 
showed reduced PGE2 synthesis with no statistically significant difference from 
a no intervention group where no IL-1 was added. This indicates that 820 nm 
radiation at higher energy density appears capable of inhibiting PGE2 formation 
and this may be one of the mechanisms of the analgesic effect of GaAlAs LILT 
on trigger points in muscle. 
Overall Low Intensity Laser Therapy (LILT) given at high energy density has been 
shown to be a valuable addition to the repertoire of treatment methods for 
Temporomandibular Pain Disorder. 
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PART I 
INTRODUCTION AND REVIEW OF THE LITERATURE 
20 
INTRODUCTION 
Low Intensity Laser Therapy (LILT) is reputed to have an analgesic effect and in 
this role is used to treat musculoskeletal injuries, pain and inflammation. Two 
recent meta-analysis studies, however, showed controversies over the effect of 
LILT on musculoskeletal pain (Beckerman et al. 1992; Gam et al. 1993). A 
number of clinical studies have reported the benefit of LILT on pain related to 
temporomandibular disorders (Bezuur et al. 1988; Arao et al. 1995; Bradley and 
Rehbini, 1995; Rehbini, 1995; Conti, 1997), although infrequently in the context 
of randomly allocated double blind trials. 
Thus, there is still a lack of properly designed research concerning the 
parameters and mechanism of LILT on TMD (Beckerman et al. 1992; Ohshiro et 
al. 1994). This study sets out to investigate the efficacy of LILT in 
temporomandibular disorder pain associated with clinical outcomes and study 
the biological effect of LILT on a key pain substance prostaglandin E2 in skeletal 
muscle culture. 
The thesis will begin with a review of the literature together with a statement of 
the aims and hypothesis of the study. The study comprises two main parts 
namely clinical trial and in vitro experiment for which the methodology and 
results will be explained separately. Discussion and conclusions based on 
clinical trial and in vitro experiment will be undertaken. 
21 
REVIEW OF THE LITERATURE 
This review comprises three main parts concerning temporomandibular 
disorders (TMD), low intensity laser therapy (LILT) and skeletal muscle cell 
culture (including the influence of LILT). Influences of LILT on pain control will 
also be reviewed from clinical trials and in vitro studies. 
TEMPOROMANDIBULAR DISORDERS 
DEFINITION 
Temporomandibular disorders are the musculoskeletal disorders involving the 
masticatory muscles and temporomandibular joint. There have been a number 
of nomenclatures describing the clinical conditions associated with 
musculoskeletal. pain and dysfunction in the temporomandibular system as 
follows: - 
temporomandibular joint dysfunction (syndrome). 
temporomandibular pain dysfunction. 
facial arthromyalgia. 
* myospasm. 
* temporomandibular disorders. 
22 
Nowadays the term "temporomandibular disorders (TMD)", described by the 
American Academy of Orofacial Pain, is more acceptable than others, in that, it 
is compatible with the terminology used by the American Dental Association 
and also recognised by the International Headache Society. The definition of 
temporomandibular disorders is "a collective term embracing a number of 
clinical problems that involve the masticatory musculature, the 
temporomandibular joint (TMJ) and/or associated structures" (McNeill, 1993). It 
was emphasised that the non-musculo skeletal disorders in the orofacial region, 
such as vascular, neoplastic or infectious disease, which may produce similar 
symptoms are not considered to be TMD (McNeill, 1993; Jagger et al. 1994). 
EPIDEMIOLOGY 
A cross-sectional epidemiological study in USA showed that about 75% of 
normal populations had at least one sign of temporomandibular (TMJ) 
dysfunctions such as abnormalities of movement, joint sounds and tenderness 
on palpation. Thirty three percent had at least one episode of facial joint pain 
(Rugh and Solberg, 1985). 
Recently, Dworkin et al (1990) conducted a cross-sectional case-control study on 
242 TMD patients in clinic (clinical cases) and 121 TMD patients who were on the 
waiting lists (community cases) by using 210 normal subjects drawn from an 
unrelated clinic as controls (control cases). It was found that clinical findings 
did not vary by age either in the case or control groups. Ninety-seven percent of 
the clinical cases sought treatment for relief of pain related to TMD. Similarly, 
McNeill (1993) stated that the most frequent presenting symptom is pain, 
usually localised in the masticatory muscles, the preauricular area and/or the 
TMJ. 
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In the study by Dworkin et al (1990) as mentioned above, there was no 
statistically significant difference among the groups in terms of occlusion. In 
every group, males showed significantly greater unassisted maximum mouth 
opening without pain than females. Compared with the control group of the 
same gender, a more distinct limitation of mouth opening was found in the 
clinical cases than the community cases. However, defining restricted opening 
as below 30 mm. for females and 35 mm for males, only 22% of clinical cases 
were found to have limitation of opening. The range of lateral excursions were 
not significantly different among the groups. joint sounds in the clinical cases 
were also significantly more frequent than in the community and control cases. 
A number of subjects had tender masticatory muscles (except 
sternocleidomastoid muscle) and TMJs on palpation with a statistically 
significant difference among the groups at P value = 0.001. The prevalence of 
muscle pain was highest in the clinical group and lowest in the control group. 
The clinical cases also had significantly higher pain scores on palpation than the 
community cases. The community cases also had significant higher pain scores 
than the controls. The self reported symptoms of the clinical cases were higher 
than either community or control cases. 
The TMD patients who sought treatment seemed to have more distinct signs and 
symptoms such as report of pain particularly in response to palpation, limitation 
of mouth opening and joint sounds than TMD patients in the community. 
However, there were no significant differences between the cases and controls in 
the particular aspects of occlusion and lateral excursion (at 
least in the above 
study). Gender had an influence on the pain free maximum mouth opening 
which was less in the female. 
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AETIOLOGY 
An aetiology of TMD used to emphasise abnormality of occlusion which as the 
principle factor could lead to the dysfunction of the TMJ and masticatory 
muscles (Clark, 1991). Not only has the occlusion factor been related to TMD, 
but also many other factors have been suggested to have some relationships to 
TMD. DeBoever and Carlsson (1994) have summarised theories regarding wider 
aetiologies of TMD namely; mechanical displacement, neuromuscular, muscle, 
psychophysiological and psychological theories: - 
The concept of mechanical displacement concerned the lack of posterior teeth 
support or functional occlusal prematurities causing an eccentric position of the 
condyle in the glenoid fossa leading to dysfunction and pain of the 
temporomandibular organs and ear symptoms. The inappropriate position of 
the condyle was able to initiate an inadequate and adverse muscle activity. 
The neuromuscular theory hypothesised that occlusal interference in 
combination with stress and tension caused parafunctions such as grinding and 
clenching. Also occlusal interference could provoke muscle spasm and 
hyperactivity. On the other hand, the muscle theory stated that the primary 
cause was in the masticatory muscles and denied the influence of occlusion. 
Overstimulation was able to increase the tension in muscles constantly which 
could lead to Painful spasm of muscles at the end. TMJ pain was included in 
general muscle disorders in this theory. 
The psychophysiology theory proposed that the primary factor was the spasm of 
the masticatory muscles which caused over-extension, over- contraction or 
muscle fatigue from parafunction. The psychological theory, on the other hand, 
propounded that parafunction was initiated by emotional disturbances which 
could stimulate centrally-induced muscular hyperactivity. The abnormality of 
occlusion played an indirect role in this theory. 
25 
Following the evolution of assessments of TMD and research on that area, it has 
now been accepted that the aetiology of TMD is multifactorial (Parkerg 1990; 
Clark, 1991; McNeill, 1993; DeBoever and Carlsson, 1994). The early 
multifactorial model during the '80s had three main contributing factors 
namely; anatomical, neuromuscular and psychological factors (DeBoever and 
Carlsson, 1994). These three factors and their overlapping factors were considered 
together in individual patients. The predominant factor varied in individual 
cases. For example, a TMD patient who had a distinct abnormality of occlusion 
together with difficulty in social activity and a grinding habit would have an 
anatomical factor as a dominant factor w[th psycholoocAl and neilromuscular factors 
as minor factors. 
Parker (1990) proposed the aetiology of TMD using a dynamic model that can be 
a simple and fle)dble model for the aetiological dynamics of myogenous and 
arthrogenous TMD. This concept concerns a balance in the masticatory system 
between pathofunction and orthofunction. Hyperfunction is the driving force 
toward pathofunction which is the principal cause of TMD. On the other hand, 
adaptability is the biological process which determines whether orthofunction 
or pathofunction results from a given degree of hyperfunction. Therefore, a 
high degree of hyperfunction and/or a low levellof adaptability are more likely 
to shift toward pathofunction. 
The above dynamic model has been accepted and become the basis of a recent 
multifactorial model (DeBoever and Carlsson, 1994). The aetiology of TMD was 
divided into three further factors (McNeffl, 1993; DeBoever and Carlsson, 1994) 
as follows: - 
Predisposing factors, the factors that increase the risk of TMD. 
Precipitating or initiating factors; the factors that cause the onset of TMD 
Perpetuating or sustaining factors; the factors that interfere with healing or 
enhance the progression of TMD 
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'Ors: 
0 Systemic factors : such as psoriasis and rheumatoid arthritis 
0 Psychological factors : regarding personality and behaviour for 
example personalities vulnerable to stress and anxiety 
0 Structural factors: such as occlusal discrepancies, improper 
dental treatment and joint laxity 
Precipitating or initiating Lactors: 
0 Trauma: This may be direct trauma from injuries such as blows to 
the jaw and whiplash injury. This kind of trauma usually produces injury 
to the TMJ and leads to problems such as an internal derangement or 
osteoarthritis. Clark (1987) recognised this kind of trauma as 
macrotrauma. 
0 Adverse influences or overloading to joint structures: such as 
overstretching and overuse of the joint and iatrogenic stretching during 
dental treatment. 
0 Parafunctional habits: such as tooth grinding, clenching and atypical 
chewing 
The adverse influences or overloading to joint structures and parafunctional 
habits produce microtrauma to the masticatory system and lead to painful TMj 
and masticatory muscle disorders (Clark, 1987). 
Pe )etuating or sustaining Lacto 
9 Behavioural, social and emotional difficulties 
Mechanical and muscular stress 
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The above two factors are normally increased in the chronic type of TMD and 
tend to retard healing. Some TMD patients responded to painful TMD by an 
increase in parafunctional habits such as clenching. Therefore, these factors 
play a part in producing a vicious circle for TMD. 
* Metabolic problems: for example, the degradation of various enzymes, 
metabolic by-products and pain transmitters cause pain, inflammation and 
degeneration in the TMJ. 
Aghabeigi et al (1993) conducted a controlled study on 29 chronic orofacial pain 
patients (23 facial arthomyalgia subjects) comparing them with 29 controls. 
The patients had statistically significant, lower levels of tyramine-0-sulphate (a 
metabolic breakdown product of tyramine) in their urine than the control group 
suggesting a defect in tyramine metabolism. 
As mentioned above, the current concepts of TMD aetiology tend not to draw a 
absolute line for the types of aetiological factors or causes of TMD. The 
multidimensional approach is considered in terms of the roles of factors. 
Therefore, one condition such as parafunction can be both a precipitating andlor 
perpetuating factor. 
DIAGNOSTIC CLASSIFICATION 
The definition of TMD is an umbrella term for musculoskeletal disorders of 
masticatory muscles and/or temporomandibular joint. Therefore, sub- 
categories of TMD are extremely important for clinical work and research. 
Although numbers of diagnostic procedures and subgroup-classifications for 
TMD have been established, most of them have not been tested for reliability 
and validity, or have a lack of standardisation (Clark et al. 1993; Fricton, 1995). 
There are different concepts of defining and classifying TMD for clinical and 
research settings. For research purposes, the new "Research Diagnostic Criteria 
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for Temporomandibular Disorders" (RDC), published in 1992 by Dworkin and 
LeResche, are regarded as the standard diagnostic strategies (Clark et al. 1993; 
Fricton and Dubner, 1995 b). The RDC are divided into a clinical examination 
based axis and a chronic pain disability and psychological-based questionnaire 
axis: - 
RDC Axis I. - 
The guidelines of A3ds I are shown in table 1. It is recognised that these criteria 
are the first serious attempt to define a system that will lend itself to studies of 
standardisation and validation (Fricton and Dubner, 1995 b). 
Table 1: Research Diagnostic Criteria for TMD (Axis 1) 
Muscle Disorders : 
- Myofascial pain 
- Myofascial pain with limited opening 
Disc Displacement: 
- With reduction 
- Without reduction, with limited opening 
- Without reduction, without limited opening 
Arthralgia, Arthritis, Arthrosis: 
- Arthralgia 
- Osteo-arthritis of the TMJ 
- Osteo-arthrosis of the TMJ 
Dworkin and LeResche (1992) stated the definitions of the sub-groups of TMD as 
follows: - 
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lisorders 
This terminology deals only with the painful disorders related to TMD. It is 
divided into two categories. 
La. Myofascial pain: pain of masticatory muscle origin, including a complaint 
of pain, as well as pain associated with localised areas of tenderness to 
palpation in muscle. 
I. b. Myofascial pain with limited opening: limited movement and stiffness of 
the muscle during stretching in the presence of myofascial pain. The 
limitation of mouth opening is indicated by pain-free unassisted mouth 
opening less than 40 mm. 
Group IT Disc displacements 
Disc displacements can be divided into three types as follows: - 
H. a. Disc displacement with reduction: the disc is displaced from its normal 
position between the condyle and the eminence to an anterior and medial 
or lateral position, but reducing on full opening, usually producing a joint 
sound. 
H. b. Disc displacement without reduction, with limited opening: the disc is 
displaced from the normal position between the condyle and glenoid 
fossa to an anterior and medial or lateral position, associated with 
limited mandibular opening. The limited opening is indicated by 
maximum unassisted opening less than 35 nim. 
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H. C. Disc displacement without reduction, without limited opening: the disc is 
displaced from its normal position between the condyle and the eminence 
to an anterior and medial or lateral position, not associated with limited 
mouth opening. 
It is emphasised that when disc displacements are accompanied by pain 
in the joint, a diagnosis of Arthralgia (III. a) or osteoarthritis (HI. b) must 
also be assigned. 
Group III. - Arthralgia. Arthritis and Arthrosis: 
This classification involves the presence of pain and tenderness in the TMJ, not 
included polyarthridites, acute traumatic injuries and infections in the joint. 
HI. a. Arthralgia: pain and tenderness in the joint capsule and/or the synovial 
lining of the TMJ. 
Hl. b. Osteoarthritis of the TMJ: an inflammatory condition within the joint that 
results from a degenerative condition of the joint structures. 
1H. c. Osteoarthrosis of the TMJ: degenerative disorder of the joint in which 
joint form and structure are abnormal. 
The rules for making diagnoses are as follows: - 
1. subject will be assigned with at the most one muscle 
disorder ( Group 
of either myofaScial. pain or myofascial. pain with a 
limited range of 
motion, but not both. 
2. Each joint may be assigned at the most one diagnosis from Group II and 
one diagnosis from Group 1H 
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RCD Axis H 
The proposal of axis 11 is to assess pain related and psychological status in TMD 
patients in terms of pain-related disability, depression and non-specific physical 
symptoms based on a symptom checklist-90 (Dworkin and LeResche, 1992). 
Pain-related dUahjUty 
A grading of chronic pain severity and disability based on questionnaires by Von 
Korff et al (1992) is used as the assessment of pain related disability. The 
grading is as follows: - 
Grade 0: No TMD pain in the prior 6 months 
Grade I: Low disability-Low intensity pain 
Grade 11 : Low disability-High intensity pain 
Grade III : High disability-Moderately limiting 
Grade IV : Fhgh disability- Severely limiting. 
Depression and non-speciCic physical symptom 
These assessments are based on a standard SCL-90 checklist plus some 
vegetative symptom scales which can divide patients into normal, moderate and 
severe by using standard scores. 
Axis 11 is recommended to be repeated at not less than 6 monthly intervals to 
detect psychological change in chronic pain. 
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OTHER RELATED DIAGNOSES OR CONDITIONS FOR PAINFUL TMD 
There are also some other relevant diagnoses or conditions associated with TMD 
pain either in the masticatory muscles or TMJ: - 
a) Myofascial trigger points 
A myofascial trigger point is defined as aI or 2 cm diameter localised deep 
tenderness area in a taut band of skeletal muscle, tendon or ligament which has 
the ability to cause referred pain in a definite anatomic distribution when 
stimtdated (Pertes and Gross, 1995). The clinical characteristics of active 
myofascial. trigger points are as follows (Travell and Simons, 1983; Baldry and 
Thompson, 1998): - 
9 Structures liable to contain trigger points include muscles, tendons, joint 
capsules, ligaments, periostium and skin. 
*A history of sudden onset during or shortly following acute overload stress 
or gradual onset with chronic overload of the affected muscle 
9 Myofascial, patterns are specific to individual muscles 
9 Weakness and restriction in the stretch range of motion of the affected 
muscle 
A taut, palpable band in the affected muscle 
Exquisite, focal tenderness to digital pressure in the band of taut muscle 
fibre 
eA local twitch responding to snapping palpation or needling of the tender 
spot 
Reproduction of pain by pressure on or needling of the tender spot 
Active trigger points can induce referral pain, either locally or at some 
distant site, or both. 
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e The elimination of symptoms by therapy directed specifically to the affected 
muscle 
Graff-Radford (1984) summarised the factors which precipitate or perpetuate 
trigger points as follows: - 
* physical factors such as chilling of the musculature by changes in weather, 
trauma producing muscle strain or fatigue and habitual poor posture 
e medical factors such as acute fibrile illness, recurrent infection, neuralgias 
and metabolic disturbances 
9 pathophysiological factors such as a decrease in circulation due to 
inflammation of connective tissue or local hypoxia and hyperactive or 
hypersensitive reflexes. 
Histobiological findings associated with myofascial trigger points were 
hypothesised by Travell and Simons (1983): - 
9 The nearly total depletion of adenosine triphosphate (ATP) can lead to 
muscle contraction with electrical silence. Owing to the lack of ATP, myosin 
heads do not release from actin filaments. 
o Nerve- sensitising substances such as histamine, serotonin, kinins and 
prostaglandins may be released in the trigger point areas. These substances 
not only sensitise the nerves but also cause local ischaernia. 
The hypothesis of prostaglandin release in trigger points is supported by a 
single blind randomised controlled trial by Frost (1986). A statistically 
significant reduction of pain scores was found in the group receiving diclofenac 
(a prostaglandin synthesis inhibitor) by intra-trigger point injection at 4 hours 
after injection while such an effect was not found in the group with lidocaine 
mJection. 
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b) Facial arthromyalgia 
Facial arthromyalgia is one category of orofacial pain which also includes 
atypical facial pain, atypical odontalgia and oral dysaesthesia. This term was 
described by Feinmann and Harris (1984 a; 1984 b) to be a condition affecting 
the TMJ and its musculature with associated disturbances of joint function such 
as clicking, sticking and trismus and occasionally aural symptoms such as 
tinnitus and a sense of fullness in the ear. Other pain disorders such as 
headache, migraine, neck and back aches, spastic colon and dysfunctional 
uterine bleeding can often be found in associated with facial arthromyalgia. The 
writers believed that this type of pain had a psychogenic basis and could be 
effectively treated by low dose antidepressants acting to potentiate the action of 
5 hydroxytriptamine (SHT) in the central nervous system; 5 HT is released by 
neurones involved in inhibitory circuits modulating pain response in the central 
nervous system. 
MANAGEMENT OF TMJ DISORDERS 
The aims for the management of all patients with TMD have been summarised 
as follows (McNeill, 1993): - 
reduce pain 
restore normal jaw function 
reduce the need for further health care 
restore normal lifestyle functioning. 
Basically, treatments for temporomandibular disorders are 
divided into two 
categories; non- surgical/non-invasive treatment and 
surgical/invasive treatment. 
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NON-SURGICAL/NON-INVASIVE TREATMENT (CONSERVATIVE) 
Non-surgical treatment, conservative or non-invasive treatment, is considered to 
be the first choice for TMD in the opinion of aH authorities. There are various 
forms of treatment as follows: - 
Patient education and self care 
TMD patients should be informed by clinicians about the clinical findings, 
diagnosis data, treatment options, prognosis and self care. Interactions for 
routine self care are as follows: - 
* rest of the masticatory system through voluntary reduction of mandibular 
movement 
9 habit awareness and modification 
home physiotherapeutic programmes such as massage, thermal treatment 
and jaw exercise. 
The success of a self care programme depends on patient motivation, co- 
operation and compliance (McNeill, 1993; McNeill, 1997). 
Cognitive behavioural intervention 
One of the contributing factors of TMD is habit and behaviour causing 
parafunction. Behaviour modification by such measures as 
habit reversal 
programme, lifestyle counselling, progressive relaxation, 
hypnosis and 
biofeedback is the main strategy for this treatment. The individual programme 
depending on types and severities of habit and behaviour has to be set up for 
each patient (McNeill, 1993; McNeill, 1997). Studies by Dworkin et al 
(1994) and 
Turk et al (1996) found that cognitive behavioural therapy combined with other 
conservative treatment such as an occlusal splint could provide a continued 
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improvement in pain relief in TMD patients. However, a study by Harrison et al 
(1997) in patients suffering from orofacial pain including facial arthromyalgia 
failed to show the benefit of a cognitive behavioural programme when combined 
with antidepressant therapy. 
Psychotherapy 
The main idea of psychotherapeutic intervention for TMD patients is to help the 
patient to solve his or her problems by translating the somatic symptoms into 
their psychological and interpersonal equivalents. The patients' care need to be 
undertaken by a mental health professional. Those TMD patients who have 
experienced multiple treatment failures with long-standing pain may 
particularly need to be evaluated for a psychological treatment need (McNeill, 
1993; McNeill, 1997). 
Phannacotheraphy 
Analgesic agents used for management of TMD pain are nonsteroidal anti- 
inflammatory drugs (NSAID), cortico steroids, muscle relaxants and 
antidepressants (McNeill, 1993; Bush and Dolwick, 1995; Pertes and Gross, 1995; 
McNeill, 1997). 
NSAID, such as ibuprofen, melofenamate, salicylate and naproxen are used for 
myogenous pain and osteoarthrosis (Bush and Dolwick, 1995; Gray et al. 1995). 
These drugs provide only symptomatic relief and cannot change the progreýsion 
of pathologic tissue injury except possibly in active inflammatory joint 
disease 
(McNeill, 1993). However, a double blind study by Singer et al (1987) in chronic 
orofacial pain characterised as of myogenic origin showed no significant 
analgesic effect of ibuprofen in a 4-week period of treatment 
by comparison 
with the placebo. Similarly in a study on the effect of piroxicam 
by Gordon et al 
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(1990) in 28 TMD pain subjects, there was no significant therapeutic advantage 
of 20 mg piroxicam daily cornpared with placebo. 
On the basis of extensive review, Dionne et al (1997) suggested that NSAID may 
be considered for prescription to TMD patients who have an apparent 
inflammatory component to their pain complaint present for a short-period of 
time. The drug should be discontinued in the event that there is a lack of 
therapeutic effect after 7 to 10 days or the development of any gastrointestinal 
symptoms. 
Systemic corticosteroid is used only in acute, generalised muscle and joint 
inflammation associated with polyarthritides (McNeill, 1993). Details of local 
steroid used for intra-articular injection will be mentioned in the section of 
injection therapy (page 46). 
Muscle relaxants such as carisoprodol, methocarbamol and chloroxazone have 
been used for excessive muscle activity related to TMD (McNeill, 1993). 
According to an extensive review by Dionne et al (1997), a distinct effect of 
carisoprocol on musculoskeletal pain was not detected in placebo controlled 
trials while cyclobenzaprine seemed to show a superior effect on chronic 
musculoskeletal. pain in some control trials. However, the authors pointed out 
that there is still a lack of clinical controlled trials on this form of medication in 
TMD patients. 
Tranquillisers such as bezodiazepines can produce muscle relaxation due to 
their sedative effect (McNeill, 1993). These drugs should only be used short- 
term for acute muscle pain and sleep disturbances with associated anxiety in 
view of the risk of habituation (McNeill, 1997). Nitrazepam has been reported to 
be useful in nocturnal bruxism (Bradley, 1987). A double blind controlled trial 
on 20 myofascial pain patients showed a superior benefit of clonazepam in 
comparison with placebo (Harkin et al. 1991). A double blind study by Singer et 
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al (1987) in patients with chronic orofacial pain of myogenic origin evaluated the 
benefits of ibuprofen, diazepam and the combination of the two incomparison 
with placebo for 4 weeks. VAS was significantly decreased in the diazepam and 
diazepam plus the ibuprofen groups compared with the placebo. However, there 
was no statistically significant differences of VAS between the ibuprofen and 
placebo groups. 
Low dose tertiary tricyclic antidepressants such as amitriptyline and dothiepin 
have an analgesic effect reputedly due to their ability to work as 5 
hydroxytryptamine (5HT) agonists. These medications are prescribed for 
chronic pain TMD patients suffering from neuropathic pain, chronic muscle pain 
and sleep disturbance (McNeill, 1993; Gray et al. 1995; Bush and Dolwick, 1995; 
McNeill, 1997). A double blind control study by Feirumann and Harris (1984 b) 
compared the benefits of antidepressant dothiepin, a bite guard and the 
combination of the two treatments with placebo in 93 patients who suffered 
from chronic orofacial pain including facial arthromyalgia. The bite guard failed 
to provide any benefits to the patients during the 9-week trial. The mean 
amelioration in pain (rating scale 0 to 4) at 3 weeks was 0.7 (SE = 0.8) in the 
dothiepin group compared with 0.3 (SE = 0.6) in the placebo group (P value less 
than 0.0 S). There was no statistically significant difference of the mean 
improvement in pain at 6 weeks follow up. At 9 weeks, there was a statistically 
significant difference between the dothiepin group (1.3, 
SE = 1.0) and the 
placebo group (0.8 SE 0.8). The writers claimed a significant 
difference in the 
number of pain free patients in favour of the 
dothiepin group. It should be 
noticed that the pain free group comprised those patients who 
had a zero pain 
score and a mild occasional pain score 1. 
Dao et al (1995) studied the effect of sumatripan 
(an agonist of 5 HT 1D) in 7 
patients who had temporalis myofascial pain. 
On the basis of a double blind 
cross over placebo controlled trial, they 
found no benefit of this drug on pain 
relief in comparison with a placebo. 
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There has been no strong evidence to support any medication as a totally 
effective drug of choice for TMD, therefore the side effects and adverse effects 
of all medications may outweigh their benefits particularly in long-term usage 
(Dionne, 1997). 
Physiotherapy 
There are various kinds of physiotherapy which have been used for myofascial 
pain and TMJ pain dysfunction such as thermal treatment, exercise therapy, 
ultrasound, transcutaneous electrical nerve stimulation (TENS), acupuncture and 
low intensity laser treatment (LILT) (McNeill, 1993; Gray et al. 1995). The main 
aims of these therapies are relief of musculoskeletal pain, restoration of 
normal function and promotion of healing response (Gray et al. 1995; McNeill, 
1997). The reported efficacy of these forms of physiotherapy on TMD is 
reviewed as follows: - 
Thermal treatment 
Fluori-Methane vapourcoolant spray followed by muscle stretching can relieve 
tightness and soreness from acute muscle spasm (Bradley, 1987; McNeill, 1997). 
From an extensive review by Feine et al (1997), the local application of cold 
therapy can provide a short term relief of pain due to its analgesic effects and 
ability to reduce inflammation. The use of a hot pack 
for myofascial pain 
reduction has a lack of support from scientific articles. 
However, Gray et al 
(1994) used short wave diathermy at mild thermal setting 
for 10 minutes and 
also Megapulse (a pulsed short wave diathermy at 
60 microseconds and 100 
pulse per second) for 20 minutes for providing 
deep heat to treat TMD pain 
patients. On the basis of a double blind trial, the results of 
3 month review 
showed that the numbers of patients who 
had clinical improvement in the 
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groups treated by these two types of heat treatment were significantly larger 
than the placebo group. 
Jaw exercise 
Physical jaw exercises are also recommended in order to improve mandibular 
range of motion and restore the proper movement of the TMJ (McNeifl, 1993; 
Gray et al. 1995). Bradley (1987) suggested three jaw exercise regimes for TMD 
patients namely straight opening, suprahyoid and finger and thumb dilatation 
exercises. These physical exercises were recommended to patients at a stage 
when they could be performed without pain and discomfort. 
Ultrasound 
According to an extensive review by Murphy (1997), ultrasound provides benefit 
to TMD in terms of increasing joint range of motion and tissue healing, 
reduction of muscle spasm, pain relief and reduction of chronic inflammation. 
In the same study by Gray et al (1994) as mentioned in the section of thermal 
treatment, ultrasound at 0.25 W/CM2 2-1,2 pulse for 2 minutes treating patients 
3 times weekly for 4 weeks produced the significantly larger number of patients 
who recovered from TMD pain at a 3-month review 
in comparison with the 
placebo group. Comparing the ultrasound group with 
the other treatments in 
this study namely short wave diathermy, 
Megapulse and 904 nm Gallium 
Arsenide low intensity laser, there was no statistically significant 
difference in 
the number of patients who had a clinical 
improvement among the groups. 
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A double blind controlled trial in 60 patients suffering myofascial pain in the 
head and neck region by Graff-Radford et al (1989) reported a significant pain 
reduction in a group treated with TENS at 100 Hz, 250 msec stimulation 
followed by 100 Hz, 50 msec compared with other regimes and control. 
However, a significant difference of pressure pain threshold was not found 
among groups. Linde et al (1995) compared outcomes of a 6-week trial with 
TENS course with the use of an occlusal splint in 31 patients diagnosed as 
having temporomandibular joint disc displacement without reduction. 
Regarding criteria of improvement as 50% pain reduction at rest and function, 
50% of patients treated with the occlusal splint and only 6% of patients treated 
with TENS met these criteria respectively. If only 501/6 pain reduction at rest was 
considered alone, there were two thirds of the occlusal splint group and a half 
of patients in the TENS group who reached this point. 
Acupuncture 
There have been clinical trials comparing the efficacy of acupuncture with 
occlusal splint. johansson et al (1991) compared the dysfunction score, VAS and 
clinical signs in 45 patients who suffered from head or facial pain with 
myogenic origin among the groups treated by either acupuncture or acrylic resin 
occlusal splint or no treatment (3-month waiting list). The results from 3 month 
follow up showed a statistical improvement in dysfunction score, VAS and 
clinical assessment in both of the treated groups compared with the non-treated 
group. However, there was no statistically significant difference in all 
assessments between the acupuncture and the occlusal splint groups. These 
results led the authors to conclude that acupuncture could 
be an alternative 
treatment for myofascial pain of masticatory muscles to occlusal splint therapy. 
interestingly, a similar trial by List et al (199 2) in I 10 patients showed a superior 
benefit of acupuncture in subjective symptoms in comparison with occlusal 
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splint in the immediate results after a 2-month treatment. From the continued 
study in the same group of patients at 12 months after treatment, 57% of 
patients in the acupuncture and 67% of patients in the occlusal splint group 
showed subjective and clinical benefits. There were no statistically significant 
differences in assessment variables between the two groups (List and Helkimo, 
1992). 
LIL T 
The efficacy of LILT on TMD pain is reviewed on page 61. 
Splint therapy 
Orthopaedic type appliances may be referred to as an interocclusal splint, night 
guard or bruxism appliance (McNeill, 1993; McNeill, 1997). Bradley (1987) 
summarised the possible mechanisms whereby occlusal splints could exert their 
benefits on TMD patients as follows: - 
e reduction of aberrant muscle activity 
* rendering the patient free of premature occlusal contact 
preventing terminal closure and thereby reducing stimulation of posterior 
articular nerves by opening the bite 
9 an upper occlusal. splint covering the palate can alter patterns of muscular 
activity such as by stimulating a reflex lowering of the mandibular rest 
position with increase in free way space. 
9 placebo effect 
There are two main types of orthopaedic appliance namely; stabilisation and 
anterior positioning appliances. Stabilisation appliances are normally 
designed 
to provide joint stabilisation, protect the teeth from the effect of 
bru, -dsm, 
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redistribute forces and relax the elevator muscles. These appliances can be 
made from hard or soft material (McNeill, 1993; McNeill, 1997). 
Anterior positioning appliances have been used for acute joint pain, pain 
associated with joint noise, closed lock and also associated secondary muscle 
symptoms from articular inflammation and pain (McNeill, 1993; McNeill, 1997). 
Their particular function may be to recapture an anteriorly positioned meniscus. 
There is a risk that they may cause secondary occlusal compensation. 
All orthopaedic appliances are suggested to be worn during sleep. In acute pain 
cases, appliances may be worn whole full time apart from meal times (Bradley, 
1987; McNeill, 1993; McNeill, 1997). 
Tsuga et al (1989) reported the efficacy of a stabilisation type of occlusal sphnt 
in 30 TMJ dysfunction patients. More than 50% of patients were free from TMJ 
pain after 4 weeks of treatment. There was a significant improvement in TMJ 
sounds in comparison with baseline assessment at 10 weeks. A significant 
improvement in mouth opening was found compared with the baseline after 13 
weeks of therapy. Gray et al (1991) conducting a study in 68 TMD patients 
compared the success rate between a stabilisation splint (SS) and a localised 
occlusal interference splint (LOIS). The success rates based on subjective 
assessments were 67.6% and 80.9% for SS and LOIS respectively but there was no 
statistically significant difference. Some works related to comparative study 
between occlusal splint and other physiotherapies were mentioned in the part of 
the review in on physiotherapy (page 42). 
Occlusal therapy 
Occlusal. therapy is treatment to J. Lmprove and adjust the occlusion aiming for 
the following objectives (McNeffl, 1997): 
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* maximum symmetrical distribution of intercuspal contacts in the 
predetermined jaw relationship 
axial or near axial loading of the teeth 
an acceptable occlusal plane 
guidance contacts that allow freedom during closing and lateral movement 
without deflection of the mandible and teeth 
* an acceptable vertical dimension of occlusion and interocclusal resting range. 
Occlusal therapy can be undertaken using occlusal adjustment, restorative 
treatment or orthodontic-orthognathic treatment (McNeill, 1993). 
It is recommended that this therapy should be considered on an individual basis 
to be conducted after the patient has had a significant pain relief and 
improvement in the range of mandibular motion from other treatment 
modalities (McNeill, 1997). Occlusal. adjustment for prevention of TMD 
particularly in young adults and children, is not recommended due to the lack 
of comparative study on this area. Also there is no reliable evidence to prove 
that occlusal interference can cause nocturnal bruxism or remedy it if the 
interferences are removed (Clark et al. 1997). 
Dahlstrom (1992) stated as an overall impression of conservative treatments, that 
well-controlled, randomised clinical studies with well defined diagnosis were still 
needed for a confirmation of the real beneflts of these therapies in several 
subgroups of TMD. 
In the case of a patient who fails to respond to conservative treatments, 
surgicallinvasive treatment is considered. Indications 
for surgery include one or 
more of the following, moderate to severe pain, 
dysfunction that is disabling 
andlor evidence of pathological conditions 
(National Institutes of Health 
Technology, 1996, Dolwick et al. 1997). There is no indication for surgical 
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treatment either for asymptomatic or minimally symptomatic patients or for 
preventive reasons (Dolwick et al. 1997). 
SURGICAL/INVASIVE TREATMENT 
There is a wide range of invasive treatments for TMD from trigger point 
injection to open jaw joint surgery. Injection therapy and arthrocentesis which 
are minor invasive procedures can also be categorised into an intermediate level 
of treatment between non-surgical and surgical treatment. 
Injection therapy 
Injection therapy can be divided into two main methods; intra-articular injection 
for TMJ disorders and trigger point injection for muscle disorders. 
Intra-articular iniections 
A single dose of intra-articular methyl prednisolone trimethylacetate injection 
into TMJs with osteoarthrosis provided complete pain relief and increased joint 
functions in 30 cases out of a total 46 cases at a 6-month review (Toller, 1973). 
The best responses were in the group of over 35 years of age and results in the 
younger age group were poor. 
Kopp and Wenneberg (1981) conducted a 2-year parallel study on patients who 
had tenderness on palpation of the TMJ. Fifteen patients were treated with 
combined intra-articular steroid and local anaesthesia injections once a week for 
three weeks while 18 patients were treated with occlusal therapy. A more 
effective means of improving maximum mouth opening was found in the group 
treated with the injection than the group treated with occlusal therapy. The 
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least improvement after steroid in ection was found in patients who had i 
abnormalities of shape (remodelling) of the condyle on radiographic findings or 
systemic disturbance such as rheumatoid arthritis. According to a review by 
Bush and Dolwick (1995), injections of corticosteroid into the upper 
compartment of the TMJ can produce pain relief particularly in osteoarthritis 
cases. 
Bradley (1987) suggested that the sclerosant 3% sodium tetradecyl sulphate 
injected into lateral aspect of the TMJ capsule could be used in excessive 
hypermobility of TMJ associated with recurrent pain. It was reported that a 
single injection will reduce inter-incisal clearance by about 2-3 mm. Two 
injections separated by about 6 weeks may be necessary in a particular case. 
Trigger point injection 
Injections of local anaesthetic agent into trigger points in the masticatory 
muscles can reduce muscular pain (Graff-Radford, 1984; Bush and Dolwick, 
1995; Gray et al. 1995; Pertes and Gross, 1995). For diffuse muscle pain, 
repeated injections may be required to gain lasting results. However, it has been 
suggested that the injection may be able to produce necrosis of muscle in some 
patients which takes about I month for regeneration (Bush and Dolwick, 1995). 
McMillan and Blasberg (1994) also found a significant increase in pressure pain 
threshold in trigger points of masseter muscles after 0.5 ml of 1% procaine 
injected into active trigger points of 10 myofascial pain patients. 
Arthrocentesis 
This treatment is a procedure to provide lavage and manipulation of the TMJ 
with minimised trauma. This technique may be particularly useful 
for internal 
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derangement of TMJ with closed lock in the acute stage to improve range of 
motion and function and to decrease pain (Dolwick et al. 1997). Dimitroulis et 
al (1995) reported benefits of TMJ arthrocentesis and lavage in 
46 patients in a range of 6 to 30 months follow up. There was a statistically 
significant improvement in the mean maximum mouth opening from 24.6 mm 
(SE = 5.2) to 42.3 (SE = 6). The mean visual analogue score (0-15) for pain was 
decreased from 8.8 (SE = 2) to 2.2 (SE = 0.6) significantly while the score for 
dysfunction was decreased from 10 (SE = 2.1) to 2.7 (SE = 2). 
Arthroscopy 
Arthroscopy was firstly introduced as a tool for investigating structural 
abnormalities of the TMJ. The results of this procedure then showed an 
improvement in range of motion and pain relief. Therefore, arthroscopy, now 
plays an important role in clinical practice particularly in the management of 
chronic closed-lock of the TMJ. Operative techniques involve lavage and lysis of 
adhesions (Dolwick et al. 1997). A four-year follow up study by Murakami 
(1996) in 24 TMJ dysfunction patients with disc displacement 
diagnosed by magnetic resonance imaging (MRI) showed 93.3% success rate in 
terms of pain relief and clinical findings. There were statistical improvements 
in mean maximum mouth opening from 33.0 mm (SE = 4.4) to 38.8 mm (SE = 
5.8), pain score based on VAS from 7.0 (SE = 4.1) to 1.3 (SE = 2.1) and jaw 
dysfunction score from 7.2 (SE = 1.9) to 2.1 (SE = 1.8). 
Interestingly, a randomised comparative study by Fridrich et al (1996) 
comparing the results of arthroscopy and arthrocentesis in 11 and 8 
internal derangement patients respectively showed no statistical difference in 
pain score and mouth opening between the two groups. 
At 6 to 24 months 
review, there were decreases in VAS from 6.5 to 1.7 in the arthroscopy group 
and 6.6 to 2.3 in the arthrocentesis group. Mean maximum mouth opening 
in 
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the arthroscopy group was improved from 30 to 47.5 mm while in the 
arthrocentesis group, it was increased from 33 to 41 nun. 
Denervation procedures 
Bradley (1987) suggested an operation to divide the posterior articular nerves 
with prevention of reinervation by a fascial flap in persistent TMD pain patients 
who do not have radiographic abnormalities of the TMJ or internal derangement 
but fail to response to conservative treatments. This procedure could give 
lasting pain relief in suitable cases. It was a useful addition to operations 
intended to free a trapped meniscus such as the Toller capsular rearrangement 
procedure if pain was a prominent symptom. Cryosurgery to the articular nerves 
is an alternative although reinnervation will occur after approximately 6 
months. 
Condylotomy 
Condylotomy is a surgical procedure to increase the joint space, without 
interfering with the articular compartments, by sectioning bone at the condylar 
neck. This procedure has been used for management of painful TMJ 
dysfunctions and arthritis TMJs (Bush and Dolwick, 1995; Upton, 1997). 
According to extensive reviews by Bush and Dolwick (1995) and Upton (1997), 
condylotomy techniques are categorised as follows: - 
Closed condylotomy A subcondylar cut is made through the neck of 
the condyle through stab incisions allowing introduction of a 
Gigli saw. 
There may be a potential for haemorrhage and injury of the 
facial nerve by 
using this method though these complications are uncommon. 
49 
Open condylotomy A preauricular approach is used to gain an 
access for the condylar neck section. 
Modified condylotomy : The lateral aspect of the mandibular ramus is 
exposed through a transoral, incision. A vertical cut extending from the 
sigmoid notch to the angle is made parallel to the posterior border of the 
mandible. 
Recently, Upton (1997) reported the results of modified condylotomy for 
management of painful TMD with reducing disc displacement diagnosed by 
symptomatology and arthrographic findings in 34 patients. The results from 6 
months follow up showed moderate to complete pain reduction in 85% of cases 
and relief of clicking in 94%. There was 100% success rate in terms of relief of 
locking. 
Open jaw joint surgery 
The usual approach to the TMJ is exposure of the joint capsule particularly the 
upper compartment via a preauricular incision. There are various operations 
from simple lavage and debridement of the j oint to complete removal of the 
disc. The commonest procedures are disc repositioning and discectomy. Disc 
repositioning is the management for internal derangement. Discectomy is 
performed in cases where the disc is found to be diseased or structurally 
compromised as a result of tears, perforations or persistent symptoms of pain 
and dysfunction after previous disc surgery. Arthroplasty is the procedure to 
recontour the articular eminence or condyle in cases of gross mechanical joint 
interference and advanced degenerative joint disease (Dolwick et al. 1997). 
so 
Some studies concerning the efficacy of surgical treatment on TMD are reviewed 
as follows: - 
A retrospective study by Eriksson and Westesson (1987) on post-operative 
follow up between 6 months and 20 years after discectomy in 69 TMJ 
dysfunction patients (36 anterior disc displacement patients) showed good to 
acceptable results in 72% of cases and bad results in 28% of cases. Seventy four 
percent of patients had a decrease in pain frequency and intensity. 
In a study by Dolwick and Nitzan (1990) with 8 years follow up of 152 internal 
derangement patients who had disc repositioning, there were 52% and 28% of 
cases with excellent and good results respectively. Nonetheless, 5 to 10% of 
patients had no improvement or worse dysfunction of the TMjs after operation. 
Upton (1997) reported mild to moderate pain relief in 46% of patients after disc 
repositioning for internal derangement. Relief of locking and clicking was S8% 
and 61% respectively. In the same paper, a comparative study of the outcomes 
was reported between 34 disc repositioning and 34 condylotomy cases. It was 
found that the patients who had undergone condylotomy were significantly 
better than those after disc repositioning procedure in terms of pain, clicking 
and locking. There was no significant difference between the two treatments in 
limitation of movement and muscle pain. 
Stassen and Currie (1994) conducted a pilot study on the use of eminectomy in 
management of closed lock in 18 patients. The results from a 7-month follow 
up when compared with baseline showed statistically significant decrease in 
mean VAS pain scores from 74.3 to 20.7 and improvement in mean inter incisal 
distance from 21.7 mm to 39.6 mm. 
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Overall perspective on TMD management 
A long term result of treatment for TMD was presented in a prospective study 
by Mejersjo and Carlesson (1983) on 208 TMD patients. 7-year subjective and 
clinical outcomes from various conservative treatments such as counselling, 
occlusal adjustment, exercises, physiotherapy, orthopaedic appliances, 
pharmacotherapy and chemical injections were compared with baselines. 
Symptom score at the baseline for two thirds of the patients was classified as 
severe pain while 84% of patients reported nil or mild symptoms after 7 years. 
From the end of initial treatment until the 7-year follow up, 80% of patients had 
no symptoms or only occasional mild symptoms while 11% had occasional 
severe symptoms or constant pain. From this point, it should be noticed that a 
definition of initial treatment was not clearly mentioned. The clinical 
examination at the 7-year follow up still showed that muscle tenderness and 
impaired TMJ function was the most common residual clinical finding. 
However, there was a statistically significant decrease in clinical index at the 7- 
year result compared with baseline. 
There was an interesting retrospective study by Upton and Barber (1991) on 
173 internal derangement and TMJ arthralgia patients. The treatments used in 
this study were categorised into active non-surgical treatment such as 
physiotherapy, soft-diet and orthopaedic appliances, passive non-surgical 
treatment such as ibuprofen, moist heat, biofeedback and stress counselling and 
surgical treatment. Comparing relief of TMJ symptom scores at 2 to 4 years 
follow up, the most distinct improvement was found in the group with a 
combination of active and passive treatments plus surgical treatment. 
According to the above review of management for TMD, conservative treatments 
or non-invasive and reversible techniques are considered to be the 
flrst treatment 
choices for TMD. Surgical treatment is reserved for the patients who 
have failed 
to respond to conservative treatments. Combined treatments seem to provide 
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more benefit than single treatment . Well designed studies are still necessary to 
prove not only the real benefit of many treatments but also their specificity to 
subgroups of TMD. In order to evaluate the response to the treatment, reliability 
and validity of assessment for TMD patients are crucial and will be considered in 
the following section. 
ASSESSMENTS OF TREATMENT RESULTS FOR TMD 
The most effective methods of measuring outcome of treatment for TMD are 
multidimensional measurements. An objective measure of pain and dysfunction 
is also required to establish the validity of changes in the subjective symptoms 
(Fricton and Dubner, 1995 b). Apart from assessments using clinical 
examinations, there are a number of subjective and objective assessments for 
TMD. 
Pain questionnaires such as the symptom severity index (SSI) based on visual 
analogue scale and the McGill pain questionnaire play important parts in the 
subjective assessment. Objective measurements need validity and reliability of 
clinical examination methods and frequently special apparatus such as 
algometer, electromyography (EMG), mandibular kinesiology using jaw tracking 
and sonography of temporomandibular joint sound records. Cooper (1997) 
reported a case series of 1181 TMD patients assessed by EMG and jaw tracking 
in various applications before and after treated by TENS and occlusal therapy. It 
was found that these electronic devices were useful to detect progress of 
patients in relation to clinical symptoms. However, the prime purpose of using 
those electronic devices as mentioned above needs to be emphasised; this is to 
be for assessing or detecting the progress of a patient's response to treatments 
and not for diagnosis. 
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Measurements and instruments used for assessments of the treatment outcome 
of TMD particularly for research in this area are summarised as follows: - 
Subjective symptom measures 
Subjective components should be multidimensional in nature and include 
sensory and affective intensity, frequency and duration of symptoms, number of 
different symptoms as well as tolerability of symptoms (Fricton and Dubner, 
1995 a; LeResche, 1997). In terms of pain assessment, LeResche (1997) 
mentioned the components of pain assessments for TMD as follows: - 
pain perception using measurements such as self-report, verbal descriptor 
scales, visual analogue scales and numerical rating scales. 
* pain appraisal using measurements such as Beck Depression Inventory, 
Spielberger State Trait Anxiety Scales and Symptom Checklist-90 
9 pain behaviour; evaluation of activity level and expressive behaviour such as 
facial expression, pain related modification of motor behaviour 
* social roles using measurements such as self-report, graded chronic pain 
scale and the multidimensional pain inventory 
e pain satisfaction (the standard has not been established yet. ) 
Multidimensional measures are recommended. Standard Research Diagnosis 
Criteria for TMD is the one of the combination of various types of pain 
assessments (LeResche, 1997). For the routine pain assessment of 
TMD pain, 
Symptom Severity Index (SSI) and McGill Pain questionnaire are suggested 
instruments (Fricton and Dubner, 1995 a). 
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Objective measures 
Alqomeer 
The algometer is a device used for measuring the pressure pain threshold (PPT). 
The unit of PPT employed depends upon the type of algometer. It is in 
kilograms per square centimetre (kg/cm1) for the mechanical algometer and 
kilopascals (kpa) for the electronic algometer. 
There have been a number of studies showing the acceptable reliability and 
validity of pressure pain threshold measured by algometer in specific muscle 
sites in normal subjects (Jensen et al. 1986; Fischer, 1987 a; Ohrbach and Gale, 
1989 a) and patients suffering from musculoskeletal disorders Uaeger and 
Reeves, 1986; Reeves et al. 1986; Ohrbach and Gale, 1989 b). From an extensive 
review by Clark et al (1993) based on the studies by Jensen et al (1986), Fischer 
et al (1987 a), Fischer et al (1987 b) and Lest et al (1989) good-to- excellent 
intra- and inter-examiner reliability was reported for the assessment of 
pressure-pain threshold and muscle tenderness. PPT has been used for 
assessment of the outcome of treatment for trigger points in masticatory 
muscles (Graff-Radford et al. 1989; McMillan and Blasberg, 1994). 
The following are notifications from the previous studies concerning the 
applications of the algometer. -- 
e Numbers of measurements 
Ohrbach and Gale (1989 a) studied the PPT in normal temporalis and masseter 
muscles. They found that the mean of the first 
2 measurements at each site 
gave a better estimation of PPT than a single measurement. 
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0 Sizes of tips 
The majority of studies in head and neck areas tended to use aI cm diameter 
tip or approximately 1 CM2 tip (Jaeger and Reeves, 1986; Reeves et al. 1986; 
Graff-Radford et al. 1989; Fischer, 1987 a; Ohrbach and Gale, 1989 a; Ohrbach 
and Gale, 1989 b; Jensen et al. 1988; Bovim, 1992; McMillan and Lawson, 1994). 
Jmsen et al (1986) found that PPT was relatively less with the larger tip. McMillan 
(1995) used a 4.8 nun diameter tip to measure PPT of human gingivae. 
* Rate of force application 
Jensen et al. (1986) studied the normal temporalis muscles applying various rate 
of force. It was found that the PPT was higher if the rate of force was increased. 
Therefore, constant pressure is crucial for the reliability and validity of 
measurement. The optimum rate of force was recommended at 7 kpa per 
second. This rate of force was claimed not to take a long duration to reach the 
threshold so that damage to muscle did not occur. On the other hand this rate 
was slow enough for subjects to detect the threshold precisely. 
9 Activity of muscle 
McMillan and Lawson (1995) found that the PPT of masseter and temporalis 
muscles was increased corresponding to the magnitude of tooth clenching in 
normal subjects while degree of opening did not effect PPT. Slight clenching 
(tooth contact position about 10% maximum voluntary clenching) was 
recommended. 
9 Matched control muscle for PPT 
Ohrbach and Gale (1989 b) reported that there was no statistically significant 
difference of PPT between the no-pain control site and primary pain site in the 
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same muscle while PPT was significantly lower at the pain site compared with 
the no-pain control in contralateral muscle. Therefore, a contralateral control 
site is indicated. 
* Landmark of PPT measurement 
The landmarks for PPT measurement on masticatory muscle are also important. 
McMillan and Blasberg (1994) detailed the optimal landmarks in masseter and 
temporalis muscles in their control study on the effect of trigger point injection 
on PPT. 
FMG 
EMG has been used under the assumption that dysfunctions of the masticatory 
system such as postural hyperactivity, abnormal occlusal positions, functional 
hyperactivity and hypoactivity, muscle spasm, fatigue and muscle imbalance, 
can be detected by the EMG activity of the masticatory muscles (Mohl et al. 
1990). According to some extensive reviews, the reliability and validity of EMG 
especially surface EMG is still not adequate particularly for diagnostic purposes 
to identify TMD patients from normal subjects (Mohl et al. 1990; Mohl, 1993). 
Some experiments have not been able to prove the differences of EMG in rest 
and clenching positions between TMD patients and normal subjects (Lund and 
Widmer, 1989; Rugh and Davis, 1990; Schroeder et al. 1991). These results led 
McNeill (1993) to state that EMG is at least useful as a measure of functional and 
postural acts. However, EMG can be useful for studies of reflex activity and 
nerve conduction and for the assessment of parafunctional behaviour in 
patients. 
In contrast, there have been still some recent works which find different 
patterns in EMG for TMD patients in comparison with normal subjects. Gay et al 
(1994) studied the characteristic of muscle fatigue in 17 myofascial pain TmD 
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patients compared with 15 normal subjects using surface EMG. An incisal bite 
force level of 10 N was used as a model to produce the muscle fatigue. The 
decrease in mean power frequency of EMG in the TMD patients was significantly 
greater than in the control group. Kumai (1993) reported an imbalance of EMG 
(integrated EMG ratios) at maximum clenching in masseter and temporalis 
muscles in unilateral TMD patients while there was no such obvious evidence in 
normal subjects. 
The surface EMG has standardly been used as the instrument for evaluation of 
the response of muscle activity in TMD patients after treatment. Holmgren et al 
(1985) described the influence of posture on the EMG record of temporalis and 
masseter muscles in TMD patients when the mandible was in the rest position 
(postural activity). In the supine position, postural activity particularly in 
temporalis muscle was less than in the upright position. Sheikholeslam et al 
(1986) conducted a study on postural activity in a group of patients after they 
had hard occlusal splint treatment. The difference in postural activity of EMG 
was reduced in both temporalis and masseter muscles after treatment. 
Carlson et al (1993) conducted a cross-over trial on 15 TMD patients comparing 
the mean EMG of temporalis and masseter muscles when the patients were 
clenching on two types of muscle relaxation appliances and cotton roll. A 
statistically significant difference of mean EMG clenching was found on the 
cotton roll which was higher than for the two types of appliances while there 
was no statistical difference of mean EMG clenching between the two types of 
appliance. 
Two studies by Copper et al (1991; 1997) in large sample sizes 
(641 and 1181 
patients respectively) reported the statistical correlation 
between a decrease in 
electrical activity of masticatory muscles at rest plus change of 
EMG in 
maximum voluntary clenching and reduction of symptoms. 
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Although the reliability and validity of EMG has been in doubt in terms of using 
this device as a diagnostic tool, using FMG for comparing muscle activity within 
patients can provide some meaningful information along with other assessments. 
Mandibular King9qLqa 
Limited jaw opening is commonly seen in TMD patients. Measurement of 
maximum pain-free, maximum unassisted and maximum passive opening range 
of mandibular movement is an essential element in clinical assessment (Clark et 
al. 1993). According to an extensive review of devices for the diagnosis and 
treatment of TMD, an electronic jaw tracking instrument is a useful means to 
measure the range of mandibular movements and the velocity of voluntary jaw 
movements (Fricton and Dubner, 1995 b; Cooper, 1997). Cooper (1997) 
recording free way space in vertical, frontal and sagittal plane in 1182 TMD 
patients before and after treatment with TENS, found that the average free way 
space was increased by 1.68 mm in vertical plane, 0.16 nun in frontal plane and 
0.48 nim in sagittal plane after the treatment. jaw tracking combined with EMG 
has been suggested to be useful in the assessment of mandibular function 
during chewing activity in subjects with and without jaw dysfunction (Howell et 
al. 1992). The reproducibility of this recording was tested in 20 normal subjects 
(Howell et al. 1993). All subjects differed in their chewing movements from one 
another. However, 15 subjects from 20 subjects showed good inter and intra 
recording reproducibility. 
SonQgraphy 
There are three methods to detect joint sounds namely; digital palpation, 
stethoscope auscultation and sonography (Clark et al. 1993). 
Sonography is the 
technique of recording and graphically representing joint sounds (McNeffl, 
1993). Prinz (1996) conducted an intensive study on TMJ sounds using 
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sonography and found that the interpretation and differentiation of TMJ sounds 
depended on their behaviour under the variables of load and speed. However, 
the clinical significance and reproducibility of sounds emanating from the TMJ 
are not clear as means of assessment of treatment of TMD (Toolsen and 
Sadowsky, 1991). 
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LOW INTENSITY LASER THERAPY (LILT) 
Lasers are named according to their abilities to emit a constant radiation of a 
known wavelength. The wavelength is measured in nanometers (nm) or microns 
(ýLm); I ýtm equals 1,000 nim. Nowadays, the HeNe gas laser (632.8 nm, the 
infrared (IR) GaAlAs (820-830 rum) and GaAs diode (904 Dm) lasers are typical 
lasers employed in LILT (Basford, 1995). 
Recently, there have been two meta-analyses concerning the efficacy of LILT on 
musculoskeletal pain. Gam et al (1993) conducted a meta-analysis on 23 LILT 
published papers from 1987 to 1988. Of these, 17 were controlled trials, 10 
double blind trials and 7 insufficiently blinded trials. The conclusion based on 
the double blind trials was an 0.3% (SE =4.6%) mean difference in pain between 
LILT and placebo in favour of LILT. In the insufficiently blinded trials, the mean 
difference in pain was 9.5% (SE 4.5%). These results led the writers to state that 
LILT had no demonstrated effect on pain relief in musculosketetal disorders. 
However, a similar meta-analysis by Beckerman et al (1992) on 36 randomised 
clinical trials from 1985 to 1990 showed that the efficacy of LILT for 
musculoskeletal disorders seems to be greater than the efficacy of placebo. The 
crucial point was raised about insufficient design in the majority of trials on 
LILT. Further investigation on effective dose could not be concluded due to the 
lack of information about energy density. Therefore, it was suggested that trials 
on LILT should avoid this methodological error and that the effective dose of 
LILT for musculoskeletal pain still needs to be established. 
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Ohshiro et al (1994) suggested some critical considerations in protocol design 
for investigation of LILT on pain control as follows: - 
" Trials should be double blinded. 
" Using inactive laser as a placebo 
"A comprehensive record in terms of subjective and objective outcomes 
should be sufficient. 
As reviewed, the overall outcome of LILT on musculoskeletal pain is still a 
potential area for investigation not only its efficacy but also of appropriate 
regimes. A double blind trial with placebo control is the recommended protocol 
to explore these points. Regarding the effect of LILT on TMD pain, relevant 
studies will be reviewed in the following section on roles of LJLT in TMD 
treatment. Protocol and results of those studies will be discussed on the basis 
of wavelength, dosage and application. Relevant studies on the biological effect 
of LILT on pain will reviewed in the section on mechanism of LILT. 
ROLES OF LILT IN TMD TREATMENT 
A number of clinical studies have reported the role of LILT in pain related to 
TMD. LILT with near infra-red radiation in the range of 820 nm, was shown in 
an uncontrolled clinical trial to provide significant relief of pain and of 
dysfunction, in approximately 60 % of cases (Bradley and Reynolds, 1994). 
Moreover, changes in eletromyographic recording (EMG) of irradiated 
masticatory muscles were observed after LILT in over 88% of treated cases 
(Rehbini, 1995). The most frequently encountered group of such patients were 
those with chronic facial arthromyalgia, where symptoms had been present for 
more than 8 weeks. In these subjects, LILT was found to be particularly effective 
when combined with an auxiliary method of treatment, particularly splint 
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therapy (Bradley and Rehbini, 1995), although the precise mechanism of each 
component of therapy has not yet been researched. 
There appear to be few studies of LET confined to TMD but other research on 
musculoskeletal pain in head and neck areas has been published. Studies on the 
analgesic effect of low intensity treatment on musculoskeletal pain in head and 
neck regions from 1966 to July 1997 were, therefore, recruited by including the 
subtypes of musculoskeletal pain in the orofacial area based on the categories 
by Okeson (1995): - 
muscle pain, 
e TMJ pain, 
o osseous and periosteal pain, 
* soft connective tissue pain 
9 and dental pain of periodontal origin. 
An Overview of published studies is given in table 2. 
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Some of the tabulated studies reported successful outcomes following LELT used 
for musculoskeletal pain control and a few obtained no success. The variables 
in these studies can be described in terms of; effective wavelength, efficient 
dosage and suitable application. 
Wavelength 
A variety of wavelengths have been reported for the same purpose; these tended 
to be visual red Helium Neon (HeNe) at 632.8 nm and Gallium Arsenide (GaAs) at 
904 nm going to Gallium Aluminium Arsenide (GaAlAs) at 820-830 nm in later 
reports. A double blind experiment using the LILT in the surgical removal of 
impacted lower third molar model showed no significant effect of HeNe laser on 
reduction of post-operative pain and swelling but trismus measurement was 
found to show a significant reduction in both the HeNe laser and the ibuprofen 
treatment groups (Carrillo et al. 1990). Fernando (1993) using GaAlAs (830 nm) 
laser for the post-operative sequalae of impacted teeth removal still found no 
benefit of LILT in pain reduction and swelling. A study by Roynesdal et al (1993) 
on the influence of GaAlAs on post-operative pain from impacted tooth removal 
showed statistically significantly less pain score in the laser group compared 
with the placebo at 6 hours and 2 days postoperation although they concluded 
that there was no overall benefit of LILT in pain control. 
GaAlAs 830 nm laser was found to reduce visual analogue scale (VAS) median 
scores in subjects undergoing orthodontic tooth movement, even though, there 
was no statistical difference between the treated and placebo groups (Lim et al. 
1995). The study by Shimizu et al (1995) confirmed the above results. An in 
vitro study by these workers found that GaAlAs could inhibit Prostaglandin E2 
(PGE2) production in a cell culture model using stretched human periodontal 
ligament ceRs. 
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LILT has been shown to be effective for myofascial trigger point treatment in the 
neck and back muscles. A double-blind controlled study in 24 patients showed 
both a statistically significant reduction of pain and an increased skin resistance 
of trigger points in the group irradiated with a 0.95 mW HeNe constant wave 
(CW) laser (Snyder-Mackler et al. 1989). Similarly, the study on 18 subjects by 
Olavi et al (1989) found that the 904 mW IR laser irradiation significantly 
increased pain thresholds of trigger points. In addition, Laakso et al (1994) 
reported the accumulative increase in beta-endorphin after 820 inm laser 
treatment on trigger points in the neck, shoulders and upper thoracic regions at 
certain energy parameter which was 5 J/cml . 
Benefits of LELT on the relief of TMD pain appear to be favourable. Bezuur et al 
(1988) found that the 904 nm laser could improve the mouth opening in an 
arthrogenous group. Gray (1994) found that 904 m-n laser produced the larger 
number of TMD pain patients who had clinical improvement at a 3-month review 
by comparison with the placebo group. Rehbini (1995) reported in a change of 
EMG findings of the masticatory muscles after 820 nm GaAlAs irradiation of 
painful masticatory muscles in 88% of subjects. Moreover, Conti (1997) found 
that GaAlAs had an effect of pain reduction in a myogenous group and 
improvement in mouth opening in an arthrogenous group. 
There was a double-blind cross over study on chronic oro-facial pain patients 
treated with 904 rim laser (Hansen and Throroe, 1990). This study failed to 
show any benefit of LILT in pain relief. However, it should be noticed that one 
of the inclusion criteria for this study was chronic oro-facial pain patients who 
did not have demonstrable pathology responsible for the pain. The majority of 
subjects were oral dysaesthesia patients (burning tongue) so that there was no 
relationship to myofascial pain. 
From the above review, 830 nm GaAlAs tended to provide more effective results 
on pain control in head and neck areas than the other wavelengths. Ohshiro 
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and Calderhead (1988) supported the efficacy of GaAlAs as the wavelengths of 
830 nrn is extremely near the optimal wavelength for peak penetration of tissue. 
Overall from the review of the above studies, LILT especially GaAlAs (820-830 
nm), tended to be more effective for muscle pain such as trigger points and TMJ 
pain rather than for osseous and periosteal pain such as post-operative pain from 
impacted tooth removal. This wavelength appeared to have the best potential for 
a trial on TMD pain. 
Dosage 
The standard protocol to define LILT dose is still not agreed and unclear. Baxter 
et al (1992) suggested that the dose of LILT can be defined by energy density 
which involves power density times treatment time. The unit of measurement is 
Joules per square centimetre U/cm'). 
Response to laser treatment appears to follow the classical principle of a 
biological reaction to expended energy namely; the hypothesis of Arndt-Schultz. 
This states that in a biological system, weak stimuli will elicit strong reactions, 
medium stimuli will cause moderate reactions, moderately strong stimuli will 
slightly inhibit the system and very strong stimuli will completely retard it 
(Ohshiro and Calderhead, 1988). The rule implies that the higher the energy 
density, the greater will be the tendency to reduce or retard the pain. 
Accordingly in comparing the results of the three clinical trials on the effect of 
LILT on post-operative pain after impacted tooth removal (table 2), the study 
using the highest power and energy density (Roynesdal et al. 1993) showed a 
more favourable effect than the others (Carrillo et al. 1990; Fernando et al. 
1993). 
In practice, laser therapy has typically involved the delivery of between 1-4 J/Cnl2 
to treatment sites with lasers having output powers between 10 mW and 90 mW 
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(Basford, 1995). Ohshiro and Calderhead (1988) stated that GaAlAs penetrated 
deeply at output powers of around 60 mW with an oval spot size of 2 mm xI 
nim. They suggested irradiating points for rheumatic pain relief with a power 
density calculated as 3.82 W/cm' making about 11.46 J/cml of energy density. 
Baxter et al (1992) suggested energy densities at 8 to 12 J/cml for TMJ pain. 
However, Arao et al (1995) using low power Nd: YAG laser at 350 mW for 15 
minutes at a much high energy rating of at least 3 15 joules per point found that 
even in chronic cases with internal derangement in the form of anterio-medially 
displaced menicus, there was a much improved response rate with a success 
rate approaching 100% in a small group of 15 patients. As reviewed above, the 
regimes for musculoskeletal pain control may be categorised into two groups 
namely low and high energy densities. 
Application 
The method of application is as crucial as the dosage. Baxter et al (1992) stated 
that the most effective method for applying the laser is to use a medium 
pressure to a cluster of points around and over the affected joint. One needs to 
be careful to ensure that the probe is appropriately angled for treatment of the 
joint; normally this should be at right angles. Bezuur (1988), irradiating a near 
infrared laser to TMJ areas, reported an improvement of maximum mouth 
opening in the arthrogenous patients but not in myogenous patients. A study 
by Rehbini (1995) showed a positive clinical benefit and changes in EMG after 
820 nim laser irradiation of the TMJ, sigmoid notch and trigger points in the 
masticatory muscles. It was suggested that the slight pressure of application 
wiH disperse tissue fluid aiding penetration and that a perpendicular angle of 
application will minimise reflection of the laser beam from the skin surface. 
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MECHANISMS OF LILT 
Baxter et al (1992) stated that LILT plays a part on the neurophysiology and 
neuropharmacology of pain. The mechanisms of LILT particularly the observed 
analgesic effect is still a matter for discussion. The following mechanisms have 
been described: - 
Neurophysiology of pain 
Kudoh et al (1988) measured the activity of Na-K-ATPase complex via K- 
dependent p-nitrophenyl phosphatase (K-NPPase) activity of rat saphenous nerve 
in the normal situation and after irradiation by GaAlAs laser at 60 mW with a 
variety of energy densities. On the basis of histochemical and biochemical 
assays, K-NPP-ATPase activity of the Na-K-ATPase complex in the myelinated 
nerve was increased in response to the range of low energy densities and vice 
versa to the high energy densities. This pattern of stimulation with low energy 
and inhibition with high energy conformed to the Arndt-Schultz hypothesis. 
There have been a number of studies on the neurophysiology of LILT in relation 
to nerve action potentials using electrophysiological techniques. Mezawa et al 
(1988) conducted an experiment on a single-unit of heat nociceptor of the 
lingual nerve of cat tongue using a GaAlAs semiconductor laser (904 nm at 3040 
Hz) in a variety of energy densities. Firing frequencies of the action potential 
following heat stimulation were decreased in the irradiated group by 
comparison with the control group. The most distinct effect was found with the 
higher energy densities of irradiation. The hypothesis was drawn that LILT 
irradiation could have an analgesic effect on tongue pain. Due to the fact that 
the reduction in firing rate was stable with in 5 to 10 min of laser irradiation, a 
plateau reaction at a range of energy densities was also suggested. 
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On the other hand, Jarvis et al (1990) studied the effect of 632.5 ]rim HeNe at 4 
mW for 20 second, on receptors in rabbit cornea (which was claimed to be equal 
to 1 mW for 20 seconds irradiated on the skin according to a thermodynamical 
model calculation) on peripheral A delta and C-fibres. There was no influence 
on the nerve activity either in normal activity or nerve activity after mechanical 
stimulation during irradiation at 5 to 10 minutes after irradiation. However, 
Baxter et al (1992) pointed out that the thermodynamic model calibration used 
might not be able to reflect the exact dose of LILT due to the non-thermal effect 
of this therapy. 
Walker and Akhanjee (1985) conducted an in vivo study investigating evoked 
potential at Erb's point stimulated by irradiation of the skin overlying the 
median nerve at the wrist in 10 humans with 632.5 inm HeNe at I mW 3.1 Hz. 
There was statistically no significant difference of the means of latencies 
between electrical stimulation and laser irradiation. However, the laser induced 
potential showed lower amplitude than electrical stimulation. A control 
experiment was set up to prove that the electrical equipment used in the 
experiment and constant pressure from the laser probe could not produce an 
evoked potential. Moreover, it was found that the prolonged laser irradiation at 
4800 pluses and 3.1 Hz resulted in a remarkable depression in the amplitude of 
the electrical evoked potential compared with the amplitude prior to laser 
exposure. This result could not be obtained after up to 800 shocks of 
suprathreshold electrical stimulation. The results implied that peripheral nerve 
had a photosensitivity to the lower level laser which was relevant to therapeutic 
applications. Nevertheless, Wu et al (1987) using the protocol of Walker and 
Akhanjee (1985) failed to evoke a neural potential by laser irradiation. Baxter et 
al (1992) raised the points of the difference of laser dosages 
between the two 
experiments in terms of laser pulsing and also queried a possible electrical 
artefact inherent in the recording device or even the 
laser shutter. 
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Snyder-Mackeler and Bork (1988) conducted a double-blind controlled study in 
40 subjects and found that aI mW HeNe laser percutaneous irradiation 
propagated superficial radial nerve distal latencies. A duplicated experiment by 
Basford et al (1990) on the effect of bilateral superficial radial nerve and right 
median nerve irradiation failed to show significant differences between the 
irradiated and the control groups in terms of amplitudes, distal latencies and 
forearm skin temperature. 
There have also been some studies on the effect of GaAlAs 830 nm on 
conduction latency. Lowe et al (1994) studied antidromic conduction in the 
human median nerve irradiated with 830 inm at various energy densities from 
1.5 to 12 J/cml at 10 areas along the nerve. A statistically significant increase in 
negative peak latency difference scores implying a decrease in conduction 
velocity was found in the group irradiated with 830 nim at 1.5 J/CM2 in 
comparison with the no intervention control group. The higher energy densities 
showed either only initial effect or no effect on conduction latency. The skin 
temperature of the group irradiated with 830 m-n at 1.5 J/cml was significantly 
lower in comparison with the control. Baxter et al (1994) conducted an in vivo 
experiment on the antidromic conduction latencies of the median nerve using a 
variety of laser, placebo and control groups with two-site recording distal to 
irradiated sites. It was found that 830 nm at 9.6 J/cml was able to increase 
latency by about 0.4 ms while the other parameters showed no such an effect. 
Therefore, the conclusion was drawn that the above laser parameter irradiating 
intact skin might induce a direct, localised effect on conduction in underlying 
nerve. 
However, double blind trials on the analgesic effect of LILT irradiation of Erb's 
point on experimental ischaernic pain by Mokhtar et al. (1995) using combined 
monochromatic laser (660-950 nm at 31.9 J/cml) and by Lowe et al (1997) using 
830 nm at 1.5 and 9 J/cml did not show a distinct pain reduction as evidenced 
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by VAS and McGill pain score in the LILT group by comparison with the placebo 
group. 
NeuroPharmacology of pain 
Some pharmacological substances have been proved to be influenced by LILT as 
follows: - 
Serotonin: 
One of the substances that has been considered in relief of pain is serotonin. 
Walker (1983) using a helium neon laser, reported an increase in urinary 5- 
hydroxyindoleacetic acid (5-HLAA), a metabolite product of serotonin, in patients 
who had symptomatic relief of chronic pain disorders in the head and neck. In 
contrast, Hansen and Throroe (1990) found a significant increase in 5-HLAA 
excretion in the placebo group in a double blind placebo controlled cross-over 
study of LILT using 904 rim in 40 chronic oro-facial pain patients. The 
relationship between serotonin and LILT is still unclear, not only from the 
diversity of published results but also due to the complicated functions of 
serotonin itself. Serotonin has various functions depending on the types of 
serotonin receptors found on the cell. Only one type of receptor in the brain can 
respond although it is known that 5-HT is implicated in inhibitory pain 
pathways. The 5-HLAA content in urine is used merely as an index of the rate of 
serotonin metabolism in the body (Ganong, 1995). The level of 5-HLAA in urine 
may not be able to reflect directly the activity of serotonin in the central 
nervous system nor on pain. Thus, it is not appropriate to infer a correlation 
between 5-HLAA and pain relief after LILT on present evidence. 
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, ndorvhin: 
The other interesting substance postulated for the LILT mechanism is beta- 
endorphin. A study by Laakso et al (1994) in 56 chronic myofascial pain patients 
investigated ACTH and beta-endorphin release into the blood steam in 
relationship to LILT regimes of 820 nm IR GaAlAs at 25 mW, 670 nm (red light) 
at 10 mW and 660 nm-monochromatic (red) light emitting diode at 9.5 mW, in 
two dosages of I J/CM2 and 5 J/cm'. It was explained that ACTH and peripheral 
beta-endorphin levels would be possible reflections of a central response to 
peripheral stimulation with LILT. Beta-endorphin was noted to be significantly 
elevated between days one and four in the subjects who received 5 J/cm2 of the 
infra-red laser at 820 inm. Ohshiro and Calderhead (1988) hypothesised a role of 
LILT in the production of endorphins and also of prostaglandins. Endorphin 
released from pituitary sites is triggered by pain stimuli. This substance works 
in the cerebral cortex to block pain reception. Prostaglandins can accelerate 
synaptic reaction to pain stimuli. Therefore, prostaglandins can be an 
antagonist of endorphins. It was hypothesised that LILT could increase 
endorphin production and inhibit prostaglandin synthesis. 
Prostaglandins: 
Naveh et al (1991) reported that the 632.8 nm HeNe laser at 15 mW for 2 
minutes inhibited the enhancement of prostaglandin E2 (PGE2) and leukotriene 
B4 production in crushed optic nerves of animals. Similarly, Shimizu et al 
(1995) studied the effect of 60 mW GaAlAs 10.8-36.0 j on irradiation of 
stretched human periodontal ligament (PDL) cells. The increase in PGE2 and 
interleukin I-beta produced by stretching was significantly inhibited in the laser 
treatment groups while the control showed remarkable elevation of both 
substances. Thus, the analgesic effect of LILT may be explained 
by alteration of 
arachidonic acid metabolism associated with PGE2 production. 
Due to the 
hypothesis that PGE2 may be released in myofascial trigger points (Travell and 
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Simons, 1983; Frost, 1986), a mechanism of LILT on musculoskeletal pain relief 
may be explained by the local inhibitory effect of LILT on PGE2 release as found 
in the tissue experimental models. 
In vitro correlates: 
Much greater control over change in the variables of light, power, time of 
exposure can be obtained under laboratory conditions by comparison with the 
clinical setting. Techniques used have included cell cultures. A number of 
studies on low intensity lasers in vitro showed a change in the activities of cell 
as a result of certain exposures. Karu et al (1995) measured the ATP level in 
proliferating and non-proliferating HeLa cells after being irradiated with 632.8 
nm HeNe laser 100 J/mI for 10 seconds. The ATP level increased significantly in 
the log phase of growth of the cultured cells but not significantly in the lag 
phase of growth of the same cells. The enhanced ATP production was found 
within 15 minutes and post treatment reaching a maximum in 20 minutes 
before decreasing slowly to the control level. Similarly, Ricevuti et al (1989) 
found HeNe laser at 4J induced increases in ATP release and granulocyte 
aggregation in peripheral blood leukocytes from healthy subjects. The HeNe 
laser has also been reported to accelerate the repair of y-radiation damage in 
irradiated HeLa cells with 632.8 nm HeNe laser 100 J/m2 for 60 or 180 min. 
There was no significant effect during a5 min exposure (Karu et al. 1995). 
Not only the HeNe laser which comprise monochromatic visible light but also 
the near infrared light range lasers have been found to affect biochemical 
activity. Herbert et al (1989) reported increases in the amount of ATP in 
irradiated human peripheral lymphocytes with the 820 nm laser. The 812 nm 
laser 450 mJ/cm2 can induce increased DNA synthesis in human oral mucosa 
fibroblasts in vitro (Loevschall and Arenholt-Bindslev, 1994). 
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As in the above review, the alternation of biological substances and cellular 
activities due to low intensity laser (varying in relationship to the ordinary 
activities of cells and parameters of exposure) needs to be studied in order to 
understand the mechanism of of LILT in clinical work. In vitro study of skeletal 
muscle cells in relation to LILT is a potential area of investigation. In order to 
understand the analgesic mechanism of LILT on musculoskeletal pain of TMD, 
an in vitro study on the influence of LILT on alterations of pain substances such 
as prostaglandins in skeletal muscle will no doubt provide a relevant avenue for 
exploration. 
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SKELETAL MUSCLE CELL CULTURES 
There are various methods that have been described to culture skeletal muscle 
cells. The differentiation and activities of the cultures not only depend on a 
myogenic component but also on neurogenic and humoral components. 
Differences of specific gene expressions can be found between adult innervated 
muscle and myotube cultures (Sturek, 1987). There are a number of studies on 
rat and avian muscle cultures confirming the differences of myosin heavy chain 
between adult skeletal muscles and cultured muscle cells (Whalen et al. 1981; 
Bader et al. 1982; Periasamy et al. 1984). Therefore, complex methods such as 
tissue culture and co-culture (neurogenic and myogenic culture) normally need 
to be undertaken in order to obtain adult myotubes. 
However, since the C202 mouse skeletal muscle cell line was originally cloned 
by Yaffe and Saxel (1977), there have been a number of studies concerning the 
gene expression of this cell line because of its self-differentiated ability. These 
myogenic cells are able to proliferate under Dulbecco's Modified Eagle Medium 
(DMEM) with high concentration of serum (10%-20% foetal calf serum). The 
differentiation comprising cell fusion and differentiation to multinucleated 
myotubes is induced by either low serum medium concentration (1%-2% foetal 
calf serum or horse serum) or cell confluence (Yaffe and Saxel, 1977; Silberstein 
et al. 1986; Collo et al. 1993; Ebisui et al. 1995; Moore, 1996). Apart from the 
morphological differentiation, the transition from foetal myosin expressed by 
F1.652 to late myosin expressed by N3.36 which occurs in normal human 
skeletal muscle cells was reported in the cultures without neural contact tissue 
components or complex substrates. The replacement of early myosin with the 
late myosin which is found in adult innervated limb muscle is detected by day 8 
of differentiation (Silberstein et al. 1986). A study by Collo et al 
(1993) in adult 
rat skeletal muscle, heart, C202 cells and myocardial cells showed that a7A, 
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the exclusive isoform for induction of differentiation and fusion, was found in 
only the adult skeletal muscle and the differentiated C202- 
These advantages of C2CI2 allow in depth in vitro study in pure skeletal muscle 
which was not possible previously (Silberstein et al. 1986). 
Regarding local algesic substances associated with myofascial pain and the 
analgesic effect of LJLT, prostaglandin particularly PGE2 synthesis from skeletal 
muscle is one of the relevant subjects due to the hypotheses of PGE2 release in 
trigger points (Travell and Simons, 1983, Frost, 1986) and the potential effect of 
LILT on inhibition of PGE2 production (Naveh et al. 1991; Shimizu et al. 1995). 
On the basis of an extensive review on studies of isolated sensory neurones in 
culture, Cesare and MeNaughton (1997) states that PGE2 plays an important part 
in peripheral pain modulation by alteration of the voltage threshold of ion 
channels particularly the Na+ channel in such a way that initiation of action 
potential is facilitated. 
Possibilities to stimulate PGE2 production in skeletal muscle cultures are 
mentioned as follows: - 
PGE2 STIMULATION IN CULTURED MUSCLE CELLS 
There are two main methods to stimulate PGE2 synthesis in cultured muscle 
cells as follows: - 
* Mechanical stimulation 
9 Interleukin I supplement 
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Mechanical stimulation 
Vandenburgh et al (1990; 1991) conducted extensive in vitro and in vivo 
experiments on mechanically stretch-induced alterations in avian myogenic 
cultures. On the basis of a control experiment, it was found that repeated 
intermittent mechanical stretching could inducing an increase of 97% PGE2 
efflux significantly from ordinarily synthesised and stored prostaglandins using 
a stretching regimen. This comprised 10%-20% vertical deformity of flexible 
wells with three repeated cycles of a 20-second stretching and a 10-second 
relaxation followed by 15 min rest periods for 4-5 hours. 
Interleukin I supplement 
Interleukin I (IL-1) is a cytokine peptide which can be produced by all nucleated 
cells. The main cell types which can synthesis IL-1 are monocytes, macrophages, 
B lymphocytes, natural killer (NK) cells, T lymphocyte clones grown in cell 
culture, keratinocytes, dendritic cells and smooth muscle cells. There are two 
kinds of IL-1 depending on the number of amino acids as follows: - 
e IL-Icc comprising 159 amino acids 
9 IL- 10 comprising 15 3 amino acids. 
Virtually, the potency and biologic activities of IL-I(x and IL-1P are identical. 
Many cells can produce both types of IL-1 but their relative levels of expression 
can vary widely. A few tissues, such as skin, synthese IL-I spontaneously. On 
the other hand, macrophages and most of the other cells produce IL-I only in 
response to external stimuli such as bacterial lipopolysaccharide and residual 
particles. The cellular targets of IL-I are various, for example, 
brain, 
fibroblasts, lymphocytes, macrophages, muscle cells, osteoclasts, hepatocytes 
and synovial cells. IL-I plays a known important role in inflammation and 
fever 
and also stimulates adjacent cells to produce other cytokines 
(Oppenheim et al. 
1994). 
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There is a distinct effect of IL-1 on inducing PGE2 release from fibroblasts, 
sYnovial and other cells (Dinarello, 1989) In the control study on mice skeletal 
muscle cells by Moldawer et al (1987), a significant increase in PGE2 production 
was detected by 2 hours after 1,000 U/ml of murine interleukin 1-CC supplement. 
Additionally, increasing the quantity of IL-1a 10-fold resulted in a further 
significant increase. 
Models ofIL-1 stimulation on skeletal muscle cells inducing PGE2 production 
There have been a number of studies on protein degradation using the model of 
IL-I stimulation on dissected rat muscles. Muscle specimens were 
recommended to be incubated with IL-1 supplemented medium for 2-3 hours 
before the related biological substances assay was undertaken (Baracos et al. 
1983; Hasselgren et al. 1986; Moldawer et al. 1987; Hasselgren et al. 1990). In 
these studies the amount of PGE2 was increased significantly in comparison 
with control although the significance of protein degradation could not be 
detected in the studies by Moldawer et al (1987) and Hasselgren et al (1990). 
The models of cytokine stimulation of biological substances in skeletal muscle 
are proposed but still limited in numbers. Ebisui et al - 
(1995) studied 
the effect of Interleukin-6 and Tumour necrotic factor (TNF) on proteolysis by 
activating intracellular protease in C202 myotubes. Differentiated 
C202 
cultures were incubated in medium either supplemented with 
IL-6 or TNF for 48 
hours before the proteolytic activity was measured. McCachren et al (1989) 
conducted an in vitro experiment on collagenase messenger 
RNA (mRNA) in 
human synovial fibroblasts regulated by IL-1. The collagenase mRNA 
accumulation was found at 6 hours after IL-1 stimulation. 
A study by Tominaga 
et al (1991) on adrenal cells showed an increase 
in PGE2 concentration in the 
medium during the first 4 hours to 24 hours after the cultures 
were incubated 
with IL- I supplemented medium. 
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The incubation time for obtaining biological substances induced by cytokines 
between dissected tissue and cell culture appears to be different. The dissected 
tissue is likely to require less duration (2 to 3 hours after stimulation) to 
respond while various models in cell cultures needed to be incubated in cytokine 
supplemented medium for about 4-48 hours. Dinarello (1989) also pointed out 
that prostaglandin was able to accumulate under in vitro cultures, whereas, it 
was metabolised more rapidly under in vivo conditions. 
From the above extensive review, there has been evidence on the basis of clinical 
trials showing that LILT has an analgesic effect on pain in the head and neck 
area particularly when this therapy is used as a conservative treatment for 
painful TMD myofascial disorders. However, the efficacy of this treatment is still 
a potential area of controversy due to a lack of properly conducted controlled 
clinical trials with appropriate methods of assessments of treatment outcomes and 
clearly defined treatment regimes and applications. 
Regarding the mechanism of LILT on pain control, there have been a number of 
in vitro and in vivo studies on the action of LILT in relation to neural tissue and 
its substance and neurophysiology. Study of the local reaction from skeletal 
muscle tissue which has been subjected to irradiation from LILT is an appropriate 
investigation to be conducted in parallel to a clinical study on the influence of 
LILT on the masticatory musculature and TMJ. 
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AIMS AND HYPOTHESIS OF THE STUDY 
General aims of the study 
This study was set up in order to explore the influence of LILT on the physical 
treatment outcome of TMD patients who have myofascial pain of masticatory 
muscle. A mechanism of LILT on skeletal muscle was investigated by in vitro 
studies on PGE2 production from skeletal muscle cultures. 
Speciftc objectives of the study 
1. To compare the short term clinical outcome using pressure pain 
threshold as a main assessment and other related parameters namely; 
symptom severity index score, electromyography, range of mandibular 
movements, among the following groups of myofascial pain TMD patients 
who had different interventions as follows: - 
a) 820 nm GaAlAs LILT at the output energy density 21.4 J/cmý 
b) 820 nm GaAlAs LILT at the output energy density 107 
J/CM2 
C) Placebo inactive laser. 
2. To investigate the effect of 820 nm GaAlAs on PGE2 production from 
differentiated C202 murine skeletal culture stimulated by either 
mechanical stretching or ý IL- I supplement. 
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Hypothesis of the study 
It was hypothesised that the two LILT regimes used in this trial could show a 
greater benefit in the clinical outcome compared with placebo. Improvement in 
clinical status could be due to an effect of LILT on production of algesic 
substances in muscle cells which would be capable of detection in a C202 
muscle cell culture stimulated by stretching or IL-1 supplement. 
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PART 2 
CLINICAL TRIAL ON TEMPOROMANDIBULAR PAIN DISORDER 
PATIENTS 
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MATERIALS AND METHODS OF A CLINICAL TRIAL ON 
TEMPOROMANDIBUL4LR PAIN DISORDER PATIENTS 
A clinical trial was conducted on patients who had Temporomandibular 
Disorders (TMD) with pain as chief complaints. The diagnosis was based on 
research diagnostic criteria; RCD (Dworkin and LeResche, 1992). Two dosages of 
LELT varied by the power and energy densities were used as interventions. The 
light guide from the same laser machine was used as a placebo control. The 
double blind design was applied as the design of the trial. The patients were 
randomly aflocated into the groups on the basis of randomised control parallel 
trial. Objective and subject measurements were undertaken using standardised 
and calibrated machines and recommended questionnaires on the basis of serial 
measures. The analysis was conducted to detect the effect of LILT compared 
with placebo. 
This chapter will begin with the main methods of study composed of criteria for 
study population, sample size estimation, sample allocation, interventions, and 
assessments. Specifications, standardisation and calibrations of machines will also 
be briefly described. Then statistical analysis methods will be mentioned. 
DESIGN OF THE STUDY 
This clinical study was based on the double blind placebo controlled trial. The 
sequential design was also applied to the method of sample size estimation. 
The method of block randomisation was used in order to allocate the patients 
into three equal parallel groups. 
STUDY POPULATION 
TMD patients, attending the Royal London Dental Teaching Hospital were 
invited 
to take part in the double blind placebo controlled trial of 
LILT which was 
approved by the ethical conunittee of the college. 
The inclusion and exclusion 
criteria were considered as follows: - 
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L Age 
TMD patients were recruited from the normal age of consent namely 18 to 50 
years. 
A GenderlRace 
The ratio of TMD patients between women and men has been variously 
estimated between 3: 1 to 9: 1 (McNeill, 1993). Therefore, female patients would 
be acceptable to represent the overview of TMD patients. 
Patients from racial groups with deep melanin pigmentation of the skin were 
exempted lesS strong absorption of 
sensation with the high energy regimen. 
radiation should produce a burning 
III Diagnosis 
Regarding the Research Diagnostic Criteria (RDC) for TMD, there are two axes; 
Axis I for clinical TMD conditions and Axis H for pain-related disability and 
psychological status (Dworkin and LeResche, 1992). 
Axis I: Clinical TMD Conditions 
There are 2 subgroups of TMD which have pain as symptoms; 
a) Muscle disorders 
b) Arthralgia. 
According to the definitions of those diagnoses, osteo-arthritis and osteo- 
arthrosis of the TMJ based on RDC (Dworkin and LeResche, 1992) as mentioned 
in the review of the literature on page 31 were excluded using clinical and 
radiographic examinations. 
only unilateral painful TMD patients were recruited in order to obtain more 
homogeneity of samples. The data from the unaffected side was also recorded 
and analysed using the same process as the affected side in order to confirm the 
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effect of the interventions on the affected side. 
Axis II: Pain-Related Disability and P achological Status 
Chronic TMD patients who had pain for more than 3 months were recruited. The 
assessments of axis H were composed of the grading of the chronic pain 
severity, the depression and somatisation according to the SCL-90-R and the jaw 
disability checklist. These assessments were undertaken for all recruited 
patients to fulfil the RDC. 
All inclusion and exclusion criteria were summarised as follows: 
1. Female patients 
2. Unilateral Muscle disorders and Arthralgia patients. 
3. Ages of 18-50 years 
4. Chronic pain; pain duration more than 3 months 
5. No severe systemic disease 
6. No radiological abnormalities of TMJ 
7. The presence of at least one muscular trigger point 
The screening was undertaken by the supervisor and the author on separate 
occasions. The patient was invited to join the trial when there was an 
agreement between the two examiners as to suitability. 
SAMPLE SIZE ASSUMPTION AND ESTIMATES 
According to ethical considerations and to achieve the effects of the treatments 
using appropriate sample size, sequential design is considered to be reasonable 
in this circumstance. The decision to stop the investigation at some stages 
depends on the results which are obtained. The block randon-lisation is also 
used to allocate the samples (Armitage and Berry, 1994). 
As mentioned above, the sequential design is suitable for this clinical trial which 
studies chronic pain patients. Additionally, there has 
been no other similar 
trials to this study conducted before. In order to obtain a specified precision 
for 
sample size, an initial analysis is also crucial. 
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Regarding the block randomisation, the number of patients for each block needs 
to be indicated. Although it is not essential to calculate the sample size for this 
design, a sample size estimation based on available data was undertaken as 
information for the block design. 
The sample size estimation 
The sample size estimation was based on the data from temporomandibular 
disorder patients who had been treated previously by Low intensity laser (LILT) 
in the Oral and Maxillofacial Surgery Department, Dental institute, Royal London 
Hospital. The response to the treatment had been assessed by visual analogue 
scale (VAS) and professional judgement. 
The power of the test was set up at 80%. Therefore, the type H error rate is at a 
maximum value of P=0.2 or 20%. The type I error is set at an acceptable value 
which is cc = 0.05. 
The sample size of each group is estimated using the formula as follows: - 
n (each gToup) p. -q. + i: ), -q, 
) Zl-9/2 + ZIA-Z 
(pl p, )2 
in which Pi the proportion of patients who recover from 
TMD among cases 
PO the proportion of patients who recover from TMD 
among controls 
q, Pý 
qO PO 
z value of the standard normal distribution 
corresponding to a significance level of 
alpha (1.96 for test at 0.05 level) 
ZI-P value of the standard normal distribution 
corresponding to the desired level of power (0.84 for 
a power of 80%) 
P, is the proportion of the patients who had pain reduction (response grades 
fair 
to excellent i. e. 25 -100% reduction in VAS) after 
LELT which is 77% or 0.7 
(Bradley and Reynolds, 1994). 
po is the proportion of the patients who had pain reduction without receiving 
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any treatments. Fricton (1995 a) reported that 41.9% of Grade I TMD patients 
(N=62) became pain free in I year follow up. Greene and Laskin (1971) reported 
31% of patients with myofascial pain- dysfunction taking placebo had 
improvement. Regarding the fact that the duration of the study of which the 
results will be recorded is I week, the maximum of PO value can be over 
estimated at not more than 30% or 0.30. 
The sample size was calculated using PO = 0.10 - 0.30 as shown in table 3. The 
number of patients in each group is between 5-14. 
Table 3. The sample size estimation 
Control 0.10 0.15 0.20 0.25 0.30 
0 OYO) (1 5YQ (2 OYQ (25%) (30%) 
P (LILT) 0.77 0.77 0.77 0.77 0.77 
, 
Sample n=4.7 n=6.21 n=8.1 4 n=1 0.6 n=1 3.7 
size 
Repeated significance tests should also be considered in the sequential and 
block designs. The significance at 0.05 P value can be used in case repeated 
significance tests are less than 5 times (Armitage and Berry, 1994). 
According to the approximate sample size estimation, the block of five patients 
would not provide more than 5 repeated significance tests. The detail of the 
block allocation was mentioned in the section of sample enrolment on page 93. 
Provisionally, the number of sample size was between 10 to 14 patients each 
group. The decision of actual sample size was based on the data from the 
first 
block of trial. 
The sample size was recalculated using the data from the ftrst block of the 
trial. 
The sample size re-estimation based on the difference of pressure pain 
threshold (PPT) which was used as the main result of this study. The patients 
were randomly allocated into 3 groups based on LILT regimens as 
follows: - 
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Group 1; Conventional regime low intensity laser (CULT) 
Group 2; Modified regime low intensity laser (MLELT) 
Group 3; Inactive laser (Placebo) 
The sample size estimation was calculated using the formula as follows 
(Kirkwood, 1995): - 
Comparison of two means (Sample size of each group): 
(u+v)I 
11+a 22) 
- 42) 
u One-side percentage point of the normal distribution 
corresponding to 100% -the power; 80% power of the 
test, u. = 0.84 
v Percentage point of the normal distribution 
corresponding to the (two-side) significant level; 
significant level = 5%, v=1.96 
ý11 - ýt2 Difference between the means 
a, 
2, (T 
22ý Variances 
The PPT from the first block of experiment is shown in table 4. 
Table 4. The means and variances of the differences of averages pain pressure 
threshold (kpa)of the triggerpoints before and after interventions from the first 
block of the trial 
Variables Experimental group 
CULT MULT Placebo 
Mean (kpa) 11.2 38.7 3.7 
Variance 246.23 411.67 106.16 
The calculation of the sample size at 80% power of the test and 5% level of 
significance is in table 5. 
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Table 5. The sample size calculation for a difference of PPT based on the data 
from the first block of the trial 
Comparison Sample 
size/group 
CULT vs Placebo 47 
MULT vs Placebo 4 
MULT vs CULT 7 
From the sample size estimation in table 5,10 subjects in each group would be 
enough to show significant differences of PPT of the MLILT group compared 
with the CULT and the placebo groups. Therefore, the second block of 5 was 
continued to make the total number of patients to 10 patients in each group. 
ENROLMENT OF PARTICIPANTS 
As mentioned above, the first block was composed of 15 subjects; 5 subjects in 
each group. All participants were be allocated by randomisation into three 
groups namely; group 1, group 2 and group 3. After that the first initial analysis 
was performed. The second block would be repeated with the same method as 
the first block. 
INTERVENTIONS 
The participants received the interventions in a week-experiment as follows: 
Group 1; Three treatments of 60 mW of LILT (Conventional regime 
low intensity laser - CULT) 
Group 2; Three treatments of 300 mW of LILT (Modified regime 
low intensity laser - MLILT) 
Group 3; Three treatments of inactive laser (Placebo) 
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Laser apparatus and the output setting 
The Unilaser 301P (Asah Medico) with 820 Dm GaAlAs adjustable 300 mW laser 
probe was used in this clinical trial (figure 1). The specifications of the laser 
machine are as follows: - 
Wavelengt 
The wavelength is 816 to 823 nm (approximately 820 nm) infra-red (IR) beam 
GaAlAs with the red light guide from laser diode (670 nm wavelength) 
Spectral poin 
The spectral width of the IR beam is I nm. 
Output power densi 
The maximum power density of IR beam at the tip of the laser probe is 
approximate 4 W/cmI. The power of IR diode is adjustable. 
The power density of light guide is approximate 0.015 W/cmI. The power of light 
guide, 670 nm, diode is adjusted at 0.001 W (0.004W/cml). 
Mechanical spectral sizes 
9 The mechanical size of the treatment IR beam is close to the probe tip 
approximately 4x1.5 nun in radius (18.8 mm'). 
9 The mechanical size of the visible light guide is close to the output tip of the 
probe approximately 4x2 mm in radius (2 5.1 1=2). 
DiversLty 
9 The IR beam is diverging. The size of the spot is approximate 10 x3 cm at a 
distance of 3 meters. 
* The visible light guide is not so diverging. At a distance of 3 meters, the size 
of spot is 6x4 mm. 
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Figure 1. The laser apparatus; Unilaser 30 1P (Asah Medico), used in this study 
C= Control panel, P= the 300 mW power adjustable probe, M= the built in 
power meter and S= information screen 
The 300 mW power adjustable probe (P) 
Fibres for acupuncture (FI) and intra-oral (F2) are shown on the left but were not 
used in this study 
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-Programmes of output setting 
The Unilaser 301P has 8 built in memories allowing possibilities to set up 
various LILT regimes (fi_qure 2A). A programme in memory win display on the 
screen when a memory button is operated. 
In this trial, the built in programme memories were designated by the 
supervisor. The information screen was covered. The probe was fitted with an 
insulating sleeve to prevent detection of heat when the modified high energy 
programme was operated (figure 2B). The clinician was only allowed to know 
the codes of the buttons after the first baseline assessment was undertaken. 
The codes were changed after the trial on 15 patients was finished. This was to 
prevent the clinician recognising the treatment protocol being used and bias on 
baseline assessment. From the patient's viewpoint there was no possibility of 
recognising when the laser was active or inactive, or when it was delivering a 
CLILT or MLILT. Hence double-blinding was maintained. 
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Figure 2A The memory buttons and B. the modification of laser apparatus for 
double blind trial 
Figure 2A. The built in 
programme memories 
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Figure 2B. The modifications for double blind purposes are shown namely: - the 
laser apparatus with screen information cover blanked out (B) and the laser probe 
with an insulating sleeve (S) to prevent the experimenter detecting heating effects 
from the higher energy MULT regime. 
The programmes were set up as foRows (figure 3): - 
Two buttons for CULT 60 mW power/4 joules11.07 minutes 
Two buttons for MULT 300 mW power/20 joules11.07 minutes 
Two buttons for Placebo Zero mW/Zero joules11.07 minutes. 
Figure 3. The output settings of LILT regimes for the clinical trial 
The output setting for CULT 
The output setting for MULT 
The output setting for Placebo 
From this setting, there was no power output of the GaAlAs probe 
which could be detected by either the built in power meter or 
isotropic detector. 
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From the output settings as mentioned, the power and energy densities are 
shown in table 6. 
Table 6. The power and energy densities of the output setting of 820 nm IR used 
in clinical trial 
Doses Power/spot size 
(. 188 cml) 
Energy/67 
seconds 
Power density 
(W/cmI) 
Energy density 
O/cm') 
CULT 60 mW 4j 0.319 21.373 
MULT 300 mW 20J 1.596 106.932 
Placebo 0 MW 0.1 0 0 
Note : 670 nm light guide was constantly adjusted at I mW/spot size (. 251 CM2), 
0.004 W/cmI power density, . 067 J/67 seconds and . 268 
J/CM2 Energy density. 
Calibrations of power and eneM densities Lrom the output setting Lor the clinical 
trial 
From the above output setting, the real output of LILT was measured with the 
built in power meter measuring the 820 nm power per spot and an Isotropic 
detector measuring the power density of the 670 nm light guide. Measurements 
were repeated 30 times. 
The power and energy densities of the output at the tip of the probe are shown 
in table 7. 
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Table 7. The power and energy densities of the output at the tip of the probe of 
820 nm IR and 670 nm visible red light guide which were used in the clinical 
trial 
Power W Energy/67 Power density Energy density 
seconds Uoules) (W/cml) O/cm') (spot size) 
Doses 820 nm 670 nm 820 nm 670 nm 820 670 nm 820 nm 670 
(0.188 cm') (0.25 CM2) 
nm nm 
CULT 0.054 0.00025 3.618 0.017 0.287 0.001 19.245 0.067 
SD = 0.001 
range = 0.50 to 
0.55 
MULT 0.284 0.00025 19.028 0.017 1.516 0.001 101.213 0.067 
SD = 0.002 
range = 0.280 
to 0.285 
Placebo 0 0.00025 0 0.017 0 0.001 0 0.067 
SD = 
0.0004 
range =0 
to 0.002 
Note: The power and power density obtained by measurement are shown with mean 
and its SID and range. Other calculations are based on the measured values. 
In order to detect the exact power density with which the masticatory muscles 
and TMJ areas in relationship with the areas of LILT would be irradiated, the 
following procedure was undertaken on a volunteer patient who needed to have 
an open TMJ operation undertaken (figure 4). 
1. After the standard incision for access an isotropic detector was placed in the 
following areas: - 
o under the skin flap on the masseter muscle 
posterior to TMJ related to the posterior articular nerves 
On the lateral capsule of the TMJ. 
2. Low intensity laser at 60 mW, 300 mW power and inactive laser (visible light 
guide) was irradiated on the above areas for I minute. (The isotropic detector 
was adjusted at zero before irradiation. ) 
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Figure 4. The measurement of power density under the skin flap using an 
isotropic detector 
S= The screen of the isotropic dectector meter showing the power density under 
the skin flap 
The tip of the isotropic dectector and fibre optic were covered in a sterile 
plastic tube which were placed under the skin flap for measuring the actual 
power density of LILT on masseter and TMJ areas 
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3. The power densities were recorded at 30 seconds and I minute (see details in 
table 8). 
Table 8. The power densities of 60 mW, 300 mW IR (820 nm) and 670 nm visible 
light guide in relationship with the treated areas for patients in clinical trial 
Power density (W/cm') 
Types of LILT over the masseter Posterior to TIVIJ over lateral capsule 
of TIVIJ 
60 mW IR 0.089 
(0.060 to 0.118) 
0.0065 
(0.005 to 0.008) 
0.003 
(0.002 to 0.004) 
300 mW IR 0.447 
(0.350 to 0.544) 
0.013 
(0.0 10 to 0.0 16) 
0.006 
(0.004 to 0.008) 
visible light guide 0 0 0 
The energy densities of the regimes for the clinical trial are shown in table 9 for 
the treatment area itself. 
Table 9. The total energy densities of CULT, MULT and placebo (visible light 
guide) used in the clinical trial at the treatment site 
Energy density 0/cm') 
Type of LILT Over masseter Posterior to Over lateral 
muscle TMJ capsule of TIVIJ (setting up for Uni Laser 301 P) 
CULT 
(60 mW IR / 4j/ 67 seconds) 5.963 0.436 0.201 
MULT 
(300 mW IR/20j/ 67 seconds) 29.949 0.871 0.402 
Placebo 
(0 mW IR/ Qj/ 67 seconds) 0 0 0 
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Application 
Laser therapy (LILT) was carried out three times a week with one regimen as 
randon-Ay allocated. This allocated dose was given to each patient at 6 sites in 
the order as foRows :- 
a) posterior aspect of the affected TMJ to irradiate the richest part of the 
innervation namely the posterior articular nerves Oaw open) as shown in 
figure 5 
b) sigmoid notch to irradiate the motor nerve to masseter and other elements 
of the mandibular division of the trigeminal nerve Oaw closed) and lateral 
pterygoid muscle insertion (figure 6) 
c) joint interface to irradiate the synovium (jaw open) as shown in figure 6 
d) each of the three worst trigger spots in the masticatory muscles (figure 7) 
If there were less than three clinically obvious trigger points to treat, the 
pressure pain threshold points (see figure 8) with the lowest threshold would be 
selected. 
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Figure 5. The irradiation of posterior articular nerves at the posterior aspect of 
the TMJ 
Figure 6. The positions of irradiation at the sigmoid notch and lateral capsule of TMJ 
S= the position for 
irradiation at sigmoid 
notch for the motor nerve 
of masseter and lateral 
pterygoid muscle insertion 
T= the position for 
irradiation of the synovium 
(,: )f TMJ 
ii1 ; 4f 
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-' 
4 
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A: J 
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Figure 7. The irradiation of trigger point on the masseter muscle 
A 
I 
00,0910 
I 
r*wl I 
Note: The insulating sleeve on the probe to prevent detection of heating effects 
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TREATMENT AND FOLLOW UP PROCEDURES 
The general format of the trial was that patients had baseline investigations 
carried out on the Thursday of the week preceding the start of LELT (day zero). 
LILT and routine assessments were carried out for the three-week days; Monday, 
Wednesday and Friday with one regimen Q treatments). On the following 
Monday full investigations were undertaken to establish response to the first 3 
treatments (see the overall schedule in table 10). 
Table 10. The schedule of the clinical trial in week I and week 2. 
Before week I week 2 
treatment 
day 0 day I day 2 day 3 day 4 day 5 day 6 
Group Th u rs. Mon. Wed. Fri. Mon. Wed. Fri. 
(end of 
trial) 
CULT FA RA + RA + RA + FA + RA + RA + 
CULT CULT CULT Placebo Placebo Placebo 
MULT FA RA + RA + RA + FA + RA + RA + 
MULT MULT MULT Placebo Placebo Placebo 
Placebo FA RA + RA + RA + FA + RA + RA + 
Placebo Placebo Placebo MULT MULT MULT 
Note : FA = Full assessment as mentioned in A. Baseline investigations (page 106), RA 
Routine assessments as mentioned in B. Week 1 (page 117) 
The foHowing investigations were undertaken during this overaH period: - 
A. Baseline investigations (Day 0) 
The trial took place in the same room with only the operator and subject 
present to decrease distractions from extraneous matters as recommended by 
McMIlan (1994). 
a. Questionnaires 
Symptom Severity Index (SSI) and McGill pain questionnaire were completed in 
the first visit. The patients were allowed to take the questionnaires for Axis II of 
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RCD to fill at home and returned the completed forms at the next visit (see the 
questionnaires in appendix page 268). 
b. Clinical examination 
Full oral and maxillofacial examination to allow completion of RDC axis I. This 
annotates all aspects of TMJ function, oral status and muscular palpation. It 
allowed the case to be classified according to the Systemic Classification of 
Clinical TMD Conditions (Dworkin and LeResche, 1992). The full form of Axis I 
assessment and details of examination which were used in this study are shown 
in appendix page 258. 
c. Radiographic examination 
Orthotomographic x-rays of both joints in open and closed positions (4 in I 
views) were undertaken. 
d. The pressure pain threshold 
The pressure pain threshold (PPT) in kilopascals (kpa) was recorded on the 
affected and normal side using the electronic algometer (Somedic AB, 
Stockhohn, Sweden) at five symetrical points on each side at the following 
landmarks (figure 8): - 
Point 1: The central point is located on the anterior temporalis muscle 
which is 10 mm posterior to the anterior border of the muscle and 
10 mm superior to the highest point on the zygomatic buttress. 
Point 2: The central point is located 10 nun posterior to the anterior 
border of the superficial masseter and 10 nun inferior to the 
lowest point on the zygomatic buttress. 
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Point 3: The central point is located 10 mm anterior to the posterior 
border of the superficial masseter muscle and 10 nim superior to 
the inferior border of the mandible. 
Point 4: The central point is on the deep masseter which is 10 mm 
posterior to the posterior border of the superficial masseter 
muscle and 10 mm inferior to the zygomatic arch. 
Point 5: The central point is on the lateral capsule of TMJ which is 10 mm 
from the tragus of the ear under the line between the anterior 
border of the tragus of the ear and the lateral canthus of the eye. 
The above points were marked before PPT was recorded. 
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Figure 8. The landmarks for pressure pain threshold measurements 
C 
I= The point on the anterior temporalis 
2= The point on the anterosuperior part of superficial masseter 
3= The point on the posteroinferior part of superficial masseter 
4= The point on the deep masseter 
5= The point on the lateral capsule of TMJ 
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The Somedic electronic algometer has an automatic registration of maximum 
pressure which can be connected with a patient operated cut out switch 
operated when pressure converts to pain (figure 9). There is a built in pressure 
controlled system showing the slope of force. The I cm' probe with the setting 
of force slope at 10 kpa per second was used in this trial. 
The patient was seated in an upright position in a comfortable wooden arm 
chair with high back rest and slightly clenching in the intercuspal position. 
Before the measurement, the patient was informed about the machine and 
practised to control the patient operated switch. The patient was trained to 
press the handheld switch to stop the pressure display on the algometer when 
she felt the pressure turned to pain. As 2 pounds force was recommended to be 
the normal force for extraoral muscle palpation (Dworkin and LeResche, 1992; 
Widmer et al. 1992), the equivalent of eighty-nine kpa force at the rate of 10 kpa 
per second and angle of 900 was applied to the vertex points in order to make 
the patients familiar with the pressure and rate of force. Then the PPTs were 
measured on the marked points with the same procedure as mentioned. 
Counterpressure was supplied using the hand of the operator on the 
contralateral side of the head of the patient during the measurement. 
The first round of measurements began from the normal side and was followed 
by the record of the same point on the affected side in the order of the point 
numbers (point number I to point number 5) as shown in figure 8. The second 
round of measurements was randomly undertaken. The period of rest between 
each measurement was at least 30 seconds as suggested by McMillan (1994). 
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Figure 9. The electronic algometer for pressure pain threshold measurement 
H= Handheld operating unit, P= Rubber probe, S= Patient operated switch 
and C= Calibration weight 
fl .4 
I 
PPT of a trigger point on the masseter muscle being measured using the 
algometer. A constant force was applied at a 90o angle to the muscle with 
counterpressure support. The patient is holding the switch which is activated 
when the pressure turns to pain. The registration screen (R) is clearly seen. 
III 
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A customised plastic template was constructed by placing a piece of clear plastic 
along the side of the face using the plane between lateral canthus of the eye and 
anterior border of the tragus of the ear and the lower border of the mandibles as 
references (figure 10). Marks were made on the template with a permanent 
brush pen to correspond to the sites marked on the underlying skin. The 
templates were used in the later assessments for precise and reproducible 
locations of pressure points. 
Figure 10. The customised plastic template 
The customised plastic template using the line between the tragus of the ear and 
the lateral canthus of the eye and the lower border of the mandible as references. 
The positions for PPT measurements (shown as 
dots) and EMG electrodes were 
recorded on this template for reproducible measurements at 
the next visits 
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e flectromyography and Mandibular Kinesiolog 
The electromyography of the main masticatory muscles and the mandibular 
kinesiology were recorded using K61 Myo-Tronics machine system. The records 
were undertaken on each patient as follows: - 
The EMG in the rest position 
The patient was seated upright in a comfortable wooden arm chair with a 
high back rest and looked straight ahead. The bipolar electrodes (Duo- 
trode disposable EMG electrode) were placed at the anterior temporalis, 
masseter, anterior belly of the digastric and sternocleidomastoid muscles 
on the affected and normal sides (figure 11). Palpation of the site of 
maximal contraction when the muscles functioned was used to determine 
the locations of the recording sites. The electrodes were placed on the 
distinct contraction areas and also parallel to the muscle fibres. The 
ground electrode was placed at the area behind the neck. The skin where 
electrodes were to be placed was cleaned by alcohol pads. The patient 
was asked to rest and place her jaw in the relaxed position. Then all 
electrodes were connected to the EMG amplifier box which linked to the 
computerised recording programme. After 5 minutes rest, the EMG in the 
rest position was recorded at ail EMG gain 3%tV. The second records 
were repeated after a 5-minute rest. 
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Figure 11. The positions of electrodes on the masticatory muscles for surface 
EMG recording 
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2. The mandibular kinesiology recording the maximum mouth opening 
The magnet for the sensor array was placed I mm below the gingival 
margin of the lower central incisors and parallel to the occlusal surface. 
The mid line of the magnet corresponded to the proximal contact 
between the lower central incisors which was also used as a acceptable 
reference for the mid line of the mandible. The frame connected to the 
sensor array was placed on the patient in a symmetrical position frontally 
and horizontally as directed by the instructions of the makers (figure 12). 
The relationship between the magnet and sensor array in the sagittal plan 
was adjusted using the computerised tracing of the sensor array as a 
guide to ensure the reproducibility of location. 
The patient was asked to open her mouth as wide as she comfortably 
could from the intercuspal position and then close her mouth to the start 
position. After the patient had chances to practice and familiarise with 
the apparatus, the sagittal and frontal planes of jaw tracking were 
recorded. The records were conducted twice. 
3. The mandibular kinesiology recording the range of the lateral excursion 
The patient was asked to do the same as in the record for the maximum 
mouth opening, then grind her teeth to the right side as far as possible 
and move back to the beginning position before doing the same lateral 
movement to the left. The second record was conducted when the 
patient did the same movement but began the lateral excursion to the left 
before the right. Before the recording, the patient was allowed to have a 
chance to practise. 
4. The mandibular kinesiology recording the velocity of movement 
The patient was asked to open and close her mouth as fast and wide as 
possible. The intercuspal position was used as the beginning and ending 
position. The velocity of movement in mm per second in frontal and 
sagittal tracings was recorded twice. 
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The mandibular kinesiology recording the free way space 
The patient was instructed to place her jaw in the relaxed position as 
usual for 5 minutes. Then the sweeping jaw tracking at speed 100 mm 
per second was monitored with the patient in the relaxed position. After 
the tracing was stable for at least 6 seconds, the patient was asked to tap 
her teeth together and then bite on her posterior teeth. The changes of 
the distance from the rest position to centric occlusion in vertical) 
anteroposterior and lateral planes were recorded. The second record was 
conducted after a 5-minute rest with the same procedure. 
6. The EMG in the maximum voluntary clenching 
The patient was asked to clench her back teeth as hard as possible for 2 
seconds and then relax for 2 seconds according to the timing which was 
controlled by the operator. The above procedure was repeated three 
times. The rectified EMGs of masseter and temporalis muscles were 
recorded at a gain of 100 gV. The second record was conducted with the 
same method as mentioned. The patient had chances to practise the 
procedure before the records were undertaken. 
Clear plastic templates were made individually for recording the positions of 
EMG electrodes which would be used in the later assessments. 
B. Week I (Days 1,2,3) 
The assessments on each of these days were as foRows: - 
0 ssi 
PPT measurement 
Measurement of unassisted maximum mouth opening without pain in mm 
using Willis Bite Gauge. 
C FINAL (Day 4) 
0 
. 
Repeat of investigations of day zero apart from radiographic examination to 
assess response to the first three treatments. 
For ethical reasons and blinding the clinician, the control group was treated 
using MULT for 3 alternate days in the second week while the experimental 
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groups received the placebo. 
the first week. 
E Follow-up 
The methods of assessments were similar to 
The patients were reviewed in 2 weeks, I month and 3 months after treatments 
as the normal standard for TMD follow up, although the data collection for the 
trial was fulfilled at the beginning of the second week- In case the patients had 
no positive responses after a 2-week review, other appropriate treatments were 
considered such as repeat LILT, provision of occlusal splint if parafunction was 
present or arthrocentesis if there was evidence of internal derangement. 
CALIBRATIONS OF APPARATUS 
The machines used in this study for measurement of the clinical outcome were 
calibrated: - 
Electronic algometer 
This machine was calibrated using a standard weight foRowed by instructions of 
the maker. The accuracy of mechanical calibration was acceptable at 3% error of 
reading. Pearson correlation coefficients and the P value of intra-visit and inter- 
visit measurements were calculated from repeated measures in baseline visits. 
The correlation coefficients (r) of intra and inter visit measurements of painful 
and non-painful trigger points were the same at 0.99 and 0.76 respectively at P 
value less than 0.01. 
EMG 
All of the channels from the EMG amplifier box were calibrated using an 
electrical generator with a volt meter. Ten microV and 100 microV stimulations 
were applied to each channel for 10 times. From 10 n-AcroV stimulation, it was 
found the average of EMG showed 9.3 microV constantly in every channel, while 
the average EMG showed 98.1 microV for 100 microV stimulation. Therefore, 
the calibration factors at 10 and 100 microV were 1.08 and 1.02 respectively. 
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The accuracy was 1-2% error. 
jaw tracking 
The calibration was undertaken in an area of 60 mm vertical x 20 mm frontal x 
60 mm sagittal plane in the centre of the central array area. The magnet was 
moved around this area three dimensionally at a constant distance at 10 mm 
which gave 108 points of recording. The reading from the jaw tracking machine 
in every plane was recorded. This procedure was repeated three times. The 
regression equations using an actual movement as a response and reading 
values from jaw tracking as predictors were calculated (Howell, 1997). The 
student edition of Minitab for windows version 9 was used for the calculation of 
the equations: - 
s Actual vertical movement = 2.00 + 1.11 reading vertical movement + 0.0126 
reading sagittal movement + 0.0277 reading frontal movement 
(P value : constant less than 0.001, reading vertical movement less than 0.001, 
reading sagittal movement = 0.229 and reading frontal movement = 0.206,98.9 % R- 
square and 9 unusual observations) 
Actual sagittal movement =-0.180 + 0.00161 reading vertical movement + 
I. 00 reading sagittal movement + 0.00055 reading frontal movement 
(P value : constant = 0.305, reading vertical movement 0.671, reading sagittal 
movement less than 0.001 and reading frontal movement 0.938, R-square = 99.9% 
and 10 unusual observations) 
Actual frontal movement = -0.016 + 0.00355 reading vertical movement - 
0.00174 sagittal movement + 0.989 reading frontal movement 
(P value : constant = 0.971, reading vertical movement = 
0.714, reading sagittal 
movement = 0.842 and reading frontal movement 
less than 0.001, R-square = 96.5% 
and no unusual observation) 
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A re-calibration wn-ernnducted after the trial. The equations are as Lollows: - 
Actual vertical movement = 2.05 + 1.11 reading vertical movement + 0.0110 
reading sagittal movement + 0.0281 reading frontal movement 
(P value : constant less than 0.001, reading vertical movement less than 0.001, 
reading sagittal movement = 0.294 and reading frontal movement = 0.201,98.9 % R- square and 8 unusual observations) 
Actual sagittal movement =-0.179 + 0.00158 reading vertical movement + 
1.00 reading sagittal movement + 0.00055 reading frontal movement 
(P value : constant = 0.308, reading vertical movement 0.677, reading sagittal 
movement less than 0.001 and reading frontal movement 0.938, R-square = 99.9% 
and 13 unusual observations) 
s Actual frontal movement = -0.015 + 0.00352 reading vertical movement - 
0.00174 sagittal movement + 0.989 reading frontal movement 
(P value : constant = 0.973, reading vertical movement = 0.716, reading sagittal 
movement = 0.842 and reading frontal movement less than 0.001, R-square = 96.5% 
and no unusual observation) 
The equations before and after trial were similar. Linear regression is found 
between actual movement and reading from jaw tracking in the same plane. The 
inter-plane factor in the equation is not statistically significant. 
STATISTICAL ANALYSIS 
Main response 
Repeated measurements ANOVA were applied as assessments of the response to 
treatments. Pressure pain threshold (PPT), Mouth opening (MO) and Symptom 
severity index (SSI) were recorded two times for baseline data and three times 
for the post-treatment assessments. Mandibular kinesiology EMG and McGill 
pain questionnaire were recorded on two occasions on day zero and after the 
final treatment on day 4. 
The main response to treatment was indicated before analyses were undertaken 
in order to avoid a bias. The pressure pain threshold was decided to be the 
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main response because it could present the numerical data based on the 
subjective response from patients. Also the reliability and validity of the 
method for assessment of musculoskeletal pain was satisfactory (see detail in 
review of the literature page 55). 
Owing to the different grades of psychological status of TMD patients (Axis 11), 
there could be variation in the reports of pain intensity and disability (Von Korff 
et al. 1992). The symptom severity index (SSI) was, therefore, not selected to be 
the main effect even it could reflect the subjective response from patients. The 
mouth opening (MO) was not used as the main effect because this study focused 
on the muscle disorders and arthralgia rather than limitation of mouth opening. 
However, the mouth opening could be considered as the related response as the 
mandibular kinesiology and EMG. 
Analysis of pain scores 
There were two pain measurements used in this study namely VAS and McGill 
pain questionnaire. 
VAS 
According to an extensive review by McCormack et al (1988) on the use of VAS 
for psychological assessments, the VAS has not been agreed to be ordinal, 
interval or ratio scale. Recently, Dexter and Chestnut (1995) analysed the 
accuracy and efficacy of various types of statistical tests to compare VAS among 
groups. It was found that no statistical tests incorrectly suggested a difference 
among groups when there was no difference. The t-test and ANOVA without 
transformation of data are recommended as good choices due to the higher 
power of analysis compared with non-parametric tests particularly in a clinical 
trial with small sample size. However, the distribution of data has to be checked 
to fit assumptions of the tests. 
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McGill vain aue tionnaire 
Melzack et al (1985) proposed a new method to calculate pain scores from the 
McGill questionnaire based on experiment on chronic pain patients. Weighted- 
rank score method was suggested to be more sensitive than the original rank 
score method. Parametric statistics is recommended to be the analysis method 
for McGill pain scores based on the weighted-rank calculation. 
In this study, VAS and McGill pain weight-rank scores will be treated as 
continuous data which can be analysed by parametric methods. In case, the 
assumptions cannot be fulfilled due to distribution of data and/or homogeneity 
of variances which cannot be corrected by transformation, non-parametric 
statistical tests will be used. 
Statistical method 
Frison and Pocock (1992) compared the three possible methods for repeated 
measurements which were composed of comparing post-treatment results, 
comparing the change of results between pre and post treatment and analysis 
of covariance (ANCOVA). The ANCOVA is superior to the other two methods in 
efficiency and a lack of bias (if randon-lisation is not ideal). It also has a smaller 
variance than other methods when the calculation is based on summary 
measures. The ANCOVA with more than one pre-treatment recording is more 
efficient than the ANCOVA with one pre-treatment. 
This study was designed to fit the repeated measurement design and also two 
pre-treatment recordings were undertaken to increase the efficiency of the 
analysis. The ANCOVA was selected for comparing the response to treatments. 
The assumptions of ANCOVA were tested using the Shapiro-Wilks test for 
assessing the normality of distribution and Cochrans test for assessing 
homogeneity of variances. In the case where the data did not match the 
assumptions, the non-parametric statistics was performed using Kruskal-Wallis 
comparing difference among groups and Wilcoxon matched-pairs signed-ranks 
test comparing the results pre and post treatment within group. 
Categorical data such as diagnosis of myofascial pain or arthralgia was analysed 
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by Fisher's exact test as number of expectations did not match the assumption 
for chi-square test. (Campbell and Machin, 1993). 
The SPSS 6.1.3 statistical soft ware programme for Windows was used for the 
statistical calculation in this study except the Fisher's exact test which was 
calculated using the True Epistat standard version computer software. 
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RESULTS OF A CLINICAL TRIAL ON TEMPOROMANDIBUL4, R PAIN 
DISORDER PATIENTS 
The double blind clinical trial was undertaken on 30 patients as described in the 
materials and methods of a clinical trial on temporomandibular pain disorder 
patients (page 87). On the basis of block randomised allocation, patients were 
divided into 3 groups; 10 patients in each group, depending on interventions. 
The interventions were as follows: - 
a) the conventional regime of low intensity laser therapy (CLILT) 
b) the modified regime of low intensity laser therapy (MLILT) 
the inactive laser (Placebo). 
The ANCOVA was used as the analysis to compare the response to the 
treatments on the basis of serial measurement mentioned in the section of 
statistical analysis in the material and methods (page 120). In case data did not 
match the assumption of ANCOVA, the non parametric tests would be 
performed. 
GENERAL DATA 
Age 
The average age of patients in the trial was 34.6 years old (SD = 8.58 years) in 
the range of 20 to 50 years old. The details of age by groups are shown in table 
1. 
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Table 11 . Average ages of patients and the SD and ranges by groups 
Age (years) 
Group Mean SD Range 
CULT 36.6 6.35 25 to 44 
MULT 28.7 7.42 20 to 46 
Placebo 38.5 9.06 24 to 50 
Total 34.6 8.58 20 to 50 
Pain duration 
The pain duration of TMD patients is shown in table 12. 
Table 12. Means and ranges of pain duration (months) of patients in the clinical 
trial 
Group Pain duration (months) 
Means Range 
CULT 37 6 to 120 
MULT 26 5 to 120 
Placebo 36 6 to 96 
Total 33 5 to 120 
The mean of pain duration of patients in the MULT group was less than other 
groups. However, the range of pain duration of every group was quite similar. 
The average of pain duration of the total sample was 33 months. 
Diagnosis 
The axis I diagnosis; clinical TMD conditions concerning muscle disorders, disc 
displacements and arthralgia was assessed before and after the final treatment. 
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AMS I 
Muscle disorders 
Diagnoses of muscle disorders, as determined by clinical examination according 
to RDC, before treatment and after the final treatment by groups and total 
numbers of patients are shown in table 13. 
Table 13. Muscle disorder diagnosis before treatment and after the final 
treatment by groups and total numbers of patients 
Number of patients 
Group Diagnosis before treatment Diagnosis after the final treatment 
Myofascial 
pain 
Myofascial 
pai n with 
limited 
opening 
No 
myofascial 
pai n 
Myofascial 
pai n 
Myofascial 
pain with 
limited 
opening 
CULT 1 9 4 2 4 
MULT 0 10 7 1 2 
Placebo 1 9 1 1 8 
Total 2 28 11 4 14 
All of the patients in the trial were diagnosed to be unilateral muscle disorders 
following the inclusion criteria. Most of patients had myofascial pain with 
limitation of mouth opening apart from two patients in CULT and placebo 
groups who did not have a limited opening. After the final treatment, seven 
patients in MLILT groups recovered from muscle disorders. There were four 
patients from CLELT group who had a recovery from myofascial pain. Only one 
patient had a recovery in the placebo group. 
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Table 14. The change of diagnosis of muscle disorders after the final treatment 
Group Number of patients 
Recovery Same diagnosis Changed 
diagnosis 
CULT 4 5 1 
MULT 7 2 1 
Placebo 1 8 1 
Total 12 15 3 
Note : Recovery = patients had no muscle disorders after treatments, Same diagnosis = 
patients had the same diagnosis either myofascial pain or myofascial pain with 
limitation of mouth opening, Changed diagnosis = patients who used to be diagnosed 
as myofascial pain with limitation of mouth opening had changed to be myofascial 
pain without limitation. 
From the diagnoses after the final treatments, 7 patients in the MLILT group had 
no myofascial pain. In the CULT group, there were 4 patients diagnosed as no 
myofascial pain. Only one patient in the placebo group had no myofascial pain. 
The majority of patients in the placebo group had the same muscle disorders 
while 5 patients and 2 patients in the CULT and MLILT groups had the same 
diagnosis respectively. One patient in each group had a change of diagnosis 
from myofascial pain with limitation of mouth opening to myofascial pain 
without limitation of mouth opening. Overall the WILT group showed the most 
successful recovery from myofascial. pain compared with the other two groups. 
Fisher's exact test was performed in order to compare a difference of recovery 
from myofascial pain based on muscle disorder diagnosis. A2x2 table for the 
Fisher's exact test and results of calculation are shown in table 15. 
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Table 15. Two by two tables for Fisher's exact test on the change of diagnosis for 
muscle disorders after the final treatment 
Number of patients 
Group Recovery Non-recovery 
CULT 4 6 
Placebo 1 9 
The probability of exactly the observed permutation = 0.1354, Exact P value = 0.3034 
Relative risk = 2.00, Taylor 95%Cl = -0.0294 and 0.8294 
Number of patients 
Group Recovery Non-recovery 
WILT 7 3 
Placebo 1 9 
The probability of exactly the observed permutation = 0.0095, Exact P value = 0.0198 
Relative risk = 3.5, Taylor 95%C1 = 1.2692 and 9.6518 
Note: Recovery = No myofascial pain after treatments, Non-recovery = Patients still had 
myofascial pain after the final treatment. 
The results from Fisher's exact test showed that the number of patients who 
recovered from myofascial pain in the MLJLT group was significantly greater 
than the placebo group at P value = 0.0198. Moreover, the relative risk of the 
comparison showed that the MLJLT was 3.5 times (95%CI = 1.3 to 9.7) more 
effective than the placebo in terms of the numbers of patients who had 
myofascial pain relieved while there was no such difference by comparing the 
CULT with the placebo group. 
Disc displacements 
Diagnoses of disc displacements before treatment and after the final treatment 
as determined by clinical examination according to RDC are shown in table 16. 
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Table 16. Disc displacement diagnosis before treatment and after the final 
treatment by groups and total numbers of patients 
Number of patients 
Group Diagnosis before treatment Diagnosis after the final treatment 
a b c d a b c d 
CULT 4 1 4 1 4 1 4 1 
MULT 3 0 7 0 4 0 4 2 
Placebo 1 2 6 1 2 1 5 2 
Total 8 3 17 2 10 2 13 5 
Note :a= no diagnosis for disc displacement, b= disc displacement with reduction, c 
= disc displacement without reduction with limited opening and d= disc displacement 
without reduction without limited opening 
The majority of patients in the CULT group before and after treatment had 
either no disc displacement diagnosis or disc displacement without reduction 
with limited opening. Most of patients in the MLILT group were diagnosed as 
disc displacement without reduction with limited opening. After the final 
treatment, the number of the patients who had disc displacement without 
reduction with limited opening was decreased while there was an increase in the 
numbers of no diagnosis for disc displacement and disc displacement without 
reduction without limited opening. Most of patients in the placebo group had 
disc displacement without reduction with limited opening either before or after 
treatment. 
129 
Table 17. The change of disc displacement diagnosis after the final treatment 
Number of patients 
Group No change in diagnosis Changes in diagnosis 
a b c d b to a b to c c to a c to b c to d 
CULT 4 0 3 1 0 1 0 1 0 
MULT 3 0 4 0 0 0 1 2 0 
Placebo 1 1 5 1 1 0 0 0 1 
Total 8 1 12 2 1 1 1 3 1 
Note :a= no diagnosis for disc displacement, b= disc displacement with reauction, c 
= disc displacement without reduction with limited opening and d= disc displacement 
without reduction without limited opening 
Most of patients in every group did not have a change in diagnosis of disc 
displacement after the final treatment (table 17). There was no patient who did 
not have disc displacement developing disc displacement after treatment. There 
was a patient in the MLILT group who recovered from disc displacement without 
reduction with limited opening. In the placebo group, there was a patient who 
recovered from disc displacement with reduction to no disc displacement. 
There were two patients in the CULT group and one patient in the MLELT group 
who had recovery from the limitation of mouth opening (change of category c to 
b). 
Arthralgia 
According to the recruited criteria, osteo-arthritis and osteo-arthrosis of the 
TMJ were excluded. Therefore, the diagnosis for the TMJ was categorised either 
no diagnosis for TMJ or arthralgia (table 18) as 
determined by clinical 
exan-dnation according to RDC. 
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Table 7 8. Diaqnosis of TMJ arthratqia before treatment and after the final 
treatment by groups and total numbers of patients 
Number of patients 
Group Diagnosis before treatment Diagnosis after the final treatment 
No diagnosis for 
TMJ 
TMJ arthralgia No diagnosis for 
TMJ 
TMJ arthralgia 
CULT 1 9 4 6 
MULT 1 9 9 1 
Placebo 2 8 2 8 
Total F4 26 15 15 
Most of patients in all groups had TMJ arthralgia. After the final treatment, 
there were decreases in the numbers of arthralgia patients treated by LILT 
particular in the MLELT group. 
Table 79. The change of TMJ arthralgia diagnosis after the final treatment 
Number of patients 
Group Same diagnosis Changes in diagnosis 
A N N to A A to N 
CULT 5 0 1 4 
MULT 1 1 0 8 
Placebo 1 7 1 1 
Total 7 8 2 13 
Note :A= TMJ arthralgia and N= no diagnosis for TMJ arthralgia 
In the CLILT group, 4 patients had no diagnosis for arthralgia after the final 
treatment (table 19). However, 5 patients in this group still had arthralgia and 
I patient developed arthralgia after treatment. The majority of patients (8 
patients) in the MLELT group had no diagnosis for arthralgia after the final 
treatment. There was one patient who developed arthralgia and one patient 
recovered from arthralgia after the placebo treatment. 
Fisher Is exact test was performed in order to compare differences of recovery 
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from TMJ arthralgia between groups. A2x2 table for Fisher's exact test and 
results of calculation are shown in table 20. 
Table 20. Two by two tables for Fisher's exact test on the change of TMJ 
arthralgia diagnosis after the final treatment 
Number of patients 
Group Recovery Non-recovery 
CULT 4 6 
Placebo 1 9 
The probability of exactly the observed permutation = 0.1354, Exact P value = 0.3034 
Relative risk = 2.00, Taylor 95%C1 = -0.0294 and 0.8294 
Number of patients 
Group Recovery Non-recovery 
MULT 8 2 
Placebo 1 9 
The probability of exactly the observed permutation = 0.0027, Exact P value = 0.0055 
Relative risk = 4.9, Taylor 95%C1 = 1.3665 and 17.4906 
Note: Recovery = No TMJ arthralgia was diagnosed after the final treatment, Non- 
recovery = Patients still had or developed TMJ arthralgia after the final treatment 
The results from Fisher's exact test showed that the number of patients who 
recovered from arthralgia of TMJ in the MLJLT group was significantly greater 
than the placebo group at P value = 0.0055. Moreover, the relative risk of the 
comparison showed that MLJLT was 4.9 times (95%CI = 1.4 to 17.5) more effective 
than placebo in terms of the numbers of patients who had arthralgia relieved. 
There was no such a difference by comparing the CULT group with the placebo 
group. 
Axis II 
Axis H diagnosis was assessed before treatment. This was composed of pain 
intensity and disability, depression and limitation related to mandibular 
functioning. 
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Pain intensity and disabili 
Pain intensity and disability was assessed on the basis of grading of chronic pain 
severity mentioned in RDC (Dworkin and LeResche, 1992). The grading chronic 
pain severity is shown in table 2 1. 
Table 21 
. 
Grading chronic pain s'everity by groups before treatment 
Number of patients categorised by grading chronic pain severity 
Group I II in IV Unclassified 
CLILT 0 7 2 1 0 
MLILT 1 6 2 0 1 
Placebo 0 7 0 2 1 
Total 1 20 4 3 2 
Note :I= Low disability-low intensity pain, 11 = Low disability-high intensity pain, III 
high-disability-moderate limiting, IV = high disability-severely limiting 
The majority of patients in every group were in grade 11 chronic pain severity, 
showing low disability and high intensity pain. There was no grade 1, low 
disability and low intensity pain in the CULT and placebo groups. Grade 111, high 
disability and moderate limiting was not found in the placebo group while grade 
TV, high disability and severely limiting was not found in the MLILT group. 
Depression and non-speciElc physical ýEZmptom 
Depression and non-specific physical symptoms of patients were assessed by 
using the modifted SCR 90 for RDC (Dworkin and LeResche, 1992) 
are in table 22. 
The details 
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Table 22. Classifications of depression and non-specific physical symptoms with 
and without pain before treatment 
Number of patients 
Group Depression Nonspecific physical 
symptoms included 
pain 
Nonspecific physical 
symptoms excluded 
pain 
N M S U N M S U N M S U 
CULT 6 1 2 1 2 2 5 1 4 1 4 1 
MULT 4 2 3 1 3 4 2 1 5 3 1 1 
Placebo 1 2 5 2 0 3 5 2 1 2 5 2 
Total 11 5 10 4 5 9 12 4 1 10 6 10 4 
Note: N= normal, M= moderate, S= severe and U= unclassitied due to incomplemy 
filled questionnaires 
There were 4 patients whose depression and non-specific physical symptoms 
could not be classified due to reluctance to complete the questionnaires. Most 
of patients in the CULT and MLILT groups were classified as be normal or 
moderate depression. A half of the number of patients in the placebo group had 
severe depression. Fifty percent of patients in the CLELT and the placebo groups 
had severe non-specific physical symptoms including pain; while the MULT 
group had about the same numbers of patients categorised into normal, 
moderate and severe non-specific symptoms included pain. The non-specific 
physical symptoms excluding pain in 50% of patients in the MULT group were 
normal while 50% of patients in the placebo group had severe classification. 
The 
majority of patients in the CULT group had either normal or severe non-specific 
physical symptoms excluding pain. 
Limitations related to mandibular Cynctions 
Patients were asked to fill the jaw disability checklist which was a part of axis II 
questionnaires before treatment. Limitations related to mandibular 
functions 
was composed of 12 categories. The details are shown 
in table 23. 
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Table 23. Limitations related to mandibular functions before treatment by groups 
and total numbers 
Number of patients by groups and total numbers 
Limitations of 
activities due 
to jaw 
disability 
CULT 
I 
MULT Placebo Total 
Y N U Y N U Y N U Y N U 
Chewing 8 1 1 9 1 0 8 0 2 25 4 1 
Drinking 1 8 1 2 8 0 1 8 1 4 24 2 
Exercising 1 8 1 4 6 0 2 6 2 7 20 3 
Eating hard 
foods 
8 1 1 8 2 0 9 0 1 25 3 2 
Eating soft 
food s 
0 9 1 5 5 0 2 7 1 7 21 2 
Smiling/ 
Laughing 
4 5 1 4 5 1 5 4 1 13 14 3 
Sexual activity 4 5 1 4 5 1 2 6 2 10 16 4 
Cleaning teeth 
or face 
3 6 1 5 5 0 3 6 1 11 17 2 
Yawning 10 0 0 9 1 0 6 3 1 25 4 1 
Swallowing 1 8 1 1 8 1 1 8 1 3 24 3 
Talking 3 6 1 3 7 0 3 5 2 11 17 2 
Having usual 
facial 
appearance 
0 9 1 0 10 0 3 6 1 3 25 2 
Note :Y= yes, N= No and U= Undecided 
From the jaw disability checklists, the majority of patients either in the allocated 
groups or total number seemed to have limitations of usual activities related 
directly to particular jaw functions such as chewing, eating hard foods, and 
yawning. However, the kind of diet was also a factor of limitation. Most of the 
patients in the CULT and placebo groups had no limitation of eating soft foods 
while a half of patients in MLILT had a limitation of eating soft foods. Most of 
patients did not have difficulty in drinking, exercising, smiling, sexual activity, 
cleaning teeth, swallowing, talking and facial appearance. 
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THE MAIN EFFECT 
Pain pressure threshold (PPT) 
The pain pressure threshold of the worst trigger point was measured with the 
electronic algometer twice before treatment and after each treatment. The 
individual PPT in kilopascals (kpa) by groups is shown in figure 23. 
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Figure 13. Line graphs of individual PPT by the time of assessments and groups 
of treatments 
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Baseline 2 Post 1 Post 2 Post 3 
Time 
The trends of the changes in PPT of individual patients in the CULT group after 
the first treatment (post 1) were varied. There were decreases in PPT in some 
patients. After the second treatment, the PPTs of the majority of patients in the 
CLILT group were slightly increased. In the MLILT group, the PPT was 
remarkably increased in most of the patients. A decrease in PPT in comparison 
with the baselines after MULT was not detected. The PPTs of the patients in the 
placebo group showed random changes. There were two patients who had an 
extreme increase and decrease in PPT. 
The means and the standard deviations (SD) measured at different time points 
are shown in table 24. 
Table 24. Means and the standard deviations (SD) of baseline and post-treatment 
PPT by group and time of assessments 
means PIPT in kpa (SID) 
Group\time Baseline I Baseline 2 Afte rI After 2 Afte r3 
treatment treatments treatments 
CULT 66.1 68.8 71.0 80.0 85.2 
(19.55) (22.08) (24.26) (24.73) (27.27) 
MULT 61.1 62.4 82.7 99.0 102.6 
(16.89) (21.26) (35.68) (29.84) (32.21) 
Placebo 55.2 57.9 60.4 61.2 61.1 
(19.16) (18.71) (15.19) (26.65) (27.57) 
The means of PPT of each groups by the time of assessments are also shown in 
line graph (figure 14). 
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Figure 14. Means of pain pressure threshold (PP7) measured at pre and post- 
treatment 
Mean PPT 
120 
100 
80 
T ------------------------------------------------------------------------------ ---- ý- p 
m 60 
40 
20 
-t --------------------- ------------------------------------------------------------------------------------ I 
0i 
Baseline 1 Baseline 2 Post 1 Post 2 
TIME 
-*--CLlLT -10-MLILT Placebol 
Fjost 3 
From the figure 14 there were differences of the means of the baselines among 
groups. The means of PPT of the CLILT group was slightly increased after the 
second treatment (post 2). In the MLILT group, the mean PPT was remarkably 
increased after the first treatment (post 1). The placebo group showed no 
obvious change after intervention. The ANCOVA which can correct the 
difference of the baseline was performed to detect the differences of PPT among 
groups (table 25). 
----------------------------------------------------------------------------------------------------------I 
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Table 25. Comparison of average PPT response to treatments over time by 
ANCOVA with the average of two baselines as a covariate 
Sources of Degree Mean F sig. of F Observed power at the 
variation of Square 0.05 level 
Freedom 
Within + Residual 26 243-62 
Regression 1 12039.49 49.42 <0.001 1.000 
Experimental 2 2155.71 8.85 0.001 0.953 
Group 
Note: The normality of every dependent variable and covariate was tested by Shapiro- 
Wilks test (P value >0.05). The homogeneity of variance was tested by Cochrans C and 
Baretlett-Box F (P value = 0.366 and 0.543 respectively) 
The significance of F for regression indicated that the slope of the average PPT 
after treatments predicted by the average PPT of baselines was not zero. The 
overaR difference of PPT after three episodes of treatments among groups was 
compared using the mean of two baselines as a covariate variable and the mean 
of three post-treatment assessments used as a dependant variable. There was a 
statistically significant difference of the average PPT over the time of treatment 
among groups at P value 0.001. The power of the test for 30 patient sample size 
at the 0.05 level was 95%. 
The further analysis was performed in order to examine the differences of the 
average PPT between groups using the adjusted means by the average of two 
baselines. The result is shown in table 26. 
140 
Table 26. Comparison of the differences of the average PPT between _groups 
over time by T-test with adjustment for the average of two baselines as a 
covariate. 
Placebo (Adjusted mean = 67.01) as a simple contrast 
Group Coefficient Std. Err t-value Sig. t Power 
(Adjusted mean) 
CULT 5.40 7.23 0.075 0.462 0.136 
(72.41) 
MULT 27.98 7.22 3.88 0.0001 0.961 
(94.99) 
1 1 
CULT (Adjusted mean 72.41) as a simple contrast 
Group Coefficient Std. Err t-value Sig. t Power 
(Adjusted mean) 
WILT 22.58 6.88 3.28 0.003 0.883 
(94.99) 
Placebo -5.40 7.23 -0.075 0.462 0.136 
(67.07) 
Note : Individual univariate = 0.95 confidence interval and two-tailed observed power 
taken at 0.05 level. 
According to table 26, there was a statistical significant increase in the average 
PPT in the MLJLT group compared with the placebo group at P value 0.0001. The 
difference of the mean PPT between these two groups was 27.99 kpa with the 
95% confidence interval of the difference between means (95%Cl) 13.14 to 42.82 
1--pa. LILF There was no significant difference of the average PPT between the CULT 
and placebo groups at P value less than 0.05. The average PPT of the MMLT 
group was also significantly increased in comparison with the average PPT of the 
CULT group at P value 0.003. The difference between the means was 22.58 kpa 
(95%C1 8.43 to 36.72 kpa). A statistical difference of the average PPT after 
treatment between CULT and placebo groups was not able to be obtained at P 
value less than 0.05. 
In order to detect PPT response to the number of the treatments compared 
among groups, the ANCOVA was performed using the PPT after treatments as 
dependent factors and the first and second baselines as covariates (table 27). 
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Table 27 Comparison of PPT response to treatments after the first, second and 
final treatments by ANCOVA with the first and the second baselines as 
covariates. 
Variable Mean square F Sig. of F Power at the 
(Degrees of freedom 0.05 level 
- 2,25) 
Afte r the first 1006.57 2.64 0.091 0.477 
treatment 
After the second 2834.00 9.10 0.001 0.957 
treatment 
After the final 3198.50 10.53 <0-001 0.978 
treatment 
After the first treatment, there was no statistically significant difference of PPT 
among groups at P value less than O. OS. A statistical difference of PPT among 
groups at P value 0.001 (power of the test = 9696) was found after the second 
treatment. The strongly significant difference of PPT among group at P value less 
than 0.001 (power of the test = 98%) was also shown after the third (final) 
treatment. The further analysis was undertaken in order to examine the 
differences of PPT between groups using the adjusted means based on the 
baselines (table 28). 
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Table 28. Comparison of PPT among groups after the second and final 
treatments by T-test with adjustment for the first and second baselines as 
covariates. 
After the second treatment 
Placebo (Adjusted mean = 67.05) as a simple contrast 
Group Coefficient Std. Err t-value Sig. t Power 
(Adjusted mean) 
CULT 6.70 8.19 0.82 0.421 0.155 
(73.75) 
MULT 32.32 8.18 3.95 0.0006 0.966 
(99.37) 
11 1 
CULT (Adjusted mean 73.75) as a simple contrast 
Group Coefficient Std. Err t-value Sig. t Powe r 
(Adjusted mean) 
MULT 25.63 7.79 3.29 0.003 0.884 
(99.37) 
Placebo -6.70 8.19 -0.82 0.421 0.155 
(67.05) 
1 1 1 1 
After the final treatment 
Placebo (Adjusted mean = 67.57) as a simple contrast 
Group Coefficient Std. Err t-value Sig. t Power 
(Adjusted mean) 
CULT 10.64 8.09 1.32 0.200 0.243 
(78.21) 
MULT 35.54 8.08 4.40 0.0002 0.988 
(103-11) 
1 11 1 1 
CULT (Adjusted mean = 78.21) as a simple contrast 
Group Coefficient Std. Err t-value Sig. t Power 
(Adjusted mean) 
MULT 24.90 7.69 3.24 0.003 0.874 
(103.11) 
Placebo -10.64 8.09 -1.32 0.200 0.243 
(67.57) 
1 1 1 11 
Note : Individual univariate = 0.95 confidence intervais ana two-taiiea ODservea power 
taken at 0.05 level. 
After the second treatment, the MLJLT group showed a higher PPT than the 
placebo at P value 0.0006 and power of the test 97% (9.5%CI = 15.47 to 49.17 kpa). 
The MLJLT group also had a higher PPT in comparison with the CLJLT group at P 
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value 0.003 and power of the test 88% (95% CI = 41-66 to 9.59 kpa). A statistical 
difference of PPT at P value less than 0.05 was not found between the CULT and 
placebo groups. 
After the third treatment, the MULT group still had a higher PPT than the 
placebo and CULT groups with the stronger statistical significant differences than 
the results after the second treatment. The P value of the difference between the 
MHLT and placebo groups was 0.0002 (95%CI 52.18 to 18.90 kpa). The P value of 
the difference between the MHLT and CULT groups was 0.003 (95%CI 40-73 to 
9.06 kpa). There was still no significant difference of PPT between the CULT and 
placebo at P value less than 0.05. 
PPTs were also recorded from the normal muscles of subiects at the same areas 
and same time as PPTs recorded Lrom trtq-qer points 
Mean PPTs and the SD by time of assessments in corresponding to the treatment 
schedWes are shown in table 29. 
Table 29. Means and the standard deviations (SD) of PPT of the normal muscle 
corresponding to trigger point areas by groups and time of assessments 
means PPT in kpa (SD) 
Group\tirne assessment 
1 
assessment 
2 
assessment 
3 
assessment 
4 
assessment 
5 
CULT 104.6 (24.7) 113.5 (34.7) 107.3 (38.3) 101.2 (26.9) 107.9 (26.7) 
MULT 81.6(20.4) 85.0 (22.5) 83.6(26.0) 83.3 (30.5) 86.2(27.9) 
Placebo 90.0(11.9) 80.8(15.8) 77.1 (17.3) 90.5(19.4) 83.2 (19.9) 
Note : assessment 1 corresponding to baseline 1, assessment corresponding to 
baseline 2, assessment 3 corresponding to post-treatment 1, assessment 4 
corresponding to post-treatment 2 and assessment 5 corresponding to post final 
treatment 
Mean PPT of the CULT group was higher than the other groups in every 
assessment. ANCOVA was performed to detect the difference of PPT among 
groups by using PPTs of assessment 3 to 5 as a dependent variable and 
assessment I and 2 as a covariate (table 30). This was conducted to investigate 
the PPT of the control sites which might respond to treatment intervention. 
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Table 30. Comparison of PPTs of the normal sites response to interventions over 
time by ANCOVA using a dependent variable and covariate in 
correspondence to PPT analysis of trigger points 
Sources of Degree Mean F sig. of F Observed power at the 
variation of Square 0.05 level 
Freedom 
Within + Residual 26 238.74 
Regression 1 10887.18 45.60 <0.001 1.000 
Experimental 2 26.52 0.11 0.895 0.067 
Group 
Note: The normality of every dependent variable and covariate was tested by ! snaplro- 
Wilks test (P value >0.05). The homogeneity of variance was tested by Cochrans C and 
Baretlett-Box F (P value = . 453 and . 191 respectively) 
The significance of regression line at 100% power of the test not only showed 
non-zero slope of regression line matching ANCOVA assumption but also 
confirmed reliability of PPT measured from normal sites. There was no 
statistically significant difference of PPT among groups at P value 0.05. 
The MLJLT group had statistically higher PPT than the CIJLT and placebo groups 
from the results of the overall effects after treatments. As far as the response to 
the number of treatments was concerned, the MHLT group showed the higher 
PPT in comparison with the others after the second treatment. The strongly 
statistically significant difference of PPT was found after the third treatment 
implying a carry over effect of MLJLT. The CLJLT group failed to show a 
statistical difference of PPT compared with the placebo group. The analysis 
from 
control showed no statistical difference of PPT among groups 
by time of 
assessment in correspondence to the treatment schedule. 
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THE OTHER REIATED EFFECTS 
Symptom severity index (SSI) using visual analogue pain scale 
SSI were recorded twice before the first treatment and then after each 
treatment. The maximum score was 10; the worst pain that can be imagined. 
Zero was the score for no pain. The individual SSI by groups is shown in figure 
15. 
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Figure 15. Line graphs of individual SSI by times of assessments and groups 
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From figure 15, there were 4 patients in the CLILT group who showed a decrease 
in SSI after the second treatment. However, most of patients in the CLILT group 
had no distinct change in SSI. In the MLILT group, most of patients had 
decreases in SSI after the first treatment. The SSI was also gradually decreased 
by increasing the number of treatments. The placebo group showed an 
uncertain pattern of SSI change by time. After the third treatment, SSI of the 
majority of patients in this group was about the same level as the first baseline. 
The means and SD of SSI at different time points are detailed in table 3 1. 
Table 3 1. Means and the SD of baselines and post-treatment symptom severity 
index (SSI) by group and time of assessments 
Means SSI (SD) 
Group\time Baseline I Baseline 2 After I Afte r2 Afte r3 
treatment treatments treatments 
CULT 6.8 6.5 6.7 6.3 6.1 
(2.17) (1-68) (1-65) (2.07) (2.29) 
MULT 6.3 6.3 6.3 5.7 4.5 
(2.06) (1.97) (2.64) (2.69) (2.58) 
Placebo 7.3 6.5 6.5 5.2 5.0 
(1.45) (2.64) (2.71) (3.31) (3.38) 
The mean SSI of each group by time of assessments is also plotted in figure 16. 
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Figure 16. Means of SSI measured at pre and post treatments 
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The means of SSI showed differences among groups at the first baseline. At the 
second baseline the means among groups were about the same level (6.3 to 6.5). 
A slight decline of mean SSI was found in the CLILT group by time of treatment. 
The mean SSI of the MLILT group was decreased gradually after the second 
treatment. Although a distinct decrease in mean SSI was found in the placebo 
group after the second treatment, there was no change in mean SSI after the 
third treatment. SSI among groups was compared by ANCOVA using two 
basehnes as a covariate (table 32). 
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Table 32. Comparison of the average SSi response to treatments over time by 
ANCOVA with the average of two basefine as a covariate 
Sources of 
variation 
Degree of 
Freedom 
Mean 
Square 
F sig. of F Observed power at the 
0.05 level 
Within + Residual 26 2.9 
Regression 1 86.36 30.84 <0.001 1.0 
Experimental 
Group 
2 2.71 10-82 0.94 0.194 
Note: The normality of every dependent variable and covariate was tested by Shapiro- 
Wilks test (P value > 0.05). Cochrans C (9,3) and Bartlett-Box F (2,1640) P value 
0.323 and 0.408 respectively 
A significance of F of the regression at P value less than 0.001 indicated that the 
slope of regression using baseline predicting SSI after treatment was not zero. 
There was no statisticaRy significant difference of the mean SSI among groups at 
P value less than 0.05 after the treatments. 
It was shown that a difference of SSI responding to CLJLT, MLILT and placebo 
could not be observed over the period of treatments. 
McGill pain questionnaire 
McGill pain questionnaire was used as another subjective pain assessment. 
Patients were invited to complete the questionnaires before treatment and after 
the final treatment. Pain rating index (PRI) was calculated on the basis of weight 
rank score as suggested by Melzack et al (1985). The individual total pain rating 
index (PRI-T) by groups is shown in figure 17. 
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Figure 17. Line graphs of individual total pain rating index by time of 
assessments and groups 
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The ranges of T-PRI at the baseline in the CLELT and placebo groups were grater 
than the MILT group of which the range of T-PRI was 5 to 1 S. After the final 
treatment, the majority of patients in every group showed an decrease in PRI-T. 
Owing to a non-normal distribution of the score, non-parametric statistical tests 
were used for description of data and analysis. The medians and ranges of total 
pain rating index (PRI-T) by groups are shown in table 33. 
Table 33. Medians and their 25t" to 7511, percentiles of total pain rating index (PRI- 
T) before treatment and after the final treatment by groups. 
Median (2511 to 75" percentiles) of PRI-T 
Group Before treatment After final treatment 
CULT 17.4 (8.7 to 31.9) 10.3 (6.4 to 15-2) 
MULT 11.9 0 0.6 to 14.8) 6.8 (0.7 to 11.3 9) 
Placebo 16.7 (11.4 to 2 5.7) 5.1 (3.5 to 12-3) 
Note : 25 
th to 75"' percentiles were calculated using I UKey's minges 
The medians of PRI-T before treatment of the CLILT and placebo groups were 
, -IV, about the same level while the MLELT group had distinctly lower medians than 
the others. After the final treatment, all groups had reduction in medians of 
PRI-T. The MLELT and placebo groups had lower scores than the CULT group. 
The differences of PRI-T among groups before treatment and after the final 
treatment were analysed by using Kruskal-Wallis as shown in table 34. 
Table 34. Comparison of PRI-T among groups before treatment and after the 
final treatment by Kruskal-Wallis 
Time Of Degree of freedom Chi-square Significance 
assessments 
Before treatment 2 2.80 0.25 
Afte r the 2 2.38 
0.30 
treatment 
Significant differences of PRI-T among groups were not found at P value less 
than 0.05 either before treatment or after the final treatment. The comparison 
of PRI-T before and after the final treatment within group was analysed 
by using 
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Wilcoxon matched-pairs signed-ranks test (table 35). 
Table 35. Comparison of PRI-T before treatment and after the final treatment 
within group by Wilcoxon matched-pairs signed-ranks test 
Group Z score 2-Tailed P value 
CULT -1.48 0.14 
MULT -1.99 0.05 
Placebo -1.60 0.11 
There was no statistically significant difference of PRI-T before treatment and 
after the final treatment within the CULT and placebo groups at P value less 
than 0.05. It was found that there was a reduction of PRI-T after the final 
treatment compared with the score before treatment in the WILT group at P 
value 0.05. 
The compartments of PRI-T; sensory, affective, evaluative and miscellaneous 
pain rating indexes were analysed in the same way as PRI-T. There was no 
statistically significant differences among groups either before treatment and 
after the final treatment at 0.05 p value. The within group comparisons showed 
no statistical differences in all groups apart from that evaluative pain rating 
scores were significantly reduced at P value = 0.03,0.04 and 0.04 in the CLJLT, 
MLILT and placebo groups respectively. 
Maximum mouth opening without pain (MOSP) 
The maximum mouth openings in the ranges that patients felt comfortable were 
recorded using Willis bite gauge. The measurements were undertaken twice 
before treatment and after each treatment. The individual MOSP in nun by 
groups is shown in figure 18. 
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Figure 18. Line 
-graphs of 
individual MOSP by the time of assessments and 
groups. 
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Time 
Post 1 Post 2 Post 3 
Time 
About a half of the number of patients in the CLELT group had baseline MOSP 
less than 25 mm while the others had MOSP more than 30 mm. The majority of 
patients in this group had no change in MOSP after treatments. The figure of 
baseline MOSP in the MLILT group was likely to be similar to the CLELT group 
apart from no patient had MOSP more than 35 mm. Slight increases in MOSP 
after treatments could be found in most of patients of the MLILT group. The 
baseline MOSP of the placebo group was in the range of 15 to 45 nim. The 
change in MOSP after treatments was not be remarkable overafl. 
The means and the SD of MOSP measured at different time points are shown in 
tabie 36. 
Table 36. Means and the SD of baselines and post-treatment MOSP in mm by 
groups and time of assessments 
means MOSP (SD) 
Group\time Baseline 1 Baseline 2 After 1 Afte r2 After 3 
treatment treatments treatments 
CULT 26.6 26.4 29.4 30.1 32.4 
(9-99) (9.13) (7.83) (9.76) (8.95) 
MULT 25.2 26.4 27.4 29.4 31.3 
(6.12) (4.62) (5.64) (6.92) (5.25) 
Placebo 28.6 28.8 30.5 30.1 29.2 
(8.07) (10.29) (8.06) (8.36) (8-08) 
The means of each group by time of assessments are shown in figure 19. 
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Figure 19. Means of maximum mouth opening without pain (MOSP) measured at 
pre and post-treatment 
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The placebo group had the highest mean MOSP compared with the other groups. 
On the other hand, the mean MOSP in the CULT and MLILT group showed about 
I nim difference. There seemed to be no change in mean MOSP of the placebo 
group after treatments. Mean MOSP was gradually increased after the first 
treatment in the CLILT and MULT groups. After the final treatment, both 
groups had mean MOSP more than 30 mm. 
The ANCOVA was used as analysis method to correct the bias of the baseline 
and compare differences of MOSP among groups after treatments using 
baselines as a covariate (table 37). 
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Table 3 7. Comparison of average MOSP response to treatments over time by 
ANCOVA with the average of two baselines as a covariate 
Sources of Degree Mean F sig. of F Observed power at the 
variation of Square 0.05 level 
Freedom 
Within + Residual 26 11.72 
Regression 1 1188.02 101-34 <0.001 1.000 
Experimental 2 16.66 1.42 0.260 0.276 
Group 
Note: The normality ot every dependent variable and covariate was tested by Shapiro- 
Wilks test (P value >0.05). Cochrans C (9,3) and Bartlett-Box FP value = 0.667 and 
0.492 respectively 
The regression of MOSP after treatment predicted by baseline was linear with 
non-zero slope as a significance of regression less than 0.05. There was no 
statistical significant difference of MOSP after treatments among groups at P 
value 0.05. 
Overall the MHLT and CLILT groups showed slight improvement in MOSP but 
failed to have a statistically significant difference among groups. 
Lateral movement 
The maximum lateral movement (LM) was recorded before treatment and after 
the final treatment using the jaw tracking machine (K-61). The LM can be divided 
into two movements; ipsilateral movement to the painful side (ILM) and 
contralateral movement away from the painful side (CLM). 
Ivsilateral movement to the painful side 
The maximum range of movement to the painful side was recorded using jaw 
tracking before treatment and after the final treatment. 
are shown in figure 20. 
The individual results 
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Figure 20. Line graphs of individual ipsilateral movement to the painful side pre 
and post-treatments 
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From figure 20, about a half of patients in every group had ILM not less than 7 
nim before treatment. After the final treatment, a change of ILM was found in 
two directions (increase and decrease) in a small numbers of patients in every 
group. Means of ILM and the SD are detailed in table 38. 
Table 38. Means and the SD of baseline and post-treatment of ipsilateral 
movement to the painful side (ILM) in mm by groups and time of assessments 
Means ILM (SD) 
Group/time Baseline After final treatment 
CULT 6.6(1-9) 6.9(2.3) 
MULT 6.5 (2.5) 7.5 (2.2) 
Placebo 6.3 (2.9) 7.4(2.6) 
The means of each group by time of assessments are also shown in figure 2 1. 
Figure 2 1. Means of ipsilateral movement to the painful side at pre and post- 
treatments 
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According to figure 2 1, the mean of baseline ILM in every group was ah-nost the 
same level. The CULT group had the highest ILM while the placebo group 
had 
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the lowest ILM. The assessments after the final treatment showed improvement 
in ILM in every group particular in MLILT and placebo groups. The comparison 
among groups using ANCOVA is reported in table 39. 
Table 39. Comparison of average ILM response to treatments over time by 
ANCOVA with baseline as a covariate 
Sources of Degree Mean F sig. of F Observed power at the 
variation of Square 0.05 level 
Freedom 
Within + Residual 26 3.29 
Regression 1 63-50 19.27 <0.001 0.988 
Experimental 2 1.48 0.45 0.643 0.118 
Group 
Note: The normality of every dependent variable and covariate was tested by Shapiro- 
Wilks, test (P value > 0.05). Cochrans C (9,3) and Bartlett-Box FP value = 0.831 and 
0.860 respectively 
The significance of F for regression indicated that the slope of ILM after 
treatment predicted by the baseline was not zero. The difference of ILM after 
treatment among groups was not statistically significant at the P value less than 
0.05. 
Contralateral movement away from the painLul side 
The maximum range of movement to the non-painful side was recorded using 
jaw tracking before treatment and after the final treatment. The individual 
res-ults are shown in figure 22. 
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Figure 22. Line graphs of individual contralateral movement away from the 
painful side pre and post-treatments 
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According to fi_qure 22, most of the patients in the CLELT and MLILT groups had 
CLM about 6 to 7 mni before treatment. In the placebo group, the majority of 
patients had CLM less than 7 mm but the rest of them had high CLMs at 9 to 10 
nun. After the final treatment, there were improvements in CLM in a few 
patients in every group. Means and the SD of CLM by groups are detailed in 
table 40. 
Table 40. Means and the SD of baseline and post-treatment contralateral 
movement away from the painful side (CLM) in mm by groups and time of 
assessments 
Means CLM (SID) 
Group/time Baseline After final treatment 
CULT 6.5 (1.6) 7.1 (1.9) 
MULT 7.0(1.8) 7.4(1.5) 
Placebo 6.3 (2.5) 7.4(2.6) 
The mean CLMs by groups are also illustrated in figure 23. 
Figure 23. Means of contralateral movement away from the painful side at pre 
and post-treatments 
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The mean CLM of the MULT group was at 7 mm while the means of CLM in the 
CULT and placebo groups were 6.5 and 6.3 respectively. There were increases in 
means of CLM in all groups after the final treatment which made the means of 
aH groups more than 7 nun. The comparison among groups using ANCOVA is 
reported in table 4 1. 
Table 4 1. Comparison of CLM response to treatments over time by ANCOVA 
with baseline as a covariate 
Sources of Degree Mean F sig. of F Observed power at the 
variation of Square 0.05 level 
Freedom 
Within + Residual 26 3.01 
Regression 1 37.81 12.55 0.002 0.926 
Experimental 2 0.43 0.14 0.869 0.071 
Group 
Note: The normality of every dependent variable and covariate was tested by Shapiro- 
Wilks test (P value > 0.05). Cochrans C (9,3) and Bartlett-Box FP value = 0.178 and 
0.259 respectively 
The significance of F for regression showed that the predicted line matched the 
assumption of ANCOVA. The difference of CLM among groups after the final 
treatment was not able to be detected at P value less than 0.05. 
The ranges of lateral movement either ipsilateral to the painful side or 
contralateral away from the painful side did not seem to be limited at the 
beginning of treatment using the reference of normal lateral movement at 7 mm 
as mentioned in RDC (Dworkin and LeResche, 1992). There was no statistically 
significant difference of lateral movement among groups after the final 
treatment. 
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Free way space (FS) 
Free way space (FS) in vertical, sagittal and frontal planes was recorded before 
treatment and after the final treatment. The individual records of vertical free 
way space (VFS) in mm before treatment and after the final treatment are shown 
in figure 24. 
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Figure 24. Line graphs of individual vertical free way space by time of 
assessments and groups 
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The majority of patients in every group had baseline VFS in the range of more 
than 2 mm to 4 mm. Only a patient in the placebo group has VFS at 6.5 mm 
before treatment. A slight decrease or increase (not more than I mm) was 
found in most of patients in every group. There was a distinct increase in VFS in 
one patient in the WILT group. 
Owing to the fact that the data did not match a normal distribution, non- 
parametric statistical methods were used to describe and analyse differences 
among groups. The medians and ranges of vertical free way space by groups 
were showm in table 42. 
Table 42. Medians and the 2511 to 751,1 percentiles of vertical free way space (VFS) 
before treatment and after the final treatment by groups. 
Median (2511 to 75" percentiles) of VFS in mm 
Group Before treatment After final treatment 
CULT 2.5 (2.1 to 3.0) 2.9 (2.4 to 3.4) 
MULT 2.6 (2.2 to 3.4) 2.5 (2.3 to 3.1) 
Placebo 3.4 (2.4 to 3.5) 3.1 (2.7 to 4.4) 
Note : the 2 5th to 7511, percentiles were calculated using Tukey's Hinges 
Overall the medians of VFS before treatment and after the final treatment were 
approximately the same level at between 2.5 to 3.4 mm. The placebo group had 
the highest baseline of median VFS. A slight increase in medians of VFS after 
treatment was found in the CLILT group while VSF was slightly decreased in the 
placebo group. The median VSF of the MULT group could be considered to be 
unchanged. Differences of VFS among groups before treatment and after the 
final treatment were analysed by using Kruskal-Wallis as shown in table 43. 
Table 43. Comparison of VFS among groups before treatment and after the final 
treatment by Kruskal- Wallis 
Time of Degree of freedom Chi-square Significance 
assessments 
Before treatment 2 4.12 0.13 
After the final 2 3.22 0.20 
treatment 
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A significant difference of VFS among groups were not found at P value less than 
0.05 either before treatment or after the final treatment. The comparison of VFS 
before and after the final treatment within group was analysed by using 
Wilcoxon matched-pairs signed-ranks test (table 44). 
Table 44. Comparison of VFS before treatment and after the final treatment 
within group by Wilcoxon matched-pairs signed-ranks test 
Group Z score 2-Tailed P value 
CULT -1.58 0.11 
MULT -0.30 0.76 
Placebo -0.83 0.41 
There was no statistically significant difference of VSF before treatment and 
after the final treatment within group at P value less than 0.05 (table 44). 
The free way spaces in sagittal and frontal planes were analysed in the same way 
as VSF and found to show no difference among groups and within groups at 
0.05 P value. 
Velocity of mandibular movement (VM) 
The opening and closing velocity of mandibular movement in mm/sec was 
recorded before treatment and after the final treatment using the jaw tracking 
machine. The average velocity of mandibular movement when opening and 
closing was used as the velocity of mandibular movement (VM). The individual 
VMs by groups of individual patients are shown in figure 25. 
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Figure 25. Line graphs of individual velocity of mandibular movement (VM) pre 
and post-treatment 
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The majority of patients in all groups had constancy in VM. 
decrease in VM was noticed in a few patients in every group. 
reported in table 45. 
An increase or 
Mean VM is also 
Table 45. Means and the SD of baseline and post-treatment velocity of 
mandibular movement (VM) in mm/sec by groups and time of assessments 
Means VM (SD) 
Group/time Baseline After final treatment 
CULT 83.5 (36-9) 121.3 (3 7.5) 
MULT 100.7(43.4) 122.3 (38.0) 
Placebo 96.3 (47.8) 111.9 (44.0) 
Mean VMs by groups are also illustrated in figure 26. 
Figure 26. Means of velocity of mandibular movement pre and post-treatments 
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From table 45 and figure 24, the mean VM of the CULT group was lower than 
the other groups at the baseline. After the final treatment, there was an 
increase in mean VN1 of every group which reached the point more than 100 
mm/sec. The comparison of VM after the final treatment among groups was 
analysed using ANCOVA (table 46). 
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Table 46. Comparison of VM response to treatments over time by ANCOVA with 
baseline as a covariate 
Sources of Degree Mean F sig. of F Observed power at the 
variation of Square 0.05 level 
Freedom 
Within + Residual 26 1227.25 
Regression 1 11179.98 9.11 0.006 0.826 
Experimental 2 584.21 0.48 0.627 0.122 
Group 
Note: The normality of every dependent variable and covariate was testecl uy ý)napiro- 
Wilks test(P value > 0.05). Cochrans C (9,3) and Bartlett-Box FP value = 0.829 and 
0.870 respectively 
There was a significance of regression implying that the predicted line matched 
the assumption of ANCOVA. A statistically significant difference of VM after the 
final treatment among groups was not found at P value less than 0.05. 
EMG in rest position (rEMG) 
The EMG in jaw rest position was recorded before treatment and after the final 
treatment. The average raw EMG in microV was compared among groups. All of 
the patients had trigger points and tender areas involving the masseter muscles. 
Therefore, the rEMG of the masseter muscle on the affected side was used in the 
analysis. The rEMG of the non-painful masseter muscle was also analysed as a 
control. 
The individual rEMG of painful masseter by groups is shown in figure 27 
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Figure 27. Line graphs of individual rEMG of painful masseter muscles by the 
time of assessments and groups 
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From figure 27, all of patients in every group apart from one patient in the 
MULT group had rEMG at the baseline evaluation of not more than 6 n-iicroV. 
After the final treatment, all patients had average rEMG less than 6 microV. 
Some groups of data were not in normal distribution according to the 
significance of the normality test by the Shapiro-Wilks was less than 0.05. 
Normality could not be obtained from the data transformation. Therefore, the 
non-parametric statistics was used in this case. 
Medians of rEMG of painful masseter muscles and the 25th and 7 Sth percentiles 
are shown in table 47. 
Table 4 7. Medians and their 251h and 75 th percentiles of baseline and post- 
treatment rEMG of painful masseter muscles in microV by group and time of 
assessments 
Medians rEMG (25 to 75 percentiles) 
Group/time Baseline After final treatment 
CULT 2.9 (2.4 to 3.5) 1.8 (1.6 to 2.5) 
MULT 1.9 (0.8 to 5.2) 2.2 (1.8 to 2.5) 
Placebo 1.7 (1.4 to 2.8) 2.0 (1.4 to 2.5) 
Note : the 25 
th to 75 th percentiles were calculated using Tukey's Hinges 
From table 47, there was a decrease of median rEMG of painful masseter 
muscles in the CULT group of which had the highest baseline median rEMG. 
There were slight increases in medians after the final treatments in MULT and 
placebo group. Kruskal-Wallis was performed to compare rEMG before 
treatment and after the final treatment among groups (table 48). The 
comparison of rEMG within group before and after treatment was undertaken by 
using Wilcoxon matched-pairs signed-ranks test (table 49). 
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Table 48. Comparison of EMG in the rest position (rEMG) of painful masseter 
muscles among groups before treatment and after the final treatment by 
Kruskal-Wallis 
Time of Degree of freedom Chi-square Significance 
assessments 
Before treatment 2 1.72 0.42 
Afte r the final 2 0.19 0.91 
treatment 
According to table 48, there was no statistically significant difference of rEMG 
of painful masseter muscles at P value less than 0.05 among groups either 
before treatment or after the final treatment. The difference of rEMG before 
and after treatment within group was tested by 1. using Wilcoxon matched-pairs 
signed-ranks test table 49. 
Table 49. Comparison of EMG in the rest position (rEMG) of painful masseter 
muscles before treatment and after the final treatment within group by 
Wilcoxon matched-pairs signed-ranks test 
Group Z score 2-Tailed P value 
CULT -1.68 0.09 
MULT -0.05 0.96 
Placebo -0.61 0.54 
The statistically significant difference of rEMG before and after the final 
treatment within the same group was not able to found at P value less than 0.05. 
The rEMG of the non-painful masseter muscle was not in normal distribution. 
Therefore, the non-parametric statistical approach was performed as mentioned 
in the analysis of rEMG of affected side. Medians and the 25th and 75th 
percentiles are shown in table 50. 
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Table 50. Medians and the 25t' and 7511 percentiles of baseline and post- 
treatment rEMG of non-painful masseter muscles in microV by groups and 
time of assessments 
Medians rEMG (25 to 75 percentiles) 
Group/time Baseline After final treatment 
CULT 2.4 (2.2 to 3.8) 2.6 (1.3 to 3.4) 
MULT 1.2 (0.9 to 4.5) 2.4 (1.1 to 3.3) 
Placebo 2.2 0.9 to 3.9) 2.8 (2.4 to 3.2) 
Note : the 25 th to 75 th percentiles were calculated using Tukey's Hinges 
An increase in the median rEMG of non-painful masseter muscles after the final 
treatment was found in every group particularly in -the MLELT group of which 
the baseline rEMG was lowest. The differences of rEMG among groups 
before treatment and after the final treatment were analysed by using Kruskal- 
Wallis as shown in table 5 1. 
Table 5 1. Comparison of EMG in the rest position (rEMG) of non-painful masseter 
muscle among groups before treatment and after the final treatment by 
Kruskal-Wallis 
Time of Degree of freedom Chi-square Significance 
assessments 
Before treatment 2 1.69 0.43 
Afte r the final 2 0.49 0.78 
treatment 
Significant differences of rEMG among groups were not found at P value less 
than 0.05 either before treatment or after the final treatment. The comparison 
of rEMG before and after the final treatment within group was analysed by using 
Wilcoxon matched-pairs signed-ranks test (table 52. ) 
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Table 52. Comparison of EMG in the rest position (rEMG) of non-painful masseter 
muscles before treatment and after the final treatment within group by 
Wilcoxon matched-pairs signed-ranks test 
Group Z score 2-Tailed P value 
CULT -1.17 0.24 
MULT -0-86 0.39 
Placebo -0.77 0.44 
There was no statistically significant difference of rEMG of non-painful masseter 
muscles before treatment and after the final treatment within groups at P value 
less than 0.05. 
The rEMG of masseter muscles either on painful or non-painful side showed no 
significant difference before treatment and after the final treatment by among 
groups and within group comparison. 
Electromyography from voluntary clenching (cEMG) 
The rectified EMG was recorded from interval voluntary clenching before 
treatment and after the final treatment. The average EMG was used as a result 
for comparison. Owing to the fact that every patient had trigger points and 
tender areas on masseter muscle, cEMG of masseter muscles on the painful side 
was used for the analysis. The cEMG of non-painful masseter muscles was also 
analysed as a reference. The individual cEMG of the painful masseter muscle 
by 
groups is show in figure 28. 
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Figure 28. Line graphs of individual cEMC of painful masseter muscle by groups 
and time of assessments 
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From figure 28, all of patients in the MULT group had the baseline cEMG less 
than 100 microV while some patients in the CULT and placebo groups had cEMG 
more than 100 microV. After the final treatments, cEMG of the MLELT group was 
either stable or increased. The majority of patients in the CULT group showed 
no distinct change of cEMG after the final treatment. There was a variation of 
pattern of cEMG change after the final treatment in the placebo group. 
The means and SD measured pre and post-treatments were shown in table 53. 
Table 53. Means and the SD of baseline and post-treatment cEMG of painful 
masseter muscles in microV by group and time of assessments 
Means cEMG (SID) 
Group/time Baseline After final treatment 
CULT 64.5 (46.3) 61.2 (42.3) 
MULT 36.8(25.4) 68.0(58.7) 
Placebo 58.7(35-9) 50.1 (33.2) 
The means cEMG of masseter muscles on affected sides of each group pre and 
post-treatments were also illustrated in figure 29. 
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Figure 29. Means of cEMG measured at pre and post-treatment 
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The baseline of mean cEMG of the MULT group was lower than the others. After 
the final treatment, there was a slight decrease in mean of cEMG in the CULT 
and placebo groups. On the other hand, the WILT group showed a distinct 
increase in mean cEMG after the final treatment. 
The ANCOVA was Performed using post-treatment result as a dependent factor 
and baseline as a covariate (table 54). 
Table 54. Comparison of average clenching EMG of painful masseter muscles 
response to treatments over time by ANCOVA with baseline as a covariate 
Sources of Degree Mean F sig. of F Observed power at the 
variation of Square 0.05 level 
Freedom 
Within + Residual 26 1091.37 
Regression 1 28667.06 26.27 <0.001 0.999 
Experimental 2 3640.48 3.34 0.051 0.579 
Group 
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The significance of regression was less than 0.05 showing the non-zero slope of 
a predicted line of baseline and post-treatment cEMG. The significant difference 
of cEMG of masseter muscles on affected sides among groups was marginally 
acceptably at P value 0.051 (power of the test 58%). The further analysis was 
undertaken to examine differences of cEMG between groups comparing means 
adjusted by baselines (table 55). 
Table 55. Comparison of the average clenching EMG of painful masseter muscle 
between pre and post treatments over time by T-test with adjustment for the 
baseline as covariate. 
Placebo (Adjusted mean = 45.32) as a simple contrast 
Group Coefficient Std. Err t-value Sig. t Power 
(Adjusted mean) 
CULT 6.06 14.81 0.41 0.686 0.057 
(51.38) 
MULT 37.31 15.25 2.45 0.022 0.651 
(82.63) 
11 1 1 1 
CULT (Adjusted mean = 51.38) as a simple contrast 
Group Coefficient Std. Err t-value Sig. t Powe r 
(Adjusted mean) 
MULT 31.25 15.53 2.01 0.055 0.490 
(82.63) 
Placebo -6.06 14-81 -0.41 0.686 0.057 
(45.32) 
Note : Individual univariate = 0.95 confidence intervals and two-tailed observed power 
taken at 0.05 level. 
The cFMG of the MLJLT group after the flnal treatment was statistically 
significantly higher than the placebo group at P value 0.022 (95%CI = 5.96 to 
68.66 microý). However, a significant difference of cEMG between the MULT and 
CULT groups was marginal at P value 0.055 (95%CI = -0.66 to 63.17 microV). 
There was no statistically significant difference of cEMG between the CULT and 
placebo groups. 
The cEMG of non-painful masseter muscles was also recorded at the same time 
as the painftfl side. Means and the SD are shown in table 56. 
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Table 56. Means and the SD of baseline and post-treatment cEMG of non-painful 
masseter muscles in microV by group and time of assessments 
Means cEMG (SID) 
Group/time Baseline After the final treatment 
CULT 62.2 (33.4) 65.0(42.5) 
MULT 41.6(25.2) 72.0(61.4) 
Placebo 75.9(38.7) 57.3 (25.9) 
The mean cEMG of the MULT group was still less than other groups as in the 
painful side. After the final treatment, increases in means cEMG of non-painful 
muscle were also found in the CULT and MULT groups. Conversely, the mean 
cEMG was decreased in the placebo group. The overall trend of change was 
similar to the means of cEMG of the painful side. The ANCOVA was used as the 
analysis for the difference of cEMG after the final treatment among groups 
(table 57). 
Table 57. Comparison of average clenching EMG of non-painful masseter 
muscles response to treatments over time by ANCOVA with baseline as a 
covariate 
Sources of Degree Mean F sig. of F Observed power at the 
variation of Square 0.05 level 
Freedom 
Within + Residual 26 1799.50 
Regression 1 9453.98 5.25 0.030 0.595 
Experimental 2 2434.34 1.35 0.276 0.264 
Group 
The significance of regression line was acceptably under 0.05 matching the 
assumption for ANCOVA. There was no significant difference of cEMG of the 
non-painful masseter muscles among groups at p value less than 0.05. 
The trends of changes in cFMG of painful and non-painful sides were similar in all 
groups. According to the analysis of the painful side, the MIJLT group showed a 
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significant increase in cEMG of masseter muscles of affected sides after the final 
treatment compared with the placebo. A marginally significant difference of 
cEMG was also found between the WILT and CLJLT groups with the 95% 
confident interval overlapping zero. CLJLT failed to show a statistical difference 
of cEMG after the final treatment in comparison with the placebo. There was no 
statistically significant difference of cEMG among groups by the analysis of cEMG 
of the non-painful side. 
The results after the period of the tilal 
After the last assessment for the final treatment in trial, there was routine 
follow up at about 2 to 4 weeks after the final treatment. It should be 
emphasised that the placebo group received MLJLT in the second week. 
Therefore, the results of 2 to 4 weeks follow up were response to either CULT or 
MLILT. Apart from routine assessments, SSI based on VAS was also recorded. 
Means SSI measured in the period of the trial and the 2-4 weeks follow up after 
the trial are shown in figure 30. 
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Figure 30. Means of SSI measured in the period of the trial and the 2-4 week 
follow up after the trial 
Mean SSI after the priod of trial 
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Note: The placebo group was given MULT after post treatment 3 and hence is 
indicated by a red line after this point. 
The mean SSI of every group at the 2 to 4 weeks follow up was reduced 
particularly the MLILT group and the placebo group in which the patients 
received MLILT after the first week of the trial. 
The percent pain score reduction calculated by mean VAS from the baseline and 
mean VAS at 2 to 4 weeks follow up were 44% , 50% and 
63% in the groups 
treated with CLILT, MLJLT and MLJLT after placebo respectively. Overall, the 
mean of percent VAS reduction after LILT was 52%. After 2 to 4 weeks foHow 
up, summaries of clinical follow up are shown in table 58. It should be noticed 
that the majority of patients who had arthrocentesis undertaken had pain only 
during the jaw function and had no pain from the TMJ in the rest position or 
palpation. 
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IN VITRO EXPERIMENTS ON MURINE SKELETAL MUSCLE CULTURES 
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MATERLALS AND METHODS OF IN VITRO EXPERIMENTS ON MURINE 
SKELETAL MUSCLE CULTURES 
The in vitro experiments were conducted on a C202 mouse skeletal muscle cell 
line. The amount of PGE2 release in medium by the cells was used as the main 
result to explore the effect of LILT on the formation of that pain substance. 
Mechanical stimulation and IL-1 supplement were used as methods to stimulate 
PGE2 production from the cultures. Control experiments were conducted in 
order to detect the influence of LILT on PGE2 production. 
This part will begin with materials and dilutions used in the experiment. The 
general methods of C202 culture will be described. Then the details of 
experimental and statistics methods will be mentioned. 
MATERIALS AND DILUTIONS 
Culture materials 
1. Tissue culture flasks (T-flasks): Tissue culture treated polystyrene 
flasks - 75 ml size (T-flasks) from Corning Costar 
Corporation, Cambridge, 
USA. 
2. Non-flexible dishes: Flat bottom tissue culture Polystyrene 
dishes -6 ml size from Corning Costar Corporation, 
Cambridge, USA. 
3. Flexible dishes: Flexible bottom dishes; periPERMR, from 
Heraeus instruments, Germany. 
4. Cell well plates (24-well plates): Flat bottom tissue culture wells - size 
3.4 ml, 24 weRs/plate from Corning Costra, New York, USA. 
187 
Culture medium 
There were two type of medium in this experiment as follows: 
1. Proliferation medium: 10% Foetal bovine serum (FBS) from Sigma cell 
culture Ltd., 1% Penicillin 5,000 iu/ml and Streptomycin 50 ýtg/ml (AB) and 
1% Fungizone Amphotericin B 203 gg/rnl (Anti-fungal agent) from Life 
technologies Ltd, Scotland in Dulbecco's Modified Eagle Medium with Sodium 
Pyruvate, 1,000 mg/l Glucose and Pyridoxine (DMEM) from Life Technologies 
Ltd, Scotland. 
2. Differentiation medium: 
Culture method 
1% FBS, AB and Anti-fungal agent in DMEM 
The murine skeletal muscle cell C202 myoblasts were cultured on 75 ml tissue 
culture flasks (T-flasks) in 12 ml of 10% FBS with DMEM (proliferation medium). 
The cells were be fed by changing the medium twice a week until 90% confluent. 
Then the myoblasts were trypsinised with 3 ml of 0.25% Trypsin-EDTA solution 
(1X) and neutralised with 3 ml of proliferation medium. The trypsinised cells 
were counted by using the Coulter counter ZI (Coulter Electronics Limited, 
England) and adjusted with proliferation medium at appropriate 
concentrations depending on culture materials. The high density of cell 
concentration used in this study was based on the protocol of Silberstein et al 
(1986). The optimal concentrations were adjusted for culture materials which 
allowed 80-90Y6 cell confluence to occur in 2 days in the proliferation medium 
(figure 31). After that, the cultures were fed daily with the low serum medium 
(differentiation medium). The early differentiation and cell fusion were noticed 
on the fourth day in the low serum medium (figure 32). The myotubes generally 
were found on the day 7 in the differentiation medium (figure 33). Then the 
cultures were ready for experiments. 
188 
Figure 3 1. C2C 12 proliferation on day 2 in proliferation medium 
i%ý- , 
A. 80 to 90% C2CI2 cell confluence on day 2 in proliferation medium at 
magnification xI 50 
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A 
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B. C2CI 2 on day 2 in proliferation medium at magnification x 250 
Figure 32. Early differentiated C2C 12 on day 4 in differentiation medium 
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A. Cell fusion of C2CI2 on day 4 in differentiation medium (magnification x 250) 
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B. Early myotubes (M) of C2C1 2 on day 4 in differentiation medium (magnification 
x 250) 
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Figure 33. Late differentiated C2C 12 on day 7 in differentiation medium 
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METHODS OF STIMUIATION OF PGE2 RELEASE 
The methods of stimulation of PGE2 release by C202 were divided into two 
main methods as follows: - 
A) Mechanical stretching 
B) Interleukin I supplement. 
The sample preparation, sample allocation, laser irradiation, specimen collection 
and statistical methods of analysis are detailed. 
A. THE EFFECT OF LILT ON THE STIMULATION OF PGE2 BY 
MECHANICAL STRETCHING IN C202 CULTURE 
Sample preparation 
C202 cells from a T-flask were trypsinised and adjusted with proliferation 
medium at 4x 101 cells per ml concentration. Three millilitres of the above 
preparation were plated on 6 ml flexible bottom dishes. Then the culture 
methods as mentioned were undertaken. 
Mechanical stimulation 
Intermittent repetitive mechanical stimulation modified from the study by 
Vandenburgh et al (1990) was applied to postplated C202 cultures. The 
cultures were mechanically deformed every 5 seconds for a 35-second period 
followed by a 15-minute rest period; this activity was repeated 20 times in 5 
hours. The stretching machine (figure 34) used in this experiment was able to 
deform the floor of the flexible plate causing about 10% stretching. The force 
was applied on the lids of dishes to deform bottoms of flexible dishes by 
compressing on convex bases (figure 35). Six samples was able to be stretched 
at the same time. 
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Figure 34. The customised stretching machine 
The side view of the customised stretching machine. 
C= compression operating compartment, M= the motor unit and F=a flexible dish 
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Figure 35. The compression unit of the stretching machine 
B. The force was 
applied to the lip of 
culture dish to 
compress the flexible 
floor on the convex 
base which caused 
the deformation of 
the floor of dish. 
Thus, the cells which 
were attached on the 
floor of dish would 
be stretched 
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A. A convex base (C) for deformation of the flexible floor of culture 
dish 
Low intensity laser radiation 
The Asah adjustable power probe was set up at 60 mW (4J exposure) and 300 
mW (20J exposure) of GaAlAs laser and sham laser (light guide) for irradiation 
on the differentiated C2C12 for 67 seconds in the period of 15-minute rest after 
stretching. The irradiation was repeated 20 times. 
A pair of 12 nim diameter and -12.0 focal length concave lenses (PVC lenses 
from Ealing Opticle-Electric company, UK) was used for expanding the 
irradiation to cover whole area of a dish. The calibration of power energy using 
the isotropic detector was undertaken in 160 areas all over the dish. The details 
concerning the power and energy densities of the laser are shown in table 59. 
Table 59. Mean power densities from calibration and their energy densities of 
820 nm IR and 670 visible red light guide irradiating C2C12 muscle cells in the 
mechanical stretching experiment 
Mean power density Energy density 
O/CM2 ) Total energy density 
(W/cm') and SD for 67 seconds 0/cm') for 20 times 
Doses 820 nm 670 nm 820 nm 670 nm 820 nm 670 nm 
60 mW 0.0087 0.0013 0.5829 0.0871 11.658 1.742 
(0.0025) (0.0002) 
300mW 0.0467 0.0013 3.1289 0.0871 62.578 1.742 
(0.0127) (0.0002) 
Sham 0 0.0013 0 0.0871 0 1.742 
laser (0.0002) 
Sample allocation 
The postplated differentiated C202 cultures prepared from the same original 
T-flask were randomly divided into 7 groups as follows: - 
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Group 1: No intervention 
Group 2: 60 mW GaAlAs laser irradiation 
Group 3: 300 mW GaAlAs laser irradiation 
Group 4: Sham laser irradiation 
Group 5: Stretching cell 
Group 6: Stretching cell with 60 mW GaAlAs laser irradiation 
Group 7. Stretching cell with 300 mW GaAlAs laser irradiation 
Group 8: Stretching cell with sham laser irradiation. 
On the basis of randomised control experiments, the cultures from all of 
experimental groups were undertaken at the same time as far as possible. All 
samples were taken out from the incubator to be placed in the culture hood at 
the same time. The mechanical stretching modified from studies by 
Vandenburgh et al (1990; 1991) was conducted in the hood by the customised 
stretching machine. The positions in the stretching machine were randomly 
allocated for every stretching phase. The non-stretching groups, group I to 4, 
were all placed in the same hood. After 35 seconds of stretching, all cultures 
were taken from the hood. The laser irradiation groups, group 2,3,4,6,7 and 8 
were irradiated by laser regimes as allocated. Then all of samples were placed in 
the incubator for a 15-n-linute rest. All of activities as mentioned were repeated 
20 times. 
The initial study was conducted on cell stretching with and without low and 
high energy LILT regimes (group 1, group 7 and group 8). There were three 
samples in each group for this pilot study. Then the actual study in all of the 
experimental groups was undertaken using 4 samples in each group. 
Collection of specimens 
Five hundreds niicrolitres of medium were collected from each culture, before 
the first cycle began and after a final rest period (the end of the twenty cycle). 
The specimens were immediately stored in plastic tubes and frozen at -750C. 
The PGE2 assay of all specimens were undertaken at the same time within a 
week after the coRection. 
196 
PGE2 assay 
The amount of PGE2 production into medium was estimated using Prostaglandin 
E2 enzymeimmunoassay kit from Amersham International p1c, England. The 
procedure followed the manufacturer's instructions. The amount of PGE2 was 
measured in pg per 50-ýd of medium which was used as a specimen for each a 
assay well. Regarding the accuracy of comparing the amount of PGE2 among 
experimental groups, all of specimens were assayed at the same time using the 
same standard assay curve based on the plotting of the percent optical density 
as a function of the log PGE2 concentration. 
Statistical analysis 
The descriptive statistical methods (individual data plotting, means, ranges and 
standard deviations) were used as the appropriate methods for the sample sizes 
which were less than six (Bland, 1996; Altman, 1996) . The percentage of 
PGE2 
increase was used as a comparison of the amount of PGE2 among groups. Non- 
parametric statistics was not used as Bland (1996) has proved the fact that the U 
distribution could not produce significance at the usual 5% level in the small 
sample size (less than six samples each group). 
The data from the pilot and actual study conducted at different periods of time 
were analysed separately. 
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B. THE EFFECT OF LILT ON THE STIMULATION OF PGE2 BY IL-1 
SUPPLEMENT IN C202 CULTURE 
Sample preparation 
Two millilitres of C202 at 5X 104 cells/ml were plated on 3.4 ml, 24-well plates 
(24-well plates) in specific locations (figure 36); four wells in the middle of the 
plate and each well in the corner of the plate. The wells in the middle were 
irradiated while the wells in each corner were used as control without 
irradiation exposure. The other peripheral wells were not used due to the 
overspill of irradiation from the middle wells. 
The cultures were maintained in proliferation medium for 48 hours until about 
90% confluence. The medium was then changed to 2 ml/weR of DMEM with 1% 
FBS (differentiation medium). The cultures were fed with the above medium 
daily for 7 days to allow myoblast differentiation to occur. 
Twelve samples (24-well plates) were prepared at the same time using the C202 
cells from the same T-flask. 
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Figure 36. The locations of samples in a 24-well plate 
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A. C2CI 2s were plated on the specific locations on the 24-well plate as shown in the 
coloured areas. The yellow areas represented non-radiation exposure wells while 
the red areas were radiation exposure wells. 
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B. C2CI2 was plated on the 24-well plate in the specific location as 
mentioned 
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Sample allocation 
The platform for the 24-well plates was covered with black paper beneath for all 
wells except four wells in the middle of the plates. This allowed a 24-well plate 
had non-radiation exposure wells at Al, A6, DI and D6 and radiation exposure 
wells at B3, B4, C3 and C4 (figure 36). The laser irradiated the cell layer from 
below to avoid interference from the fluid layer of medium as the set up in 
figure 37. 
C2CI2s were plated on twelve of 24-well plates as mentioned. The cultures were 
randomly allocated into 12 groups as follows : 
Group 1 no intervention 
Group 2 low concentration of interleukin 10 00 u/ml of IL-1) 
Group 3 high concentration of interleukin 1 (1,000 u/ml of IL-1) 
Group 4 sham laser 
Group 5 60 mW GaAlAs 
Group 6 300 mW GaAlAs 
Group 7 100 u/ml of IL-I plus sham laser 
Group 8 1,000 u/ml of IL-1 plus sham laser 
Group 9 100 u/ml of IL-I plus 60 mW GaALAs 
Group 10 1,000 u/ml of IL-I plus 60 mW GaAlAs 
Group I1 100 u/ml of IL-I plus 300 mW GaAlAs 
Group 12 1,000 u/ml of IL-I plus 300 mW GaAlAs 
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Figure 37. The set up of laser irradiation of C2CI2 cultures stimulated by IL-I 
supplement 
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Method of stimulation of PGE2 by IL-I 
Moldawer et al (1987) reported that IL-Icc at 1,000 and 10,000 u/ml 
concentrations induced PGE2 production in rat muscle cell, the above two 
appropriate concentrations were applied to this experiment. This laboratory 
used D-10 units of cytokine which 1,000 u/ml was equal to 100 u/ml in D-10 
units and 10,000 U/ml was equivalent to 1,000 u/ml in D-10 units. 
The preparations of IL-Icc in proliferation medium were as below: - 
100 U/ml 1gI of D-10 units of IL-1cc + 999 ýtl of differentiation 
medium 
1000 u/ml 100 of D-10 units of IL-Icc + 990 0 of differentiation 
medium 
The IL-1 medium was used within 10 minutes of preparation. The non-IL-1 
stimulation groups; group 1,4, 5 and 6, were also fed with the fresh 
differentiation medium. Therefore, the amount of PGE2 in every group at the 
end represented the PGE2 production during the inventions in the experiment. 
Laser irradiation 
Two regimes of 820 nm GaAlAs and sham laser were set up as detailed: - 
60 mW/4J/180 sec 
300 mW/4J/180 sec :0 
mW/OJ/180 sec (light guide). 
A pair of 12 mm diameter and -12.0 focal length concave lenses (PVC lenses 
from Ealing UK) was used in order to expand the laser beam to cover 4 wells in 
the middle of 24-well plate; namely B3, B4, C3 and C4. 
The 60 mW or 300 mW GaAlAs or sham laser irradiated the 8-day differentiated 
C202 at the following period of times: - 
After adding IL- I initially 
Every I hour after adding EL-I until 3 hours. 
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The power densities on irradiated weRs were calibrated using an isotropic 
detector. According to the power density recording from80areas each well 
(B3, B4, C3, C4) with 3 time repeated measure$, the mean power densities and 
their energy densities are shown in table 60. 
Table 60. Mean power densities and their energy densities of 820 nm IR and 670 
nm visible red light guide irradiating C2C12 muscle cells stimulated by IL-I 
supplement 
Mean power density Energy density 0/cm') Total energy density 
and SD (W/cm') for 180 seconds O/CM2) fo r3 times 
irradiation 
Doses 820 nm 670 nm 820 nm 670 nm 820 nm 670 nm 
CULT 0.0223 0.0003 4.014 0.054 12.042 0.162 
(0.0026) (0.0001) 
MULT 0.1039 0.0003 18.702 0.054 56.106 0.162 
(0.0078) (0-0001) 
Sham 0 0.0003 0 0.054 0 0.162 
laser (0-0001) 
note: Mean power densities among groups were compared using ANOVA. 
Significances of F=0.279,0.079 and 0.938 for 670 nm, 820 nm at 60 mW and 300 
mW respectively. 
Collection of specimens 
Owing to the variation of the duration of PGE2 production after stimulation as 
mentioned in review of the literature (page 82), the appropriate duration for the 
medium collection for PGE2 assay was estimated using the serial measurements 
of PGE2 production in the same model of cultures as the actual experiment. 
Two wells of a 24-well plate were randomised to be fed with 2 ml of 
differentiation medium with 1,000 U of IL-1. Forty eight hours incubation of the 
culture in IL-I supplemented medium applied from the study on C202 by 
Ebisui et al (1995) was used as a maximum duration. The fractions of 12 hours 
medium were undertaken. The first 6-hour medium collection was also 
conducted in order to detect the initial effect. The 0.4 ml of medium was 
collected at 6,12,24,36 and 48 hours after IL-1 stimulation. The amount of 
PGE2 in each sample after the concentration adjustment was calculated 
including the average at the different interval as shown in figure 38. 
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Figure 38. The amount of PCE2 production in medium at 6 hours, 12 hours, 24 
hours, 36 hours and 48 hours after 1000 U of IL- I stimulation. 
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The amount of PGE2 increased gradually from 6-hour to 12 hour samples 
(average PGE2 were 17 and 25 pg/50 0 respectively). At 24 hours, the detachment 
of cultures began to be noticed while the amount of PGE2 was slightly decreased 
in comparison with the result at 12 hours. This slight decline might have 
occurred from a correction of concentration (in case there was no real change in 
the concentration of PGE2). Although the average of PGE2 production at 36 
hours was increased to 36pg/50ý4 a marked difference in PGE2 alteration 
between the two samples was noted. The amount of PGE2 at 48 hours reached a 
maximum of 40 pg// 50 0 with remarkable detachment. 
As the factors related to the amount of PGE2 release in medium and cell 
detachment were considered, the collection of medium at 6 hours and 12 hours 
after IL-I supplement were selected to be appropriated durations for sample 
collection in this experiment of which this protocol can avoid the variability from 
detachment of the culture. 
In the actual experiment, the 0.5 ml of medium was collected at the exact 
durations as follows: - 
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6 hours after IL-I supplement 
and 12 hours after IL-I supplement. 
Two sets of cultures were run separately for a 6-hour and 12-hour experiment, 
therefore, the amount of PGE2 from the assay was used directly. The specimens 
were stored in plastic tubes and frozen at -750C immediately. PGE2 assay was 
undertaken on the samples 1 week after the collection. 
PGE2 assay 
This was as detailed in the method of PGE2 assay for the experiment on the 
effect of LILT on the stimulation of PGE2 by mechanical stretching (page 197). 
Statistical analysis 
According to the design of methodology, samples were regarded as independent 
samples. The comparison of independent several means was performed using 
Analysis of Variance; ANOVA. The assumptions of ANOVA (the normal 
distribution within group and uniformity of variance) were tested before the 
analysis was performed. The normal distribution was tested using the normal 
plot and significance test. The uniformity of variance were confirmed by the 
normal plot of residual and Barlett's test. Transformation of data would be 
considered if it was necessary. In case the transformed data still did not match 
the assumption, the non-parametric statistics for the same purpose as ANOVA; 
Kruskal-Wallis (Bland, 1996; Altman, 1996) would be employed. The two 
experiments were analysed separately using the methods as mentioned. The 
SPSS 6.1.3 forWindows statistical computer software was used for the analysis. 
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1-. RESULTS OF IN VITRO EXPERIMENTS ON MURINE SKELETAL MUSCLE 
CULTURES 
The results of in vitro experiments will be divided into two parts which are 
depended on methods of PGE2 stimulation by a) mechanical stretching and b) by 
IL-I supplement. Comparisons of PGE2 production were used as the main 
analysis of effect in both instances. 
A. RESULTS OF THE EFFECT OF LILT ON THE STIMULATION OF PGE2 
RELEASE BY MECHANICAL STRETCHING IN C2C12 CULTURE 
The results were from a pilot and actual studies are as follows: - 
A PILOT STUDY 
The amount of PGE2 production in the pilot study on a pure stretching cell 
group, stretching cell with either 60 mW or 300 mW GaAlAs is shown in table 61 
and figure 39. 
Table 61. The amount of PGE2 in pgl5Opl before and after pure stretching and 
stretching with either 60 mW or 300 mW irradiation. 
Experimental groups 
Samples Stretching Stretching + 60 mW 
(energy density = 0.5829 
x1 5 times) 
Stretching + 300 mW 
(energy density = 3.1289 
x 15 times) 
Initial 
PG E2 
(pg/50pl-) 
Final 
PG E2 
(pg/50pl-) 
% PGE2 
increase 
Initial 
PGE2 
(pg/50ýLQ 
Final 
PGE2 
(pg/50pl-) 
% PGE2 
increase 
Initial 
PG E2 
(pg/50pl-) 
Final 
PG E2 
(pg/50pl-) 
% PG E2 
increase 
1 9 40 344 8 60 650 20 200 905 
2 7 20 186 8 50 525 10 
------ ------ 
3 10 30 200 7 30 329 10 40 300 
Mean 8.7 30 245 7.7 
1 
46.7 
1 
506 15 120 A 700 
Note : ------ = unrecorded data due to detachment of culture after stretching. 
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Figure 39 A bar graph showing the amount of PGE2 (pgI50pl) pre and post 
stretching with and without 60 mW and 300 mW irradiation 
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From table 61. the baselines of stretching and stretching plus 60 mW Ga-AlAs 
groups were in the range of 7 to 10 pg/50pl with the means 8.7 and 7.7 pg/50ýd 
respectively. The baseline of the stretching plus 300 mW group was slight 
higher than the other groups (range = 10 to 20 pg/50ýtl and mean 15 pg/50PI). 
Due to the small sample size, the descriptive statistics was used as a method to 
compare the differences of PGE2 increase. Owing to the differences of the 
baselines, the amount of PGE2 among the groups and samples were compared 
using percentage of PGE2 increase (Fi_qure 39). The intermittent mechanical 
stimulation, following the protocol as mentioned in the section of materials and 
methods (page 192), could increase PGE2 synthesis by 245% (range 186 to 344%) 
compared with the initial amount of PGE2. The PGE2 production in the groups 
of cultures irradiated with 60 mW and 300 mW was increased 506 % (range 329 
to 650%) and 700% (range 300 to 900%) respectively. A variability of PGE2 
increase was found in the irradiated groups particularly in the 300 mW 
irradiated group. Detachment from dishes was found in some of specimens 
after stretching. There was a discarded sample in the 300 mW group due to a 
total detachment of the cell layer. 
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The intermittent stretching followed the protocol of this experiment was able to 
increase PGE2 release about 245%. There was evidence of a larger number of 
PGE2 production in the groups with 60 mW and 300 mW GaAlAs irradiation after 
the stretching. 
THE ACTUAL STUDY 
Groups of experiment involving no intervention, active and sham laser 
irradiation were also conducted on the actual study. The results are shown in 
table 62. 
Table 62 The averages and standard deviation of the amount of PCE2 (pg150pl) 
by groups of experiment (4 samples in each group) on the effect of 820 nm 
LILT on the stretching and non-stretching cultures. 
Groups Initial PGE2 
(SD) 
Final 
(SD) 
PGE2 Differences 
(SD) 
% PGE2 
increase 
No intervention 10 (8.90) 11 (9.80) 1 (12.3) 10 
60 mW irradiation 2.8 (0.29) 11.3 (10.9) 8.5 (10-8) 309 
300 mW irradiation 2.5 (0.00) 2.5 (0.00) 0 (0.00) 0 
Sham laser 2.5 (0-00) 2.5 (0-00) 0 (0-00) 0 
Stretching 7 (8.70) 16 (9.60) 9 (6.30) 129 
Stretching + 60mW irradiation 9.5 (11.8) 39 (35.3) 29.5 (24.5) 311 
Stretching +300mw irradiation 2.5 (0.00) 17.5 (22-5) 15 (22.5) 600 
Stretching + Sham Laser 3 (0.70) 16.3 (3.50) 13.3 (3.12) 442 
The means of initial PGE2 of no intervention, stretching and stretching plus 60 
mW GaAlAs irradiation groups (means = 10 ,7 and 
9.5 pg/50ýd respectively) 
were higher than the other groups of which the means were between 2.5 to 3 
pg/50gl. The standard deviation of those higher mean groups were also larger 
relative to the lower mean groups (Table 62. ) The differences of the means 
were compared using percentage of PGE2 increase as shown in figure 40. 
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Figure 40 A bar graph shown averages PGE2 (pgI50pl) before and after 
intervention and the percentages of PGE2 increase after intervention by 
groups 
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There was no change of PGE2 in the sham laser and 300 mW GaAlAs irradiation 
groups. The no intervention group showed only 10 percent of PGE2 increase 
although the baseline PGE2 was higher than the other groups. The pure 60 mW 
irradiation and stretching plus 60 mW groups had PGE2 increase 309 % and 
311% respectively. The stretching plus 300 mW GaAlAs showed the highest 
percent of PGE2 increase while the group of stretching plus sham laser was in 
the second order. 
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The intermittent stretching was able to increase PGE2 synthesis in comparison 
with the no intervention, 300 mW irradiation and sham groups. However, the 60 
mW GaAlAs group seemed to show an increase in PGE2 production at almost the 
same percentage as the group with stretching plus 60 mW irradiation. 
Comparing among the stretching groups, the groups with either 300 mw or 60 
mW GaAlAs or sham had higher percents of PGE2 increase than the pure 
stretching group. 
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RESULTS OF THE EFFECT OF LILT ON THE STIMULATION OF PGE2 BY 
IL- I SUPPLEMENT IN C2C 12 CULTURE 
The medium was collected at 6 and 12 hours after IL-I supplement in separated 
sets of samples. The amount of PGE2 released from the culture into the 
medium is used as a main result. 
6-HOUR RESULTS 
The normality of data within group was tested using the normal plot and 
Shapiro-Wilks test. The normality of all groups were acceptable due to the 
straight lines of normal plots and P value of Shapiro-Wliks more than . 05. The 
homogeneity of variance among groups was tested using the normal plot of 
residual and Bartlett's test which is shown in figure 4 IA. 
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Figure 4 1. The normal plots of residual of variance of PGE2 release at 6 hours 
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Owing to the skewness of the normal plot of residual and the P value of Bartlett- 
Box not less than 0.05 indicating the heterogeneity of variance (figure 4 IA), the 
two standard transformations; square root and natural log, were performed as 
the plots illustrated in figure 41B and C. Both transformations showed the 
acceptable homogeneity of variance as P values of Bartlett-Box test were not less 
than 0.05 which could be analysed by ANOVA with no violation. According to 
the normal plot of residual, the observation line of the natural log 
transformation is more closed to the expectation line than the line from square 
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root transformation. Therefore. data from natural loa transformation was used 
in the analysis. The inversion was also calculated based on the analysis of 
transformed data. 
The transformed means and their standard deviations in logePg/500 are shown 
in table 63. The inversions of them were also shown in the same table. The 
mean log PGE2 of the group with 1,000 U of IL-I supplemented medium seems 
to be distinctly higher in comparison with the other groups (figure 42). The 
ANOVA was performed to compare difference of mean loge PGE2 among groups 
(table 64. ) 
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Table 63. The means of natural log of PGE2 at 6 hours (1og, pg15OP1) and 
standard deviations (SD) and their antilog (pg/50, ul) by groups (6 samples in 
each group) 
Means SID 
Group logyg/50ýd pg/50ýd log pg/50ýd pg/50ýd 
No intervention 1.97 7.2 0.24 1.3 
60 mW GaAlAs 1.93 6.9 0.90 2.5 
300 mW GaAlAs 2.20 9.0 0.79 2.2 
Sham laser 2.11 8.3 0.62 1.9 
100 U of IL-I 2.11 8.3 0.27 1.3 
100 U of IL-I + 
60 mW GaAlAs 
1.84 6.3 0.81 2.2 
100 U of IL-I + 
300 mW GaAlAs 
1.83 6.3 0.82 2.3 
100 U of IL-I + 
Sham laser 
1.82 6.1 0.47 1.6 
1,000 U of IL-1 2.46 11.7 0.43 1.5 
1,000 U of IL-1 + 
60 mW GaAlAs 
1.76 5.8 0.67 1.9 
1,000 U of IL-I + 
300 mW GaAlAs 
1.77 5.9 0.45 1.6 
1,000 U of IL-1 + 
Sham laser 
1.86 6.4 0.73 2.1 
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Figure 42. A bar graph comparing means natural log of PGE2 (lo_q,, p_ql5Oul) at 6 
hours by groups 
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Table 64. The one way ANOVA table of the log, PCE2 production at 6 hours. 
Source of Degree of Sum of Mean F Sig of F Power of 
variation freedom squares Squares the test 
at . 05 level 
Within groups 60 24.34 0.41 
Between 11 2.94 0.27 0.66 0.771 0.320 
groups 
From one way ANOVA, there was no statistically significant difference (at P 
value less than 0.05) of the means Of loge PGE2 release in the medium at 6 hours 
after IL-I supplement among the groups. 
The PGE2 production from the higher concentration of IL-I supplement was 
remarkably high in comparison with the other groups. However, there was no 
statistical difference among groups. 
The results at 12 hours after IL-I supplement from another set of samples are 
reported as follows: - 
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12-HOUR RESULTS 
The normality of data within group and the homogeneity of variances were 
tested using the same methods as mentioned in the 6-hour result. The normality 
of all groups were acceptable due to the straight lines of normal plots and P 
value of Shapiro-Wliks more than 0.05. The homogeneity of variance among 
groups was tested using the normal plot of residual and Bartlett's test which are 
shown in figure 43A. 
216 
Figure 43. The normal plots of residual of variance of PCE2 release at 12 hours 
and their Bartlett's test (P value); A=a plot of non-transformed data, B=a 
plot of square root transformed data and C=a plot of natural log 
transformed (Bartlett-Box F degree of freedom = 11,2492) 
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Although P value of Bartlett-Box was not less than 0.05 which was acceptable in 
terms of the homogeneity of variances among group the normal plot of residual 
still showed a degree of skewness of the observed value from the normal 
expected line (figure 43A). Regarding the recommendation by Bland (1996) on 
comparing the means of small samples, transformation of data should be 
considered. The normal plots of residuals of two standard transformations; 
square root and natural log, were illustrated in figure 43B and C The 
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observation line of square root transformation showed less skewness than the 
plot of original data. Besides the natural log transformation showed over 
compensation of which the outlier value was detected (figure 43C). Therefore, 
the square root transformed data was used for the analysis. 
The transformed means and their standard deviations in square root of pg/50ýtl 
are shown in table 65. The inversions of them are also shown in the same table. 
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Table 65. The means square root of PGE2 at 12 hours (vlpgl5Oul) and standard 
deviations (SD) and their antilog (pgl5Oul) by groups. 
Means SID 
Group Vpg/50ýd pg/500 Vpg/50PI pg/50PI 
No intervention 4.20 17.67 0.895 0.801 
60 mW GaAlAs 5.90 34.82 0.464 0.215 
300 mW GaAlAs 5.59 31.27 0.688 0.473 
Sham laser 6.04 36-51 0.438 0.191 
100 U of IL-1 5.55 30.79 1.025 1.050 
100 U of IL-1 + 
60 mW GaAlAs 
5.64 31.76 1.376 1.893 
100 U of IL-1 + 
300 mW GaAlAs 
4.898 23.99 1.103 1.216 
100 U of IL-I + 
Sham laser 
6.17 38.03 0.607 0.369 
1,000 U of IL-1 6.93 48.09 0.540 0.292 
1,000 U of IL-1 + 
60 mW GaAlAs 
5.96 35.47 1.197 1.432 
1,000 U of IL-I + 
300 mW GaAlAs 
5.59 31.27 0.688 0.473 
1,000 U of IL-I + 
Sham laser 
5.95 35.44 1.211 1.467 
The no intervention group had the lowest mean square root of PGE2 production 
in medium while the 1,000 U of IL-I supplement group had the highest mean 
square root of PGE2 (figure 44). The ANOVA comparing mean square root of 
PGE2 are detailed in table 66. 
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Figure 44. A bar graph comparing means square root of PCE2 (vlp_ql5Oul) at 12 
hours by groups. 
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Table 66. The one way ANOVA table of means square root of PCE2 production at 
12 hours. 
Source of Degree of Sum of Mean F Sig of F Power of 
variation freedom squares Squares the test 
at . 
05 
level 
Within groups 60 49.37 0.82 
Between 11 29.79 2.71 3.29 0.001 0.984 
groups 
From the ANOVA, there was a statistically significant difference of square root 
means of PGE2 production among groups at P value . 001. Therefore, the 
further 
analysis using multiple comparison can be explored for significant differences 
between the means. The result from Duncan multiple comparison at the 
significant level 0.05 is shown in table 67. 
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From table 67, the mean of square root PGE2 of the no intervention group was 
significantly less than the other groups apart from the group of 100 U of IL-1 
supplement plus 820 nm GaAlAs at 300 mW irradiation. 
The mean of square root of PGE2 production of the 100 U of IL-1 supplement 
group was statistically higher than the no intervention group but less than the 
1,000 U of IL-I supplement. There was 
no statistical difference of the means square root of PGE2 production among the 
groups stimulated by 100 U of IL-1,60 mW and 300 mW GaAlAs and sham laser. 
The mean square root of PGE2 synthesis of the 100 U of IL-I plus 300 mW 
GaAlAs was significantly less than the 100 U of IL-I plus sham laser group. 
However, there was no statistical difference of the means square root of PGE2 
between the 100 U of IL- I and 100 U of IL- I plus 3 00 mW groups. 
The 1,000 u of IL-I supplement group showed significantly higher in the mean 
square root of PGE2 than most of groups apart from the 60 mW GaAlAs 
irradiation, sham laser, 100 U of IL-1 plus sham laser and 1,000 U of IL-I plus 
either 60 mW or Sham laser groups. The mean square root of PGE2 of the 1,000 
U of EL-I plus 300 mW GaAlAs group was statistically higher than the no 
intervention group but lower than the 1,000 U of IL-I supplement group. 
The groups which had the stimulation either from IL-1 or 60 mw, 300 mW 
GaAlAs and sham laser irradiation had higher PGE2 production in comparison 
with the no intervention group. The 1,000 U of IL-I supplement group was able 
to stimulate C2C12 to produce larger amount of PGE2 distinctly in comparison 
with the groups stimulated by either 100 U of IL-I or 300 mW GaAlAs. The 60 
mW GaAlAs and sham laser groups appeared to promote an increase in PGE2 
production as the result of multiple comparison test showed no statistical 
difference in the means square root among the 1,000 U of IL-I supplement, 100 U 
of IL-I plus Sham laser, pure Sham laser and 60 mW GaAlAs groups. On the 
other hand the group with 300 mW GaAlAs either with or without IL-1 
supplement showed the lower level of PGE2 statistically in comparison with the 
1,000 U of IL-I supplement group. 
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PART 4 
DISCUSSION AND CONCLUSION 
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DISCUSSION 
The results will be discussed in relationship to two main points; efficacy of LELT 
on TMD treatment based on the clinical trial and a possible mechanism of LILT 
based on the in vitro experiment. 
EFFICA CY OF L IL T ON TMD 
Effects of LILT on specific assessments such as PPT, pain scores, EMG and jaw 
tracking will be discussed separately. The overall clinical results based on 
outcomes from diagnoses wiH also be discussed at the end. 
THE EFFECT OF LILT ON PPT 
PPT measured by the electronic algometer was used as the main result for 
assessment of a benefit of LILT on management of myofascial pain. This 
measurement was recommended to be an assessment of myofascial trigger 
points as mentioned in review of the literature (page 55). Because the PPT is 
recorded from the judgement of patients via a patient control switch, this 
assessment can be considered as an objective measurement under subjective 
control of the patient. Moreover, Rudy et al (1995) found that the muscle 
palpation had no correlation to differences of psychological characteristics. 
The WILT group showed a distinctly higher PPT after treatment than the CLILT 
and the placebo group at a difference of coefficient equal to 27.99 kpa (95% CI = 
13.14 to 42-82 kpa) and 22-58 kpa (95% CI = 8.43 to 36.72 kpa) respectively. It 
should be noticed that the 95% CI of the differences are not lower than zero 
which implies real significant differences. 
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Regarding the clinical significance of these results, the standard threshold force 
based on RDC is 2 pounds by using index finger palpation (Dworkin and 
LeResche, 1992). This amount of force is equal to 89 kpa. The mean PPT of the 
MLILT group was higher than 89 kpa after the second treatment whiIe the means 
of the other groups failed to reach that point particularly the placebo group. 
Statistically significant differences of PPTs between the MLILT group and either 
the CULT or placebo group was also found after the second treatment. 
It should be noticed that there was an increase in PPT in the CULT group but not 
enough to show a statistical significance. According to the study by McMillan 
(1994) on the effect of trigger point injection by local anaesthesia on PPT, the 
highest mean of PPT of masseter muscles obtained after injection was 0.7 
kg/cmý (69 kpa). Regarding the mean PPT of MLELT after final treatment which 
was 102.6, the distinct benefit of MLILT on increase in PPT is demonstrated. 
The same record and analysis were also conducted on the normal side which 
showed no statistically significant difference among groups. This confirms an 
increase in PPT in the MULT group not related to the effect of time of 
measurement. 
THE EFFECT OF LILT ON PAIN SCORES 
This study used two pain questionnaires; SSI based on VAS and McGill pain 
questionnaires for measuring the results of pain relief after LILT. There was no 
significant difference in pain score either from SSI or McGill among groups after 
the final treatment which was about 10 days after the first baseline assessment 
and 2 days after the final treatment. However, a marginally significant 
reduction of total pain rating index from the McGill pain questionnaire after the 
final treatment was found within the MLILT group. 
In a study by Conti (1997) treating TMD by LILT once a week for three weeks, 
there was found to be a statistically significant differences of VAS between the 
baseline assessment (mean VAS = 5.6) and 5 minutes after the second (mean VAS 
= 2.4) and third treatments (mean VAS = 2.0) within the myogenous group of 
TMD. However, in that study there were no statistically significant differences 
of VAS between the control and experimental groups. It should be notified that 
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in the study by Conti (1997), the pain scores were recorded in a short time after 
treatment while in this study the pain was assessed at least 24 hours after each 
treatment which was felt to be more meaningful. 
The psychological background in relation to TMD should be addressed, 
according to which most of the patients in every group in the present study 
were in the group of chronic pain class H (Low disability and high pain intensity) 
and also some patients had moderate to severe scores of depression and 
anxiety. This may have affected the pain report. In a study by Von Korff et al 
(1992) on 803 chronic pain patients including TMD, only grade I chronic pain 
patients had a psychological status within normal limits. Moreover, 16.9% of 
grade H patients were assessed to be in either grade IR (Moderate limitation with 
high pain intensity) or IV (severe limitation with high pain intensity) at a 3-year 
follow up. Thus it should be considered that the majority of patients in this 
trial were in high intensity pain with some degrees of psychological change 
influenced by their chronic pain status. Therefore, the post treatment 
evaluation which was undertaken 10 days after the first assessment and 2 days 
after the final treatment may not have been able to detect an alteration of pain 
scores. 
It could be argued that the period of pain assessment in the trial should have 
been extended. However, this would have had to outweigh ethical reasons in the 
placebo group. In this study, it was decided to treat the patients who had 
placebo in the first week with MLILT in the second week so that every group 
ultimately had active treatment for humanitarian reasons. Therefore, the 
control placebo group was ended after that stage. 
However, the data of VAS in the routine follow up at 2-4 weeks demonstrated that 
the mean VAS of all patients who were treated by either CLJLT or MLJLT (in the 
first week or the second week after placebo) showed a mean 52% reduction in 
VAS. According to a study by Dworkin et al (1994) in 90 TMD patients treated 
with conventional treatment and 95 patients receiving cognitive behavioural 
intervention plus conventional treatment, it was found that the characteristic 
pain score (0 to 10) of the conventional treatment group from a 
baseline at 4.45 
was decreased to 3.14 and 3.03 at 3 and 12 months follow up respectively. 
The 
group with combined cognitive behavioural and conventional treatment 
had 
pain score reduction from 5.17 to 3.73 and 2.74 at 3 and 
12 months 
respectively. Therefore, the highest percentage of pain reduction was about 
47% 
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in the group with combined treatment at 12 months foRow up compared with 
the result of LILT in this study which showed 52% percent pain reduction at 2-4 
weeks. 
THE EFFECT OF LILT ON THE RANGE OF MANDIBULAR MOVEMENTS 
Unassisted maximum mouth opening without pain was used as measurements 
in this study in order to detect certain mandibular functions which might be 
limited by pain. 
There was no statistically significant difference of pain free maximum mouth 
opening among the groups after treatment. However, the CULT and MULT 
groups had slight improvement in mean pain free mouth opening from 26.6 to 
32.4 and Z5.2 to 31.3 mm respectively. The mean MOSP of the placebo group in 
contrast only changed from 28.6 nim at the baseline to 29.2 mm after the final 
treatment. 
The other studies by Bezuur et al (1988) and Conti (1997) reported improvement 
in maximum mouth opening in the arthrogenous group after LILT in a year and 
3 weeks respectively. Bezuur et al (1988) found an increase in maximum 
opening from 33.8 to 47.6 mm while Conti (1997) reported that a mean total 
vertical opening was improved from 36 to 41.4 nun and lateral movement was 
increased from 8.4 mm to 10 nun. Compared with the results of this study, the 
overall measurements of mouth opening of these two studies were higher. As 
far as the methods of measurement concerned, it should be emphasised that 
these two studies did not mention that the records were undertaken in pain free 
mandibular movement condition. According to a case control study by Dworkin 
et al (1990), unassisted maximum mouth opening without pain in females is 
likely to average 30 mm; the means of the CULT and MLILT groups reached this 
point after the final treatment. 
The methods of analysis in the three studies have to be addressed. The 
significant differences found in studies by Bezuur et al (1988) and Conti (1997) 
were from within group comparison. The study by Conti (1997) failed to show a 
significant difference by comparison with the control group while the study by 
Bezuur et al (1988) was a non-controlled trial. Moreover, these two studies did 
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not find a benefit of LILT on maximum mouth opening in myogenous TMD 
patients. 
Lateral movements either to ipsilateral or contralateral toward the painful side 
were not found to show significant differences among the groups. It should be 
noticed that the majority of patients seemed to have only marginal limitation of 
lateral movement in the beginning, according to RDC (Dworkin and LeResche, 
1992) which stated that contralateral excursion should not be less than 7 mm. 
The others related tests such as free way space and speed of mandibular 
movement could not be found to show statistically significant differences 
among the groups after treatment. However, in comparison with the other 
study by Cooper (1997), the median vertical free way space in this trial was 
higher than then mean vertical free way space in that study. 
Overall there were some improvements in mandibular function assessment in the 
CMLT and MLJLT groups but the results failed to show a statistically significant 
difference compared with the placebo group. It should be emphasised that this 
trial focused on myofascial pain TMD patients who might not have a major 
limitation of TMJ function as the majority of subjects were graded as class II 
chronic pain (Low disability and high pain intensity). 
THE EFFECT OF LILT ON EMG IN THE REST POSITION AND CLENCHING 
A statistically significant difference of EMG in the rest position among the 
groups and within the group before and after treatment was not be able to 
be 
obtained. This may be explained by either no benefit of LELT on EMG in the rest 
position or a low sensitivity of this type of assessment as a number of studies 
have failed to show differences of EMG in the rest position between TMD and 
normal subjects (Lund and Widmer, 1989; Rugh and Davis, 1990; 
Schroeder et al. 
1991). 
An improvement of EMG recorded during maximum clenching of natural 
occlusion was found in the MULT group. Regarding the lowest mean of 
baseline 
cEMG in the MULT group compared with the other groups, this was adjusted 
by 
the ANCOVA using the baseline as a covariate. Although it was a marginal 
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significance at P value 0.051, the 95% CI of the difference compared with the 
placebo group was 5.96 to 68.66 microV. Owing to the fact that there was no 
statistical significant difference of cEMG among the groups from the analysis on 
the non-painful muscle on the opposite side, the effect on the painful muscle by 
repeated measurement could be excluded. Therefore, the benefit of MLILT 
should be counted in terms of statistics. From the clinical consideration, there 
has still been no standardised range of maximum clenching EMG reported in 
the literature. 
THE EFFECT OF LILT ON OVERALL IMPROVEMENT BASED ON MYOFASCIAL 
PAIN AND ARTHRALGIA DIAGNOSES 
Myofasical pain and TMJ arthralgia based on RDC (1992) were assessed before 
and after treatments. In the MLJLT group, 70% and 80% of cases recovered from 
myofascial pain and TMJ arthralgia respectively while there was only a 10% 
recovery in the placebo group. This showed statistical significance with a 3.5 
relative risk in a favour of MLJLT compared with placebo. The CULT group had a 
higher number of recovered patients (409,6) than the placebo group but failed to 
show a statistical difference. According to the impression of Dahlstrom (1992) 
which was based on the extensive review on conservative treatments for TMD, 
between 72 and 97% of the patients had been described as successfully treated. 
Therefore, the benefits of MLILT on myofascial and TMJ arthralgia patients 
should be considered in the range of effective conservative treatments. 
After the trial, a routine review was undertaken as detailed in the results of the 
clinical trial (page 183). All of patients reported relief from the continuous pain 
which they had before treatment. Some of them needed additional LILT 
sessions. Arthrogenous cases tended to have a problem with pain on function 
due to internal disc displacement which was treated by arthrocentesis in some 
cases. Cases with recurrent pain associated with parafunction were given 
occlusal splints. 
MHLT was found to provide a distinct benefit for painful TMD patients by 
increasing pressure pain threshold corresponding with an improvement in 
maximum clenching FMG. The accumulative effect of WILT showed statistical 
significance after the second treatment. The effect on VAS was showed at a period 
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of 2-4 weeks after the final treatment with a mean 52% reduction. Some 
improvements from CLJLT were found but failed to show a statistically significant 
difference compared with placebo. These lead to the impression that the effect of 
LILT on myofascial pain relief is dependant on energy density and the number of 
treatments. 
MECHANISM OF LILT ON SKELETAL MUSCLE 
The results from the in vitro experiment suggest that LILT is able to stimulate 
and suppress PGE2 production from skeletal muscle culture. The lower energy 
density of LILT including 670 nm visible red light tended to enhance the effect 
of stretching and IL-1 supplement on PGE2 synthesis. The higher energy density 
was found to decrease PGE2 production induced by IL-1 supplement. This 
evidence seems to correspond with the hypothesis of An-xit-SchiAz (Ohsbiro and Caldaliead 1998) 
where in a biological system low energies tend to stimulate and high energies 
above a threshold level to inhibit. In addition, a study by Shimizu et al (1995) 
investigating the effect of 820 nm GaAlAs on PGE2 production in stretched 
periodontal ligament cells showed an inhibitory effect for higher total energy 
density irradiation groups. Regarding the stretching model experiment which 
found only a stimulative effect of LILT, it should be noted that energy densities 
at each irradiation were less than in the experiment with IL-1 supplement and 
clinically treated masseter muscle. The inhibitory action of LILT should be 
expected to happen at higher energy density. 
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THE RELATIONSHIP BETWEEN CLINICAL TRIAL AND IN VITRO 
EXPERIMENT ON SKELETAL MUSCLE CELLS 
The modified dose of 820 nm GaAlAs in the higher power and energy densities 
showed the benefits in terms of increasing pressure pain threshold of the 
trigger point and improving average EMG of maximum clenching compared with 
placebo. The lower energy dose failed to show any distinct effect statistically. 
These clinical results are also correlated with the evidence in the in vitro 
experiment on skeletal muscle culture which found that the higher energy 
densities tends to inhibit PGE2 release by IL-1 stimulation. Therefore, one of the 
mechanism of the local pain relief of trigger points treated by LILT may be from 
a decrease in PGE2 synthesis. This inhibition may be responsible for the 
improvement in pressure pain threshold observed as Travell and Simons (1983) 
hypothesised the release of PGE2 in myofascial trigger points. 
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CONCLUSION 
The results from the clinical trial on the effects of LILT on myofascial pain TMD 
patients and the in vitro experiments on the influence of LILT on PGE2 
production in murine skeletal muscle culture lead to the following conclusion: - 
1. MULT irradiation of myofascial trigger points was able to ftnprove pressure 
pain threshold significantly in comparison with CULT and placebo. The 
accumulative effect was found to be significant after the second treatment. 
There was an improvement in pressure pain threshold of trigger points after 
CLELT but not enough to show a statistical significance at least for the 
sample size used in this study. 
2. A statistically significant difference of pain scores either from symptom 
severity index or McGill pain questionnaire could not be detected among 
groups in the period of trial (10 days). However, pain rating index from 
McGill pain questionnaire showed a significant reduction within the MLILT 
group after the final treatment. At the period of 2 to 4 weeks review, the 
average pain reduction was 52%. It should be emphasised that the placebo 
group received MLILT in the second week after trial. Therefore, the results of 
the follow up after the trial were from either the effect of MLILT or CULT. 
3. Assessments of the range of mandibular movement; unassisted maximum 
mouth opening without pain and lateral excursion to contralateral away 
from painful side and ipsilateral to painful side, showed no significant 
difference among groups. A slight increase in pain free maximum mouth 
opening was found in the MULT and CLILT groups of which the means were 
more than 30 nun. 
4. The average speed of mouth opening and closing showed no statistically 
significant difference among the groups. 
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5. The free way space in vertical, sagittal and frontal planes showed no 
statistically significant difference among the groups. 
6. From the EMG record, there was no statistically significant difference of 
average EMG measured during the rest position among the groups. A 
significant increase in average EMG recorded during voluntary maximum 
clenching of natural occlusion was found in the MULT group compared with 
the CLILT and placebo groups. 
7. There was a significantly greater number of patients recovering from 
myofascial pain and TMJ arthralgia after MULT compared with placebo. The 
relative risks were 3.5 for myofascial recovery and 4.9 for arthralgia recovery 
compared with placebo. The forty percent case recovery in the CLILT group 
failed to show a significant difference compared with 10% recovery in the 
placebo group at least for the sample size used in this trial. 
8.820 nm at 60 mW energy density 0.583 J/cml, 300 mW energy density 3.129 
J/CM2 
and 670 nim visible light guide energy density 0.087 
J/CM2 irradiating 
C202 differentiated cells for 20 times following intermittent mechanical 
stretching enhanced the effect of stretching on PGE2 synthesis. 
9.820 nm at 300 mW energy density 18.702 J/cmI irradiating C202 culture for 
3 times every hour after 1,000 U IL-I supplement produced a significantly 
less amount of PGE2 compared with the group with 1,000 U EL-1 supplement 
alone. The amount of PGE2 production of the groups irradiated with 820 nm 
at 60 mW energy density 4.014 J/cmI either with or without 1,000 U IL-I 
supplement was found to show no statistically significant difference 
compared with the group with 1,000 U IL- I supplement. 
Overall in the clinical trial, 820 nm at 300 mW energy density 106.932 J/cml 
irradiating myofascial trigger points and areas of TMJ 3 times a week on 
alternate days was able to improve pressure pain threshold and EMG recorded 
during voluntary ma,, dmum clenching significantly compared with the placebo 
and lower energy density regime. The above LILT regime can provide a 3.5-time 
enhanced recovery in myofascial TMD patients and a 4.9-time enhanced recovery 
in TMJ arthralgia patients by comparison with the placebo. 
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The other LILT regime used in this study; 820 inm at 60 mW energy density 
21.373 J/cmI, failed to showed any statistically significant differences of clinical 
outcomes compared with the placebo at least in the sample size used in this 
trial, although a trend to improvement was apparent. 
From the in vitro study on murine skeletal muscle cells, the higher energy 
density of 820 nm was able to reduce PGE2 production stimulated by EL-I 
supplement. The lower energy dose used in this experiment failed to do so and 
tended to enhance PGE2 synthesis. 
A relationship between the clinical study and the in vitro study can be drawn in 
that the higher energy density of GaAlAs at least in the regime employed in this 
clinical trial had a local effect on improvement in pressure pain threshold. The 
mechanism of this effect may be able to be partially explained by inhibition of 
PGE2 synthesis which was found in the in vitro experiment on skeletal muscle 
cells. 
FURTHER WORK 
1. The present clinical study has identified a format which could be applied to 
the evaluation of other methods of treatment for TMD pain. 
2. The influence of the occlusal splint and arthrocentesis could be examined in 
this way and compared with each modality combined with LILT. 
3. Various regimes of LELT could be compared eg intensive versus spaced in 
time, constant wave versus pulsed, acupuncture points versus trigger points. 
4. The tissue culture stretched myoblast model or co-culture could possibly be 
used to evaluate the effect of LILT on other algesic substances eg free radicals 
and analgesics eg endogenous opioids. 
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APPENDIX 
This appendix comprises the forms, questionnaires and assessments which were 
used in the clinical trial: - 
THE INFORMED CONSENT FORM 
Patients were invited to participate in the clinical trial. The details of the study 
were discussed. If the patients agreed to join the trial, the informed consent 
form which approved by the ethical conu-nittee of the college would be signed. 
The example of the informed consent form is shown on page 256. 
THE EXAMINATION FORM 
The examination form for TMD assessments was based on RDC (Dworkin and 
LeResche, 1992). Some modifications of the form were made as appropriate but 
the information for making diagnoses for Axis I TMD was still fulfilled. The 
form which was used in this trial is shown on page 258. Specifications for TMD 
examinations are detailed on page 262. 
THE QUESTIONNAIRES FOR AXIS 11 
Axis H TMD assessment was based on the history questionnaire from RDC 
(Dworkin and LeResche, 1992). 
The history questionnaire which was used in this trial is shown on page 268. 
The assessment methods are detailed on page 2 78. 
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THE SUMMARY FORM FOR TMD (AXIS I AND AXIS 11) 
The form is shown on page 281. 
THE ROUTINE PAIN QUESTIONNAIRE 
Two types of pain questionnaires namely Symptom severity index (SSI) and 
McGill pain questionnaire were used in the clinical trial. SSI questionnaire and 
the scoring method are shown on page 283 and page 284 respectively. McGill 
pain questionnaire and the scoring method which was used in this study are 
detailed on page 285 and page 286 respectively. 
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THE INFORMED CONSENT FORM 
Research Project: A study of the effectiveness of Low Intensity Laser 
Therapy (LILT) in the treatment of pain arising from the jaw joint and jaw 
muscles (Temporomandibular Joint Disorder Pain) 
EAST LONDON AND CITY HEALTH AUTHORITY 
INFORMATION TO PARTICIPATE IN THE RESEARCH PROJECT 
We invite you to take part in a research study which we think may be important. 
The information which follows tell you about it. It is important that you understand 
what is in this leaflet. It says what will happen to you if you take part and what the 
risks might be. Try to make sure what you know will happen to you if you decide 
to take part. Whether or not you do take part is entirely your choice. Please ask 
any questions you want to about the research and we will our best to answer 
them. 
Information About The Research 
Low intensity Laser (LILT) is widely used in most physiotherapy departments in 
this and other countries for the treatment of pain arising from joints and muscles 
and also for healing in general. It is used extensively for example in sports 
injuries. In this department we have been using the methods for over 4 years 
now for a variety of types of pain in the face and jaws. Our impression is that the 
method is very helpful in many types of cases and we have had no adverse 
reactions. We would however like to prove its effect in a common problem, 
namely, Temporomandibular Joint Disorder Pain. As we have diagnosed this 
condition in your case we would like to ask you whether you would be willing to 
take part in the trial. 
Each patient will have 6 treatment sessions over 2 weeks. 3 of the treatments will 
be with the laser delivering infra red light as normally in either a conventional or 
modified regime but the other 3 will be with the laser passive. We normally find 
that 3 treatments are sufficient so that you will have had a normal treatment 
regime, but will also have had some blank sessions. Neither you nor the clinician 
carrying out the treatment will know which treatment you have had no a particular 
session until the trial is finished. This is called a double-blind study and is a 
standard way of assessing the effectiveness of a treatment. The benefit of the 
trial to us will be to enable us to prove the effectiveness of LILT conclusively or 
otherwise. From the patient's viewpoint it will enable it to be established as to 
whether LILT is the best form of treatment for him or her in the future. This will 
avoid persevering with the treatment if it proves not to be fully effective although 
our preliminary results suggest that the latter will not be so. 
In the week prior to starting treatment, recording of the function of your jaw 
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movements (mandibular jaw tracking) and the activity of your jaw muscles 
(electromyography) will be undertaken. These are non painful tests which take 
about an hour. We will also require to see you three months after the end of the 
trial to assess your progress. During the course of the trial we will ask you to fill in 
pain questionnaires and also to carry out scoring of your pain. 
No adverse affects from Low Intensity Laser Therapy (LILT) have been recorded. 
It has been used in some parts of the world such as Japan for over fifteen years 
with many thousands of patients treated. Very occasionally in severe pain the 
discomfort may be made slightly worse for a day or so, but this is uncommon in 
our experience. The laser used in an infra red laser. It is common experience 
that infra red lamps help pain on the surface of the body but the laser is able to 
penetrate more deeply into joints and muscles. 
You do not have to join the study. You are free to decide not to be in this trial, or 
to drop out at any time. If you decide not to be in the study, or drop out, this will 
not put at risk your ordinary medical care. If Low Intensity Laser Therapy (LILT) 
does not unfortunately remedy your pain, then we will offer you a variety of other 
methods of treatment such as splints, cortisone injections or joint wash outs. If 
you are worried about anything during the trial, you will be always able to contact 
and investigator to discuss your concerns and/or to get help. 
Name: Dr. S. Sattayut 
Address: Department of Oral and Maxillofacial Surgery 
St. Bartholomew's & Royal London School of Medicine and 
Dentistry, Turner Street, London El 1AD 
Telephone: 0171 377 7050 
I have read the above and agree to take part in this trial. 
Signed ......................................................................... 
Dated: .......................................................................... 
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THE EXAMINATION FORM 
1. Do you have pain on the right side of your face , the left side , or both 
sides ? 
None ... 0 
Right ... 1 
Left ..... 2 
Both .... 3 
2. Could you point to the areas where you feel pain ? 
Right None 0 Left None 0 
Jaw Joint I Jaw Joint 1 
Muscles 2 Muscles 2 
Both 3 Both 3 
3. Vertical range of motion and the overlap 
a. Unassisted opening without pain ............. mm 
b. Maximum unassisted opening .................. mm 
c. Maximum assisted opening ......................... mm 
d. Vertical incisal. overla-D ................................ mm 
e. Horizontal mcisal overlap ............................ mm 
L Pain 
Pain Joint 
None Right Left Both Yes No NA 
o 1 2 3 1 0 9 
0 1 2 3 1 0 9 
4. Opening pattern 
Righ Left 
0 "S" Deviation on opening or closing (.! S 2mm) 0 
El Lateral deviation at full opening (.! S 2mm) 0 
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5. Excursion 
0 Protrusion- pain 
0 Protrusion- limitation 
........ mm (-> 7mm) 
0 Right laterotrusion- pain 
El Right laterotrusion- limitation 
........ mmL> 7mm) 
0 Left laterotrusion- pain 
El Left laterotrusion- limitation ........ mm(. ýý 7mm) 
El Clinically can be locked open (subluxate), right or left 
0 Clinically can be or is locked close with no translation of condyle, 
right or left 
0 Rigidity of jaw upon manipulation 
6. TMJ sounds 
TMJ noise LTN) (Check no more than two each sidej 
Right 
0 Reciprocal click 
0 Reproducible opening click 
0 Reproducible laterotrusive click only 
0 Reproducible closing click 
0 Nonreproducible click 
rý Crepitus-Fine 
0 Crepitus- Coarse 
Left 
F1 
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Joint sounds on excursions 
Right sounds: 
None Click Coarse 
crepitus 
Fine 
crepitus 
Excursion right 0 
Excursion left 0 
Protrusion 0 
Left sounds: 
2 
2 
2 
3 
3 
3 
None Click Coarse Fine 
crepitus crepitus 
Excursion right 0 1 2 3 
Excursion left 0 1 2 3 
Protrusion 0 1 2 3 
7. Muscle and TMJ palpation 
Positive= 1 
Negative =0 
Right Jaw Muscles: Extra-oral pal-patio 
0 Anterior Temporalis -------------- 
0 Middle Temporalis -------------- 
El Posterior Temporalis, -------------- 
0 Deep Masseter -------------- 
0 Anterior Masseter -------------- 
0 Body of the Masseter -------------- 
0 Inferior Masseter -------------- 
0 Posterior Digastric -------------- 
0 Medial Pterygoid -------------- 
0 Vertex -------------- 
Left 
0 
LI 
LI 
LI 
LI 
LI 
LI 
LI 
LI 
LI 
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Right Neck muscle -pali3atio Left 
0 Superior Sternocleidomastoid -------------------- 0 
0 Middle Sternocleidomastoid -------------------- 0 
F] Inferior Sternocleidomastoid -------------------- 0 
0 Insertion Trapezius -------------------- 0 
0 Upper Trapezius -------------------- 0 
0 Splenius Capitus -------------------- El 
TMJ -pal-pation 
Lateral capsule -------------------- 
Posterior capsule -------------------- 
Superior capsule -------------------- 
Jaw Muscles: Intra-gral palpation 
0 Lateral Pterygoid ---------------- 
0 Temporalis Insertion ----------------- 
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SPECIFICATIONS OF EXAMINATION FOR TMD 
The examination is conducted in a quiet room with a proper temperature. The 
patient is seated in a comfortable arm chair with high back rest at 
approximately a 90 degree angle to the examiner. The examination procedures 
are in the order on the form as follows: - 
A. SELF-REPORT PAIN LOCATION 
The patient is asked to identify the location of her pain according to item I and 
2. 
B. VERTICAL RANGE OF MOTION AND THE OVERLAP 
The reference point of measurement for the vertical range of motion and the 
overlap (item 3) is the inter-incisal edge of the upper and lower right central 
incisors. The horizontal overlap (item 3. e) is measured from the labial surface 
of the lower right central incisor to the incisal edge of the upper right central 
incisor in the centric occlusion. The vertical incisor overlap (item 3. d) is the 
distance between the edge of the lower right central incisor and the line at 90 
degree from the edge of the upper right central incisor projecting on the labial 
surface to the lower right central incisor. The measurement in mm is recorded 
using a Willis bite gauge. 
Unassisted opening without pain (item 3. a. ) is measured when the patient 
opens the mouth from a comfortable position of the mandible as far as 
possible without feeling any pain. If the patient does not open at least 30 
mm, to insure understanding, repeat the opening. If the second opening still 
does not produce more than a 30-mm opening, record the measurement. 
9 Maximum Unassisted opening (item 3. b. ) is measured when the patient 
opens the mouth as wide as possible, even if she feels pain. The location of 
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pain during the opening is recorded in item 3. f. If the patient only 
indicated feeling pressure or tightness, score as none. 
Maximum assisted opening (item 3 c) is measured when the examiner uses 
finger force to gain more maximum mouth opening of the patient from the 
maximum unassisted opening. 
C. OPENING PATTERN 
The patient will be asked to place the mandible in a comfortable position and 
then open the mouth as wide as possible. The pattern of deviation using the 
embrasures between the upper and lower incisors as references is observed and 
recorded in item 4. The record is finalised when the same opening pattern can 
be repeated at least two of three times. 
E. EXCURSION 
The ma3dmum range of motion in horizontal and frontal planes from the centric 
occlusion is measured as in item 5. The measurement is undertaken from the 
labioincisal embrasure between the maxillary central incisors to the labioincisal 
embrasure of the mandibular incisors. Any pain during the movement of the 
mandible is recorded. Clinical observation of the movement of the condyles is 
also recorded. 
F. TMJ SOUNDS 
TMJ sounds on palpation using the index finger over the preauricular area are 
investigated during the vertical movement and excursion as in item 6. 
The definitions of TMJ sounds are as follows: - 
Reciprocal click: This sound is determined by opening and closing clicking 
and the elimination of both clicks when the patient opens and closes from a 
protrusive posi ion. 
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Reproducible opening click: A clicking present on two of three opening 
mandibular movement 
9 Reproducible laterotrusive click: A clicking present on two of three lateral 
movement of the mandible 
Reproducible closing click: A clicking present on two of three closing 
mandibular movement 
Non-reproducible click: A click present periodically during mandibular 
movement and cannot be reproduced on at least two of three full mandibular 
or lateral movements. 
Fine crepitus: A fine grating sound which is continuous over a large period of 
jaw movement. It may be described as a rubbing or cracking sound on a 
rough surface. 
* Coarse crepitus: A sound which is continuous over a longer period of jaw 
movement. It is the noise of bone grinding against bone or like a stone 
grinding against another stone. 
G. MUSCLE AND JOINT PALPATION FOR TENDERNESS 
Examination of the masticatory muscles and TMJ capsules for tenderness on 
palpation is undertaken on the specific sites as in item 7. Estimated 2 pounds 
pressure from finger tips of the index and third fingers is used for extra-oral 
palpation while 1 pound pressure is used for TMJ palpation and intra-oral 
examination. Counterpressure is applied to the opposite site of the head to 
provide stability. The patient is asked to relax and place the mandible in the 
rest position. As needed, the patient is asked to slightly clench and relax in 
order to identify the masticatory muscles. Pain is recorded to correspond with 
the sites of muscles or TMJ capsules as positive = 1. Report of pressure only or 
equivocal response is recorded as no pain (negative = 0). 
Descriptions of specific muscle sites: - 
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Extra-oral muscle palpation 
Anterior temporalis: Palpate fibres over the infratemporal fossa, immediately 
above the zygomatic process. 
Middle temporalis: Palpate fibres in the depression about 2 cm lateral to the 
lateral border of the eye brow. 
Posterior temporalis: Palpate posterior fibres from behind the ears to directly 
above the ears. 
Deep masseter: Palpate fibres in the area I cm immediately in front of the 
TMJ and immediately below the zygomatic arch. 
Anterior masseter: Palpate the origin of superficial masseter which is 
anterior to the deep masseter and palpate the anterior border of the muscle 
Body of the masseter: Start just below the zygomatic process at the anterior 
border of the muscle. Palpate from the above area down and back to the 
angle of the mandible across a surface area about two fingers wide. 
Posterior masseter: Palpate the area I cm superior and anterior to the angle 
of the mandible. 
* Posterior digastric: Locate the area between the insertion of the 
sternocleidomastoid and the posterior border of the mandible. Palpate the 
area immediately medial and posterior to the angle of the mandible. 
0 Medial pterygoid: Locate the site under the mandible at a point which is 2 cm 
anterior to the angle of the mandible. 
0 Vertex: Palpate on the vertex of the head which is used as a control site. 
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Neck muscles palpation 
Superior sternocleidomastoid: The patient is asked to tip the head a little to 
identify the insertion of sternocleidomastoid. Palpate fibres at this area 
including the anterior and posterior border of the muscle. 
Middle sternocleidomastoid: After completing the palpation of superior 
sternocleidomastoid, move the finger downward to the middle part of the 
muscle. 
Inferior sternocleidomastoid: Palpate fibres I cm above the clavicle and the 
insertion of sternocleidomastoid. 
Insertion of trapezius: Palpate fibres at the medial third of the superior 
nuchal line to the spine of C7 vertebral line. 
Upper trapezius: After completing examination of insertion of the muscle, 
palpate the upper part of the muscle along the neck. 
Splenius capitus: Palpate fibres which are deep and in between trapezius and 
sternocleidomastiod muscles from the superior nuchal line to the mastoid 
process. 
TMJ palpation 
Lateral capsule : Ask the patient to open slightly and palpate on the lateral 
pole of the TMJ. 
Posterior capsule : Palpate intrameatally by placing the tip of the little finger 
toward the condyle. 
Superior capsule: Palpate the superior part of the TMJ capsule after asking 
the patient to open slightly 
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Intra-oral muscle palpation 
The patient is asked to open the mouth for the intra-oral muscle palpation. 
9 Lateral pterygoid: Place the finger on the lateral side of the alveolar ridge 
above the maxillary molars. Move the finger distally, upwards and medial to 
palpate. 
* Temporalis insertion: After completing the lateral pterygoid examination, 
rotate the finger laterally near the coronoid process. Move the finger upward 
to the anterior ridge of the coronoid process. 
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THE HISTORY DATA COLLECTION QUESTIONNAIRE 
History Questionnaire 
Please read each question and respond accordingly. For each of the questions below, 
circle oniv one resr)onse. 
1- Would you say your health in general is excellent, very good, good, fair or 
poor? 
Excellent ........... 1 
Very good ......... 2 
Good ................. 3 
Fair ................... 4 
Poor .................. 5 
2. Would you say your oral health in general is excellent, very good, good, fair or 
poor? 
Excellent ........... 1 
Very good 2 
Good ................. 3 
Fair ................... 
Poor .................. 
3. Have you had pain in the face, jaw, temple, in front of the ear or in the ear in 
the past month? 
No .............. 
0 
Yes ............ 
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(If no pain in the past month SKIP to question 14) 
IF YES 
4. How many years ago did your facial pain begin for the first time? 
............... Months or ................... Years 
5. Is your facial pain persistent, recurrent or was it only a one-time problem? 
Persistent ................ 
Recurrent ................ 2 
One-time ................. 3 
6. Have you ever gone to a physician, dentist or other health professional for 
facial ache or pain? 
No ................................................. 
Yes, in the 6 months ..................... 2 
Yes, more than 6 months ago 3 
7. How would you rate your facial pain on a0 to 10 scale at the present time, 
that is right now, where 0 is "no pain" and 10 is "pain as bad as could be"'; ' 
0123456789 10 
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8. In the past six months, how intense was your worst pain, rated on a0 to 10 
where 0 is "no pain" and 10 is "pain as bad as could be"*; ' 
10 
9. In the past six months, on the average, how intense was your pain rated on a 
0 to 10 scale where 0 is "no pain" and 10 is "pain as bad as could be"? (That is 
your usual pain at times you were experiencing pain. ) 
10 
10. About how many days in the last 6 months have you been kept from your 
usual activities work, school or housework because of facial pain? 
................................... Days 
11. In the past 6 months, how much has facial pain interfered with your daily 
activities rated on a0 to 10 scale where 0 is "no interference" and 10 is "unable 
to carry on any activities"? 
10 
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12. In the past 6 months, how much has facial pain changed your ability to 
take part in recreational social and family activities where 0 is "no change" and 
10 is "extreme change"? 
10 
13. In the past 6 months, how much has facial pain changed your ability to 
work (including housework) where 0 is "no change" and 10 is "extreme change"? 
10 
14. a. Have you ever had your jaw lock or catch so that it won't open all the 
way? 
No .......................... 
1 
Yes ......................... 
2 
(If no problem opening all the way skip to question 15) 
14. b. Was this limitation in jaw opening severe enough to interfere with your 
ability to eat? 
No ......................... 
1 
Yes ....................... 
2 
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15. a. Does your jaw click or pop when you open or close your mouth or when 
I 
chewing? 
No ......................... 
Yes ....................... 
b. Does your jaw make a grating or grinding noise when it opens and closes or 
when chewing? 
No ......................... 1 
Yes ....................... 2 
c. Have you been told or do you notice that you grind your teeth or clench your 
jaw while sleeping at night? 
No ......................... 1 
Yes ....................... 2 
I d. During the day do you grind your teeth or clench your jaw? 
No ......................... 1 
Yes ....................... 2 
I e. Does your jaw ache or feel stiff when you wake up in the moming? 
No ......................... 
1 
Yes ........................ 
If Do you have noises or ringing in your ears? 
No ......................... 
1 
Yes ........................ 
g. Does your bite feel uncomfortable or unusual? 
No ......................... 
I 
Yes ........................ 
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16. a. Do you have rheumatoid arthritis lupus or any other systemic arthritic 
diseases? 
No ......................... 
Yes ........................ 
16. b. Do you know of anyone in your famfly? 
No ......................... 1 
Yes ........................ 2 
16. c. have you had or do you have any swollen or painful joint(s) other than the 
joints close to Your ears (TMJ)? 
No ......................... 1 
Yes ........................ 2 
(If no swollen or painful joints, SKIP to question 17. cq 
If yes 
16. d. Is this a persistent pain that you have had for at least one year? 
No ......................... 
1 
Yes ........................ 
17. a. Have you had irýjury to your face or jaw? 
No ......................... 
Yes ........................ 
(If no recent injuries SKIP to question 18) 
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IF YES 
17. b. Did you have jaw pain before the in ury? i 
No ......................... 1 
Yes ........................ 2 
18. During the last 6 months have had a problem with headaches or migraines? 
No ......................... 1 
Yes ........................ 
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19. What activities does your present jaw problem prevent or limit you from 
doing? 
a. Chewing No .............. 1 ........... 
Yes ........................ 2 
b. Drinking No ......................... 1 
Yes ........................ 2 
c. Exercising No ......................... 1 
Yes ........................ 2 
d. Eating hard foods No ......................... 1 
Yes ........................ 2 
e. Eating soft foods No ......................... 1 
Yes ........................ 2 
f. Smiling/ laughing No ......................... 1 
Yes ........................ 2 
g. Sexual activity No ......................... 1 
Yes ........................ 2 
h. Cleaning teeth or face No ......................... 1 
Yes ........................ 2 
I. Yawning No ......................... 
1 
Yes ........................ 
2 
j. Swallowing No ......................... 
1 
Yes ........................ 
2 
k. Talking No ......................... 
1 
Yes ........................ 
2 
1. Having your usual facial No ......................... 
1 
appearance Yes ........................ 
2 
275 
SCL-90-R 
Instructions: 
Below is a list of problems people sometimes have. Please 
read each one carefully and circle the number to the right 
that best describes HOW MUCH THAT PROBLEM HAS DISTRESSED OR 
BOTHERED YOU DURING THE LAST MONTH INCLUDING TODAY. Circle 
only one number for each problem. 
HOW MUCH WERE YOU 
DISTRESSED BY: 
Not at all A LITTLE 
BIT 
MODER- 
ATELY 
QUITE A 
BIT 
EX--- 
TREMELY 
a. Headaches 0 1 2 3 4 
b. Loss of sexual interest or 
pleasure 
0 1 2 3 4 
c. Faintness or dizziness 0 1 2 3 4 
d. Pains in the heart or chest 0 1 2 3 4 
e. Feeling low in energy or slowed 
down 
0 2 3 4 
f. Thoughts of death or dying 0 2 3 4 
g. Poor appetite 0 2 3 4 
h. Crying easily 0 2 3 4 
i. Blaming your self for things 0 2 3 4 
j. Pains in low back 0 2 3 4 
k. Feeling lonely 0 2 3 4 
1. Feeling blue 0 2 3 4 
m. Worrying too much about 
things 
0 2 3 4 
n. Feeling no interest in things 0 2 3 4 
o. Nausea or upset stomach 0 2 3 4 
p. Soreness of your muscles 0 2 3 4 
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HOW MUCH WERE YOU 
DISTRESSED BY: 
Not at all A LITTLE 
BIT 
MODER- 
ATELY 
QUITE A 
BIT 
EX- 
TREMELY 
q. Trouble falling asleep 0 2 3 4 
r. Trouble getting your breath 0 2 3 4 
s. Hot and cold spells 0 2 3 4 
t. Numbness or tingling in parts 
of your body 
0 1 2 3 4 
u. A lump in your throat 0 1 2 3 4 
v. Feeling hopeless about the 
future 
0 1 2 3 4 
w. Feeling weak in parts of your 
body 
0 1 2 3 4 
x. Heavy feelings in your arms or 
legs 
0 1 2 3 4 
y. Thoughts of ending your life 0 1 2 3 4 
z. Overeating 0 1 2 3 4 
aa. Awakening in the early 
morning 
0 1 2 3 4 
bb. Sleep that is restless or 
disturbed 
0 1 2 3 4 
cc. Feeling everything is an effort 0 1 2 3 4 
dd. Feeling of worthlessness 0 1 2 3 4 
ee. Feeling of being caught or 
trapped 
0 1 2 3 4 
ff. Feeling of guilt 0 1 2 3 4 
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THE ASSESSMENT METHODS FOR AMS II 
Axis II is based on the data from the history data coflection questionnaire. The 
scoring methods are as follows: - 
SCORING CRITERIA FOR GRADING CHRONIC PAIN SEVERITY 
9 Characteristic pain intensity is 0 to 100 score derived from questions 7 
through 9: 
Mean (pain right now, worst pain, average pain) x 10 
Disabihty score is 0 to 100 score derived from questions II through 13: 
Mean (daily activities, social activities, work activities) x 10 
Disability points: add the indicated points for disability days (question 10) 
and for disability score 
Disability points 
Disability days (0-180) Disability Score (0-100) 
0-6 days 0 point 0-29 0 point 
7-14 days I point 30-49 1 point 
15-30 days 2 points 50-69 2 points 
31+ days 3 points 70+ 3 points 
Classiftcation 
Grade 0 No TMD pain in prior 6 months 
Low disabil 
Grade I low intensity Characteristic pain intensity less than 50 and less 
than 3 disability points 
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Grade II high intensity Characteristic pain intensity from 50 and less than 3 
disability points 
High disability 
Grade III moderately limiting 3 to 4 disability points, regardless of 
characteristic pain intensity 
Grade IV severely limiting 5 to 6 disability points, regardless of 
characteristic pain intensity 
LIMITATIONS RELATED TO MANDIBULAR FUNCTION 
No classification is proposed 
assessments. 
SCORING THE SCL-90 SCALES 
The data from item 19 is used for these 
Use the raw mean scale score, which is computed by adding up the item score 
for all items answered and dividing by the number of items answered. If less 
than two thirds of the items are answered, set the scale score to missing. 
Depression and vegetative symptom scale is the mean of question b, e, f, g, h, 
i, k, 1, m, n, q, v, y, z, aa, bb, cc, dd, ee, ff 
Somatisation scale (non-specific physical symptoms) is the mean of question 
a*, c, d*,, j*,, o*, p*. v 
f, w, Y, aa. (Items with asterisk are dropped when scoring 
the "nonpain" non-specific physical symptom scale. ) 
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Classiftcation of Depression and Non Speciftc Physical Symptoms 
Categories Normal Moderate Severe 
Depression (including <0.535 0.535 to 1.105+ 
vegetative symptoms) <1.105 
Non-specific physical <0.5 00 0.500 to 1.000+ 
symptoms (pain items <1.000 
included) 
Non-specific physical 
symptoms (pain items 
excluded) 
<0.428 0.428 to 
<0.857 
0.857+ 
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SUBJECT PATIENT SUMMARY OF FINDINGS (RDC) 
Name ........... Surname ........... HN ............ IRD ........... 
Age ............. Ethnicity .............. 
Self-reported patient characteristics: 
Click Yes No 
Grating/Grinding Yes No 
Nocturnal Clenching/Grinding Yes No 
Diurnal Clenching/Unusual bite Yes No 
Muscles Stiffness Yes No 
Ringing in Ears Yes No 
Axis I Diagnosis 
Group I Muscle Disorders (Circle only one response for qroup 
A. Myofascial pain (I. a) 
B. Myofascial pain with limited opening (I. b) 
C. No group I diagnosis 
Group 11 Disk Displacement (Circle only one response for each joint for group 
IX) : 
Right joint 
A. Disc displacement with 
reduction (II. a) 
B. Disc displacement without 
reduction, with limited opening 
(II. b) 
Left joint 
A. Disc displacement with 
reduction (II. a) 
B. Disc displacement without 
reduction, with limited opening 
(II. b) 
C. Disc displacement without C. Disc displacement without 
reduction, without limited opening reduction, without limited opening 
(II. C) (II. C) 
D. No right joint group II Diagnosis D. No left joint group II Diagnosis 
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Group = Other joint conditions (Circle only one response for each joint for 
group 111) 
Right joint 
A. Arthralgia(III. a) 
B. Osteoarthritis of the TMJ (III. b) 
C. Oseteoarthrosis of the TMJ (III. c) 
Left joint 
A. Arthralgia (III. a) 
B. Osteoarthritis of the TMJ (III. b) 
C. Oseteoarthrosis of the TMJ (III-C) 
Axis II profile: 
1. Graded chronic pain status .................. 
2. Depression score ....................................... 
3. Non-specific physical symptoms scale ....................................................................................... 
4. Limitation related to mandibular function ..................................................................... 
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SYMPTOMS SEVERITY INDEX (SSI) 
Please make a mark on line for each question 
Since your last visit, has your pain been : 
SI: How intense is your usual level of symptoms where 0 is "no pain" 
and 10 is "the most pain intensity that can be imagined? 
0 10 
Al: How unpleasant or disturbing is your usual level of symptoms 
where 0 is "no disturbing" and 10 is "the most that can be imagined? 
0 10 
TO: How difficult is it to endure the problem over time where 0 is "no 
difficulty" and 10 is "the most that can be imagined? 
10 
FR: How often do the symptoms generally occur? 
Never 1/mo 1/day 1/hour Constant 
DU: When the symptoms occur, how long do the symptoms usually 
last? 
Never I/minute I/hour 1/day I week continuous 
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THE SCORING METHOD FOR SYMPTOM SEVERITY INDEX 
The SSI based on VAS is the mean of compartments namely sensory score 
intensity (SI), affective intensity (Al), tolerability (TO), frequency (FR) and 
duration (DU). Each item is scored by the measurement of the distance in cm 
between 0 to the mark which is made by patients. 
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McGILL PAIN QUESTIONNAIRE 
Since your last yisit, has your vain been: 
FREQUENCY SEVERITY 
1 Less frequent 1. Less severity 
2. The same frequency 2. The same severity 
3. More frequency 3. More severe 
Circle the word that described how your pain feels rýght now: 
1. Nil 
2. Mfld 
Moderate 
Severe 
5. Most severe 
Circle the words below that best described your pain. Use only ONE word in each 
groups. Leave out any group if the words are unsuitable 
1 2 3 4 
Flickering Jumping Pricking Sharp 
Quivering Flashing Boring Cutting 
Pulsing Shooting Drilling Lacerating 
Throbbing Stabbing 
Beating Lancenating 
Pounding 
5 6 7 8 
Pinching Tugging Hot Tingling 
Pressing Pulling Burning Itchy 
Gnawing Wrenching Scalding Smarting 
Cramping Searing Stinging 
Crushing 
9 10 11 12 
Dull Tender Tiring Sickening 
Sore Taut Exhausting Suffocating 
Hurting Rasping 
Aching Splitting 
Heavy 
13 14 15 16 
Fearful Punishing Wretched Annoying 
Frightful Gruelling Blinding Troublesome 
Terrifying Cruel Miserable 
Vicious Intense 
Killing Unbearable 
17 is 19 20 
Spreading Tight Cool Nagging 
Radiating Numb Cold Nauseating 
Penetrating Drawing Freezing Agonising 
Piercing Squeezing Dreadful 
Tearing Torturing 
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THE SCORING METHOD FOR McGILL PAIN QUESTIONNAIRE 
The weighted-rank scoring system which has been recommended by Melzack et 
al (1985) was used in this study. The rank score of each descriptor chosen by 
the patient is multiplied by the weight for that category to obtain the weight- 
rank score. Then the Pain Rating Index (PRI) is calculated from the sum of the 
weight-rank scores. 
The weight for each category as follows: - 
Category Weight 
1 0.69 
2 1.38 
3 0.93 
4 1.59 
5 0.81 
6 1.19 
7 1.28 
8 0.70 
9 0.72 
10 0.95 
11 1.74 
12 2.22 
13 1.87 
14 1.32 
15 2.33 
16 1.01 
17 1.22 
18 0.82 
19 1.0 
20 1.15 
9 The sum weight rank score of categories 
I to 10 represents the sensory pain 
rating index (PRI-S). 
The sum weight rank score categories 11 to 15 represents 
the affective pain 
rating index (PRI-A) 
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The weight rank score of category 16 represents the evaluative pain rating 
index (PRI-E) 
The sum weight rank score of categories 17 to 20 represents the 
miscellaneous part for pain rating index (PRI-M) 
The total pain rating index (PRI-T) = PRI-S + PRI-A + PRI-E + PRI-M 
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